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Depression is the leading cause of disability worldwide and is one of the major 
contributors to the overall global burden of disease. Despite significant advances in 
elucidating the neurobiology of depression in recent years, the molecular factors involved 
in the pathophysiology of depression remain poorly understood.  
Chapter 1: An overview of Major Depressive Disorder (MDD) from epidemiological and 
clinical perspectives with a summary of the current knowledge of the underlying biology 
is provided. A review of the major pathophysiological hypotheses of MDD highlights a 
need for a more comprehensive approach that allows studying complex molecular 
interactions involved in depression.  
Chapter 2: Transcriptome signature of depression was examined using the measure of 
replication at individual gene level across different tissues and cell types in both brain and 
periphery. Fifty-seven replicated genes were reported as differentially expressed in the 
brain and 21 in peripheral tissues. In-silico functional characterisation of these genes was 
provided, implicating shared pathways in a comorbid phenotype of depression and 
cardiovascular disease. 
Chapter 3: The molecular basis of MDD using co-expression network analysis was 
investigated. The Weighed Gene Co-expression Network Analysis (WGCNA) allowed for 
studying complex interactions between individual genes influencing biological pathways 
in MDD. Utilising the Sydney Memory and Aging Study (sMAS) and the Older Australian 
Twin Study (OATS) as discovery and replication cohorts respectively, it was found that 
the eigengenes of four clusters containing over 3,000 highly co-regulated genes are 
involved in 13 immune- and pathogen-related pathways and associated with recurrent 
MDD. However, the findings were not replicated on an independent cohort at the network 




Chapter 4: Using a machine learning (ML) approach, a predictive model was built to 
identify the genome-wide gene expression markers of recurrent MDD. Fuzzy Forests (FF) 
is a novel ML algorithm, which works in conjunction with WGCNA and was designed to 
reduce the bias seen in feature selection caused by the presence of correlated transcripts 
in transcriptome data. FF correctly classified 63% of recurrently depressed individuals in 
test data using the single top predictive feature (TFRC, encodes for transferrin receptor). 
This suggests that TFRC can represent a putative marker for recurrent MDD.  
Chapter 5: Following the findings on immune-related pathways being associated with 
recurrent MDD in the elderly (Chapter 3), the role of these pathways in recurrent MDD 
was examined at individual gene levels in an independent cohort (OATS). To target the 
immune pathways, all known genes (KEGG) involved in these 13 pathways were selected 
and a differential expression analysis was conducted on 1,302 candidates between 
individuals with recurrent MDD and those without. We found that CD14 was significantly 
downregulated in recurrent MDD (FDR < 5%). Considering the key role of CD14 for 
facilitating the innate immune response, we suggest that CD14 can potentially serve as 
a peripheral marker of immune dysregulation in recurrent MDD.  
Chapter 6: A discussion on obtained findings is provided and future directions are outlined 
with a particular focus on how co-expression network and machine learning approaches 
that can enhance translation of molecular findings into clinical translation.  




I, Liliana Ciobanu, certify that this work contains no material which has been accepted for 
the award of any other degree or diploma in my name in any university or other tertiary 
institution and, to the best of my knowledge and belief, contains no material previously 
published or written by another person, except where due reference has been made in 
the text. In addition, I certify that no part of this work will, in the future, be used in a 
submission in my name for any other degree or diploma in any university or other tertiary 
institution without the prior approval of the University of Adelaide and where applicable, 
any partner institution responsible for the joint award of this degree.  
I acknowledge that copyright of published works contained within this thesis resides with 
the copyright holder(s) of those works.  
I also give permission for the digital version of my thesis to be made available on the web, 
via the University's digital research repository, the Library Search and also through web 
search engines, unless permission has been granted by the University to restrict access 
for a period of time.  
I acknowledge the support I have received for my research through the provision of an 
Australian Government Research Training Scholarship. 
 
Liliana Ciobanu,          19/06/2019 
 
  




Firstly, I would like to express my sincere gratitude to my primary supervisor Prof. 
Bernhard T. Baune for the continuous support of my PhD study and related research, for 
his patience, motivation, and immense knowledge. His guidance helped me during my 
research and writing of this thesis. I could not have imagined having a better advisor and 
mentor for my PhD study. 
Besides my primary supervisor, I would like to thank my co-supervisor Dr. Catherine 
Toben, for her insightful comments and encouragement, but also for the hard questions 
which inspired me to widen my research  perspectives. 
My sincere thanks also go to Dr. David Stacey and Associate Prof. Sarah Cohen-Woods, 
who had an enormous role in establishing this project. Without their support it would not 
have been possible to conduct this research. 
I would also like to thank the project collaborators Prof. Perminder S. Sachdev, Prof. 
Julian N. Trollor, Dr. Karen A. Mather, Dr. Anbupalam Thalamutu, and Dr. Simone 
Reppermund for providing the data from the Sydney Memory and Aging Study (sMAS) 
and Older Australian Twins Study (OATS) and for the amazing sMAS and OATS team 
support and hospitality during my 2-week visit of the Centre for Healthy Brain Ageing 
(CHEBA), UNSW, Sydney. 
I would like to acknowledge Adelaide Medical School Discipline of Psychiatry research 
team for stimulating scientific discussions, suggestions and support. 
 
Last but not the least; I would like to thank my family: Andrei Ciobanu and our three 
beautiful children – Alexei, Iurie and Ivan. Without your support and encouragement all 
this would never have happened. 





EPIDEMIOLOGY OF MAJOR DEPRESSIVE DISORDER (MDD) 
Major Depressive Disorder is a leading cause of disability worldwide, and is one of the 
major contributors to the overall global burden of disease (Whiteford et al., 2015), 
including Australia (Ciobanu et al., 2018a) (Appendix A). Globally, more than 300 million 
people of all ages suffer from depression (WHO, 2017). It has been estimated that 
depressive disorders (including MDD and dysthymia) are the top contributors to the 
disease burden attributable to mental and substance use disorders globally (Figure 1.1) 
as well as in Australia (Figure 1.2) explaining 40.5% and 30% of Disability-Adjusted Life 
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Figure 1.1. Proportions of DALYs explained by mental and substance use disorders 
globally in 2010. Disability-adjusted life years (DALYs) is a sum of years lived with 
disability (YLDs) and years of life lost (YLLs). 
 
Source: 2010 Global Burden of Disease Study. Seattle, Washington University Institute for Health Metrics 
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Figure 1.2. Proportions of DALYs for mental and substance use disorders in Australia in 
2015. Disability-adjusted life years (DALYs) is a sum of years lived with disability (YLDs) 
and years of life lost (YLLs) 
 
Source: 2015 Global Burden of Disease Study. Seattle, Washington University Institute for Health Metrics 
and Evaluation, 2015 (Ciobanu et al., 2018a)  
 
MDD is also a recognised risk factor for other health outcomes. MDD is an important 
contributor of burden allocated to ischemic heart disease (Ferrari et al., 2013). 
Furthermore, individuals suffering from MDD have a shorter life expectancy than those 
without MDD, in part due to suicidal ideation  (Cassano and Fava, 2002).  
Considering the burden of this devastating disorder on society, there have been 
substantial financial investments into improved medical services for affected individuals 
(Greenberg et al., 2015), which has led to fourfold return in better health and ability to 
work, according to a WHO-led study  (Chisholm et al., 2016). Despite these efforts the 
global burden of depressive disorders remains largely unchanged between 1990 and 
2016 (GBD, 2017).  
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CLINICAL MANIFESTATION OF MAJOR DEPRESSIVE DISORDER (MDD) 
Major depression is a psychiatric mood disorder that goes beyond the normal human 
experiences of sadness. It encompasses a broad range of symptoms such as feeling 
worthless, having thoughts of suicide, losing interest in most or all activities, experiencing 
a significant change (decrease or increase) in appetite or sleep patterns, and having 
difficulty concentrating. Long-term symptoms can cause clinically significant distress to 
the individual or lead to impairment in social, occupational, or other important areas of 
functioning. Clinical diagnosis of MDD uses a symptom-based approach as defined in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-V). According to DSM-V, a 
diagnosis of major depressive disorder is made when the following symptoms are present 
















Problematic reliability of symptom-based MDD diagnosis in clinical practice 
 
Box 1 
DSM-5 diagnostic criteria for major depression 
 A. 
Five (or more) of the following symptoms present during the same 2-week 
period and which represent a change from previous functioning; at least one 
of the symptoms is either (1) depressed mood or (2) anhedonia 
 B. 
Symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning 
 C. 
Episode is not attributable to the physiological effects of substance abuse or 
another medical condition 
1. Depressed mood most of the day (e.g., feels sad, empty, hopeless) 
2. Markedly diminished interest or pleasure in almost all activities nearly 
every day 
3. Significant appetite changes or significant weight loss or gain 
4. Insomnia or hypersomnia nearly every day 
5. Psychomotor agitation or retardation 
6. Fatigue or loss of energy 
7. Feelings of worthlessness or excessive guilt 
8. Diminished ability to think or concentrate or indecisiveness 
 
Transcriptome signature of depression 
12 
 
The value of disease diagnosis is limited by its reliability, i.e. the agreement between 
clinicians on making the same diagnosis in the same patient. Reliability is typically 
evaluated with the kappa coefficient, which ranges from 0 to 1 (from chance to perfect 
agreement). Benchmarks have been proposed with values above 0.6 considered to be 
good or very good, between 0.4 and 0.6 moderate, 0.2 to 0.4 fair, and below 0.2 poor 
(Altman, 2006, Landis and Koch, 1977). The DSM-V field trials, which are designed to 
ensure that diagnoses were carried out in a way that is representative of psychiatric 
practice and with an appropriate level of training in the use of DSM-V, have yielded a 
kappa of 0.28 (95% CI 0.20- 0.35) based on separate interviews by physicians (Darrel A. 
Regier et al., 2013). Given a low validity of DSM-V diagnosis, i.e. poor agreement 
between clinicians on symptom-based diagnosis (Uher et al., 2014), greater promise can 
be expected with biologically based diagnostic markers of MDD that are objective in both 
methodology and interpretation (Smith et al., 2013).  
Limited efficacy of antidepressant treatment  
There has been a long debate in the medical community about the effectiveness of 
currently available antidepressants, centering around whether the observed results in 
patients can be attributed to the placebo effect (Kirsch, 2014). The largest meta-analysis 
of 522 trials of 21 antidepressants in 116,477 participants compared efficacy and 
acceptability of ADs for treatment of adults with moderate to severe MDD has shown that 
all ADs were more efficacious than placebo (Cipriani et al., 2018). However, rates of total 
remission following antidepressant treatment are estimated to be only 50.4% 
(Papakostas, 2010). Because existing first-line antidepressants -  classically thought to 
modulate monoamine neurotransmission - are often insufficient for many patients, there 
is a greater requirement for improvement in pharmacological antidepressant treatments. 
The next generation of mechanistically novel therapeutic strategies needs to be more 
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effective, rapid acting and better tolerated than currently available medications.  
Given the increased health and economic burden of depression on society, there is a 
pressing need for alternative lines of intervention. These can be achieved via developing 
and implementing improved clinical diagnostic tools and novel therapeutic strategies and 
treatments. Development of novel clinical diagnostic tools and therapies is paramount in 
moving towards improved clinical response. A better understanding of the underlying 
biological pathophysiological mechanisms of depression are required to improve 
treatment response and predict response outcome. To develop unbiased biology-based 
diagnostic tools and improved pharmacological treatments, there is a need to better 
understand that molecular basis of depression.  Although decades of experimental 
research have provided several major biological hypotheses of depression, a 
comprehensive understanding of the biological correlates of depression remain to be 
determined. The major hypotheses of pathophysiology of MDD will be covered in the next 
section. 
 
MAJOR HYPOTHESES OF PATHOPHYSIOLOGY OF MDD 
Monoamine deficiency 
One of the early biological hypotheses ensued after observations in patients being treated 
for hypertension with reserpine. Acting as an antagonist reserpine blocks the vesicular 
monoamine transporter (VMAT) and thereby reduces monoamine levels within the brain. 
As a result patients were experiencing comorbid depression (Freis, 1954). Following this 
observation, the hypothesis that a deficiency or imbalance in the monoamine system of 
the brain is an underlying biological basis for depression was proposed. Monoamines 
refer to the particular neurotransmitters dopamine, norepinephrine and/or serotonin. On 
the basis of this hypothesis, various antidepressants have been designed to increase the 
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levels of monoamines within the synaptic cleft either via inhibition of monoamine 
degradation or by the blockade of their reuptake (Slattery et al., 2004). Currently marketed 
antidepressants have the monoamine hypothesis as their theoretical basis. The two 
original antidepressants were the monoamine oxidase inhibitor (MAOI) Iproniazid, and 
the tricyclic antidepressant (TCA) Imipramine. The determination of their mode of action 
led to the catecholamine hypothesis of depression being developed in the mid‐1960s 
(Schildkraud, 1965). Monoamine elevation therapies have for the large part proved 
successful and remain the most widely prescribed pharmaceuticals (e.g. TCAs, MAOIs 
and uptake inhibitors); however, two caveats remain as all monoaminergic 
antidepressants have a delayed onset of action of several weeks and therapeutic 
unresponsiveness is indicated in roughly 30% of depressed patients (Doris et al., 1999, 
Machado-Vieira et al., 2008).  Given the limited success of monoamine interventions and 
the increasing burden of the disorder on society, novel non-monoamine interventions 
have emerged. 
HPA axis hyperactivity  
The hypothalamic-pituitary-adrenal (HPA) axis is the fundamental neuroendocrine 
system that controls reactions to stress. This axis consists of stimulating forward and 
feedback inhibition loops involving the brain, pituitary, and adrenal glands, which regulate 
glucocorticoid production.  Cortisol released from the adrenal glands, binds within the 
brain with high affinity to mineralocorticoid receptors (MRs) and with lower affinity to 
glucocorticoid receptors (GRs). The hyperactivation of the HPA axis reflecting a 
dysregulation of MR and/or GR is one of the most consistent findings in neurobiology of 
depression, but the mechanisms underlying this abnormality are still unclear. This 
increased activity of the HPA axis is thought to be related, at least in part, to reduced 
feedback inhibition by endogenous glucocorticoids (Pariante and Lightman, 2008). 
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Altered neural plasticity and neurogenesis 
Neural plasticity is a fundamental mechanism of neuronal adaptation. It is becoming 
increasingly clear that altered neurogenesis and neural plasticity induced by stress and 
other negative stimuli play a significant role in the onset and development of depression 
(Duman et al., 1999). According to this theory, neural circuits and connections undergo 
lifelong modifications and reorganizations in response to external or internal 
environmental stimuli. Adult neurogenesis involves precursors of cell proliferation, 
migration and differentiation mainly occurring in the dentate gyrus of the hippocampus 
(Eriksson et al., 1998). Neurotoxic agents such as chronic stress, excessive 
concentrations of glutamate, biogenic amines and glucocorticoids may affect the 
morphology of some neural cells such as hippocampal CA3 pyramidal neurons and 
pyramidal cells of prefrontal cortex (Serafini, 2012). Reduced hippocampal volume is one 
of the most common findings in depressed individuals and longer duration of depressive 
episodes is known to be closely related to modifications in hippocampal volume 
(Lorenzetti et al., 2009). However, there is no scientific consensus to confirm the direction 
of causality. Most of the studies suggest that depression and dysfunction of neural 
plasticity act on and influence each other (Liu et al., 2017).  
Dysregulation of glutamatergic system 
Glutamate is the most abundant excitatory neurotransmitter in the central nervous 
system. It is found in substantially higher concentrations than monoamines and in more 
than 80% of neurons, highlighting its role as a major excitatory synaptic neurotransmitter 
(Mathew et al., 2005). Given that glutamate is so widely distributed in the brain, strict 
regulation is necessary to prevent undue excitotoxicity. The delicate balance of glutamate 
with the major inhibitory neurotransmitter γ-aminobutyric acid (GABA) is essential for all 
physiological homeostasis in the CNS (Schoepp, 2001). Early findings within the 1990s 
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showed that N-methyl-D-aspartate receptor (NMDA-R) antagonists possess 
antidepressant-like action (Trullas and Skolnick, 1990) leading to the ‘glutamate 
hypothesis of depression’. Later studies have found that MDD pathophysiology is 
associated with dysfunction of the predominant glutamatergic system, malfunction in the 
mechanisms regulating clearance and metabolism of glutamate, and morphological 
maladaptive changes in a number of limbic/cortical areas in the brain mediating cognitive-
emotional behaviours (Sanacora et al., 2012). Glutamate itself serves as a metabolic 
precursor for the neurotransmitter GABA, via the action of the enzyme glutamate 
decarboxylase. The role of GABA specifically in MDD is briefly discussed below. 
Reduced GABAergic activity 
GABA (γ-aminobutyric acid) is the chief inhibitory neurotransmitter in the mammalian 
central nervous system. Its principal role is reducing neuronal excitability throughout 
the nervous system. The GABAergic deficit hypothesis of depression posits that reduced 
GABA concentrations in the brain, impaired function of GABAergic interneurons, altered 
expression and function of GABAA receptors, and changes in GABAergic transmission 
dictated by altered chloride homeostasis can contribute to the aetiology of MDD (Luscher 
and Fuchs, 2015).  
Dysregulation of melatonergic system 
Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is prominently, albeit 
not exclusively, synthesised in the pineal gland and secreted in a phasic manner (its 
circulating level varies in a daily cycle). Melatonin exerts its actions through membrane 
MT1/MT2 melatonin receptors, which belong to the super family of G-protein-coupled 
receptors and are primarily expressed in the CNS (De Berardis et al., 2013). Circadian 
rhythms, regulated by the melatonergic system, have long been considered to be 
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disrupted in MDD, bringing on depressive behaviours and symptoms, disrupted sleep 
and poor regulation of neuroendocrine mediators such as cortisol, norepinephrine (NE) 
and serotonin (McClung, 2007). However, the complex relationships between the 
circadian system and the development of depressive symptoms are far from being 
elucidated (Courtet and Olie, 2012). Stimulation of melatonergic (MT1 / MT2) receptors by 
melatonergic antidepressants, such as agomelatine, purported to resynchronize circadian 
rhythms, was found moderately more effective than placebo with similar efficacy and 
fewer side effects to standard antidepressants in the treatment of depressed patients 
(Cardinali et al., 2013, Taylor et al., 2014).  
Inflammation in depression  
Finally, pathophysiology of depression was associated with the immune system and 
inflammation (Maes, 1999). Extensive findings support the role of chronic low grade 
inflammation in depression. MDD patients exhibit all of the cardinal features of an 
inflammatory response, including increased expression of pro-inflammatory cytokines 
and their receptors (McAfoose and Baune, 2009, Mills et al., 2013) and increased levels 
of acute-phase reactants (Wium-Andersen et al., 2013, Kohler-Forsberg et al., 2017), 
chemokines (Eyre et al., 2016, Singhal and Baune, 2018) and soluble adhesion 
molecules in peripheral blood and cerebrospinal fluid (CSF) (Lespérance et al., 2004, 
Dimopoulos et al., 2006). Inflammation in depressed patients has been linked to altered 
gut microbiota dysbiosis (dysregulation of gut-brain-axis) (Clapp et al., 2017, Schachter 
et al., 2018), childhood trauma (Cattaneo et al., 2015), and stress-related epigenetic 
regulations (Wang et al., 2018). Inflammation has also been observed in depressed 
patients suffering from obesity (Ambrosio et al., 2018), cardiovascular disease (Halaris, 
2017), cancer (Li et al., 2017, Weber and O’Brien, 2017), and asthma (Jiang et al., 2014), 
suggesting inflammation to play an important role in comorbid depression. Accumulating 
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evidence suggests that anti-inflammatory treatments are associated with anti-depressant 
properties. Although the therapeutic effect of anti-inflammatory drugs has been observed 
in several clinical trials (Köhler et al., 2014, Köhler et al., 2016), it has been mainly 
explored in acute disease stages, which indicates its potentially limited application in 
clinical settings (Baune, 2018).  
Although the empirical evidence for the role of the immune system in depression is 
increasing, our understanding of the immunology underlying inflammation in depression 
is limited. For instance, not all patients with increased inflammation develop MDD nor do 
all people with MDD show prominent immune activation (Steptoe et al., 2003). Therefore, 
it is becoming increasingly clear that dysregulated inflammatory responses are not 
necessary or sufficient for the development of depression, as inflammatory markers 
appear to be increased only in a subset of patients (Rosenblat et al., 2014). Furthermore, 
while both innate and adaptive immune systems seem to be involved in depression, the 
interplay between the two remains unclear. 
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WHY STUDY THE TRANSCRIPTOME IN DEPRESSION? 
Surmounting evidence suggests that depression is a multifaceted disorder with both 
genetic and environmental factors contributing to the onset and progression of the 
disorder. Despite substantial heritability of depression estimated at 31% to 42%  (Sullivan 
et al., 2000), identification of the genetic underpinnings of depression has been 
challenging. An intensive search for genetic factors of depression using a candidate gene 
approach pointed towards more than 200 genetic loci, mainly genes involved in 
neurotransmission and the hypothalamic–pituitary–adrenal axis (HPA), however, only a 
few of these findings have been successfully replicated (Rivera and McGuffin, 2015). 
Genome-wide association studies (GWAS), after several unsuccessful attempts (Flint 
and Kendler, 2014) recently revealed 18 novel loci associated with depression at 
genome-wide level. Two loci were found associated with severe depression in Han 
Chinese women (CONVERGE, 2015), and 15 loci were identified through 23andMe using 
self-report data of severely depressed individuals (Hyde et al., 2016), and one recently 
identified locus was found to be associated with late-onset depression (Power et al., 
2017). Although each of the three GWAS studies validated their findings within replication 
studies, there was no overlap in genetic variants across these studies. The discrepancies 
between the findings reflects the highly heterogeneous nature of depression (Levinson et 
al., 2014).   
Studying global gene expression is a relatively novel and promising approach to uncover 
the pathophysiology of depression as well as to possibly provide useful clinical 
information for predicting treatment response and identification of appropriate treatment 
options. Quantifying the abundance of mRNA molecules in a single cell or from within a 
population of cells provides essential information on the biological activity and functions 
of genes. Studying gene expression in depression can be viewed as being 
complementary to a gene discovery approach aimed at understanding the dynamic 
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molecular changes in depression. Given that the level and patterns of gene expression 
are influenced by both genetic and environmental factors (Wright and Sullivan, 2014), - 
such as age (van den Akker et al., 2014), sex (Jansen et al., 2014), smoking status 
(Charlesworth et al., 2010) and well-being (Fredrickson et al., 2013), - association 
between gene expression and depression may reflect an interactive effect of both.  Within 
a clinical research context, the identification of altered gene expression patterns in 
depression is of critical importance for (1) a better understanding of molecular 
underpinnings of depression, (2) establishing biological  clinical markers of depression, 
(3) increasing the  evidence-base  for the development of novel antidepressants, and (4) 
identifying  biomarkers for predicting treatment outcome, all of which are urgently needed 
for a better diagnosis and for more personalised treatments of affected individuals (Ferrari 
et al., 2013).  
Rapidly advancing technologies, such as microarrays and RNA-sequencing that allow for 
transcriptome coverage have become powerful tools to quantify levels of gene expression 
in various tissues relevant for the pathophysiology of depression. In the next chapter, the 
gene expression signature of depression is explored using the measure of replication at 
the individual gene level.  Investigation includes extraction of a comprehensive list of 
those genes which were found to be dysregulated in depression in both brain and 
periphery across the lifespan and then determination of the molecular pathways these 

















Genome-wide differential gene expression in brain and peripheral 




There is a growing body of research investigating the gene expression signature of 
depression at the genome-wide level, with potential for the discovery of novel 
pathophysiological mechanisms of depression. However, heterogeneity of depression, 
the dynamic nature of gene expression patterns and various sources of noise have 
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resulted in inconsistent findings. We systematically review the current state of 
transcriptome profiling of depression in the brain and peripheral tissues with a particular 
focus on replicated findings at the single gene level. By examining 16 brain regions and 
5 cell types from the periphery, we identified 57 replicated differentially expressed genes 
in the brain and 21 in peripheral tissues. Functional overlap between brain and periphery 
strongly implicates shared pathways in a comorbid phenotype of depression and 
cardiovascular disease. The findings highlight dermal fibroblasts as a promising 
experimental model for depression biomarker research, provide partial support for all 
major theories of depression and suggest a novel candidate gene, PXMP2, which plays 
a critical role in lipid and reactive oxygen species metabolism. 
Genome-wide gene expression in depression 
The application of high-throughput gene expression analyses has gained momentum in 
the study of molecular signatures of diseases. Microarray and next generation 
sequencing (NGS) technologies, which permit profiling the expression of many thousands 
of genes simultaneously, have been applied with success in many areas, including cancer 
research. Genomic and transcriptome alterations have enabled molecular classifications 
of cancer and revealed novel biomarkers for diagnosis, prognosis, and predicting 
response to therapies (Roychowdhury and Chinnaiyan, 2016) and inspired many other 
fields of medical research to utilize newly developed techniques. In recent decades, the 
field of psychiatry has adopted these techniques, aiming to elucidate molecular 
mechanisms, identify biomarkers and provide better treatment for depression, the leading 
cause of disability affecting more than 350 million people worldwide (WHO, 2015).  
The problem of non-replication of gene expression findings  
A growing amount of genome-wide gene expression data has been analysed using 
differential expression analysis, the most widely applied statistical method. However, 
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numerous limitations of biological and technical nature, including large biological 
variations, small sample sizes, data collection details, clinical heterogeneity, 
comorbidities, differences in microarray platforms, data quality assessment, statistical 
algorithms used and covariates accounted for, and many others, have resulted in 
inconsistent results,  questioning their validity. Biological findings need to be confirmed 
by several studies using the same method in order to be accepted. While the lack of 
replication is a major concern for transcriptome studies in depression, the systematic 
collection of replicated findings have never been performed. We address this gap by 
exploring the gene expression signatures of depression derived from both brain and 
peripheral tissues using replication as the yardstick of reliability.  
The choice of tissue for depression in gene expression research 
Depression includes dysfunction at multiple biological levels, from genes (Ripke et al., 
2013) to brain regions (Gong and He, 2015) and blood circulating throughout the body 
(Lopresti et al., 2014). The choice of tissue, therefore, is of particular importance in gene 
expression research.  Studies performed on post-mortem brains have substantially 
advanced our understanding of the pathophysiological mechanisms of depression. Gene 
expression signatures derived from various brain regions collectively point towards 
various molecular processes involving inflammatory, cell survival, apoptotic, oxidative 
stress and other pathways (Mehta et al., 2010). However, brain expression findings 
cannot be used for diagnostic purposes due to limited access to tissue from affected 
individuals. Extensive research on peripheral biomarkers of depression has revealed that 
peripheral immune response and growth factors, endocrine factors and metabolic 
markers also contribute to the pathophysiology of depression (Lin and Tsai, 2016). This 
is consistent with the close interaction between the brain and peripheral tissues. However, 
whether gene expression pattern in a peripheral tissue, such as blood, is a reflection of 
brain activity or a separate peripheral tissue process independent of the brain, remains 
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to be understood.  It is therefore necessary not only to examine peripheral gene 
expression but also to compare the brain and periphery gene expression findings to 
address some of these questions in depression research.  
The main challenge is to compile the numerous transcriptome profiles derived from 
different brain areas or/and peripheral cell types into one coherent analysis in an attempt 
to explain the mechanisms of depression. In this review, we compare transcriptomes 
obtained from multiple cell types in order to identify replicated findings. It can be argued 
that if any particular gene, in the face of various biological and technical limitations, was 
differentially expressed in depression compared to healthy controls across several 
cell/tissue types or brain areas, this gene has an increased likelihood of being truly 
involved in the pathophysiology of depression. We explore the gene expression signature 
of depression using replicability at the single gene level as a method of maximising true 
associations.  
METHODS 
Article selection process 
Using PubMed and EMBASE databases, we screened for all gene expression studies in 
depression in humans published in peer-reviewed journals using various permutations of 
the following search terms: “transcriptome”, “gene expression”, “depression”, “MDD”, 
“Major Depressive Disorder”. This preliminary literature search resulted in over 72,700 
articles. In the second step, based on the titles and information provided in abstracts, we 
selected 42 articles with genome-wide expression data. The inclusion criteria for the 
review were: (1) phenotype of depression, (2) original genome-wide gene expression 
data, and (3) differential expression analysis between depression and controls. We did 
not restrict our selection by sample characteristics, like age, gender, and ethnicity. Using 
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the reference lists checks, we obtained additional 4 articles. Finally, we identified studies 
that utilized differential expression analysis between depression and controls. This 
systematic search strategy allowed us to select 15 articles on the brain (not limited to 
specific brain areas) and 10 on peripheral tissues (Figure 2.1).  
Figure 2.1. Selection process flowchart 
 
Measure of replication as a review method 
Given that calculating the percentage of overlapping genes (POGs) to evaluate the 
replicability of the results across different studies is not a valid approach in a situation 
with unequal lengths of differentially expressed gene (DEG) lists (Zhang et al., 2009), we 
used replication of single differentially expressed gene across the studies both separately 
and together for brain and peripheral tissues studies. First, we manually extracted all 
DEGs between depression and healthy controls reported by each individual study and, 
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using the multi-symbol checker (HUGO Gene Nomenclature Committee, HGNC), 
checked if these genes were known by another name (synonyms, previous names). 
Second, we identified all replicated DEGs for brain regions and peripheral tissues.  Third, 
we performed functional annotation of replicated DEGs using Top Diseases and 
Functions Network Analysis (Ingenuity Pathway Analysis, IPA) (Figure 2). 
Figure 2.2. Workflow chart 
 
RESULTS 
Mapping the transcriptome signature of depression in the brain 
The complexity of brain function, the heterogeneous phenotype of depression and the 
inevitable limitations of post-mortem studies together create a serious problem of 
integration of multiple single gene findings into a systematic network level translatable 
into observable behaviours of depression. In this review, we attempt to compile multiple 
differential gene expression findings in depression and controls across different brain 
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regions. Transcriptomes from 12 cortical and 4 subcortical areas were derived using 
microarray and RNA-seq technologies. Over 500 genes were reported to be dysregulated 
in depression across the brain in 15 studies selected for this review. However, small 
sample sizes (ranging from 9 to 21 for MDD cases across 15 studies) in combination with 
whole-genome statistics make these findings sensitive to false positive results. Tracking 
genes replicated across multiple studies is one of the ways to increase the validity of the 
results without losing brain areas specificity.  
Replication of gene expression findings in the brain 
A thorough examination of 15 brain studies showed that 582 genes were differentially 
expressed between depression and controls. Without discriminating between the different 
brain regions there were 57 replicated DEGs (9.8%) (Table 2.1). That is each gene was 
differentially expressed in any brain area more than once irrespective of the directionality 
of expression. Only 28 genes out of the combined pool of 582 DEGs (4.8%) were 
replicated in the same brain area. Among them, 5 genes were dysregulated in opposite 
directions, which may be partially explained by methodological differences between the 
studies. Top Diseases and Functions analysis (IPA) of the 57 replicated DEGs suggests 
that these genes collectively are involved in neurological disease, connective tissue 
disorders, developmental disorder, psychological disorder, cell-to-cell signalling and 
interaction, cardiovascular system development and function, cellular assembly and 
organization, nervous system development and function, cellular development, 
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Table 2.1. The 57 replicated differentially genes expressed mapped to the 6 cortical areas 
in depression (BA 8/9, BA21, BA24, BA44, BA45, BA46). Genes are listed according to 
the Top Diseases and Functions networks identified by IPA. Blue represents 
downregulation, pink upregulation, yellow information is not available.  Numbers refer to 
the studies cited (see below) 




PMC PMC RSC PT










GRIA2 4 11 11
GRIA3 3 11 15
GRIA4
GRIK1 11
NPPC 1 11 13 11 13 11
NTRK2
PRKCI 8 14
SLC1A2 3 11 3 11 3 11 15
SNAP23
SNAP25 11 4
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PMC - Primary Motor Cortex, PC – Premotor Cortex, DLPFC – Dorsolateral Prefrontal Cortex, AnPC – 
Anterior Prefrontal Cortex, OC – Orbital Cortex, TC – Temporal Cortex, ACC – Anterior Cingulate Cortex, 
RSC – Retrosplenial Cortex, Pop – Pars Opecularis (part of the inferior frontal gyrus and part of Broca's), 
PT - Pars triangularis (part of the inferior frontal gyrus and part of Broca's area), POr - Pars orbitalis (part 
of the inferior frontal gyrus), Amy – Amygdala, LC – Locus Coeruleus, Nacc – Nucleus Accumbens, Hippo 
– Hippocampus 
Studies: 
1Aston et al. (2005), 2Bernard et al. (2011), 3Choudary et al. (2005), 4Duric et al. (2013), 5Iwamoto et al. 
(2004), 6Kang et al. (2007), 7Kohen et al. (2014a) 8Malki et al. (2015), 9Sequeira et al. (2006), 10Sequeira 
et al. (2007), 11Sequeira et al. (2009), 12Sibille et al. (2004), 13Sibille et al. (2009), 14Tochigi et al. (2008), 
15Klempan et al. (2009). 
 
The most replicated differentially expressed genes in the brain 
GABAergic and glutamatergic-related genes, which code for two major neurotransmitters 
in the brain (GABA, glutamate), show the most abundance in the replicated genes map 
with the highest dysregulation in prefrontal cortical areas, which are well known to be 
involved in mood regulation and depression (Table 2.1). However, the directionality of 
expression of GABAergic and glutamatergic-related genes across brain areas was 
inconsistent.  
The most widespread dysregulated gene across the brain is GLUL, a glutamatergic-
related gene coding for glutamate-ammonia ligase, which has been previously implicated 
in the pathophysiology of depression.  GLUL expression was dysregulated across 6 
cortical areas Brodmann Areas 8/9, 21, 24, 44, 45, and 46 (BA8/9, BA21, BA24, BA44, 
BA45, and BA46) and 2 subcortical areas (amygdala and locus coeruleus). However, the 
direction of dysregulation across different brain areas was not uniform, suggesting that 
GLUL, known to be involved in many biological functions, may be downregulated in one 
brain area/cell type and upregulated in another. Also noteworthy, the findings are 
conflicting for the two dorsolateral prefrontal cortical regions, BA46 and BA8/9.  Choudary 
et al. (2005) found GLUL to be upregulated in BA8/9, whereas Kang et al. (2007) showed 
that GLUL is downregulated in BA8/9; similarly, Sequeira et al. (2009) and Klempan et al. 
(2009) have found GLUL to be downregulated in BA46, while Choudary et al. (2005) 
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found it upregulated. This could possibly be explained by the differences in phenotype: 
MDD with unspecified cause of death (Choudary et al., 2005) vs. SMD – suicides with 
major depression (Sequeira et al., 2009, Klempan et al., 2009).  
The glutamate transporter gene SLC1A2, which has been previously shown to be 
dysregulated in depression, shows consistent dysregulation of gene expression across 
three brain areas: the dorsolateral prefrontal cortices (BA8/9, BA46) and anterior 
cingulate cortex (BA24).  Although dysregulation in BA8/9 and BA24 has been replicated 
twice and in BA46 three times, the direction of dysregulation is inconsistent. Choudary et 
al. (2005) found SLC1A2 to be upregulated in BA8/9, BA24 and BA46, whereas Klempan 
et al. (2009) found it to be downregulated in BA46. The directionality of dysregulation of 
SLC1A2 in BA8/9, BA24 and BA46 identified by Sequeira et al. (2009) was not reported. 
Another gene showing dysregulation across multiple brain areas is the GABRD - 
GABAergic gene, coding for gamma-aminobutyric acid type A receptor delta subunit, 
which was previously shown to play a role in depression (Feng et al., 2010). GABRD 
expression was consistently upregulated across 5 brain areas (BA6, BA8/9, BA44, BA45, 
and BA46) irrespective of phenotype (MDD vs. SMD) or sex (males only in Sequeira et 
al. (2009), Klempan et al. (2009), and both sexes in Choudary et al. (2005). This strongly 
suggests that upregulation of GABRD in aforementioned brain areas is related to 
depression for both males and females.  
Another group of consistently replicated genes are those from the serotonergic family, 
HTR1A, HTR1B, HTR2A, HTR2C, which were predominantly observed in the dorsolateral 
prefrontal cortex (BA8/9), pars orbitalis, part of the inferior frontal gyrus (BA47) (Sibille et 
al., 2004) and hippocampus (Duric et al., 2013). The HTR2A gene, in addition to BA8/9, 
BA47 and hippocampus, was also upregulated in the temporal cortex (BA21) (Sequeira 
et al., 2009) but downregulated in BA46 (Klempan et al., 2009). While these genes show 
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replication across different brain regions, none was replicated within the same brain area. 
Since serotonergic genes are known for their role in suicidal behaviour (Antypa et al., 
2013), interpretation of these replications in regards to depression only should be treated 
with caution as all four studies used the combined phenotype of depression and suicide.  
The PXMP2 gene, known to be involved in reactive oxygen species (ROS) metabolism, 
was replicated by three studies. The level of PXMP2 was found upregulated in the BA8/9, 
BA24, and BA46 (Choudary et al., 2005), downregulated in BA21 (Aston et al., 2005), 
and dysregulated in BA21 (Sequeira et al., 2009). 
The first RNA-seq study did not replicate microarray findings  
An important factor in brain research that is often not taken into account is the cellular 
heterogeneity of investigated brain areas. From which cells mRNAs are extracted may 
greatly affect the overall pattern of expression as functional distinct cells may express 
mRNAs in different amounts. To overcome this limitation, Kohen et al. (2014a) performed 
the first whole transcriptome sequencing (RNA-seq) of dentate gyrus (DG) granule cells 
captured by the challenging but powerful laser capture microdissection (LCM). None of 
27 genes (P<0.001) identified as significantly involved in shaping gene expression 
differences between depression and controls was replicated by any of the 14 reviewed 
brain whole-genome microarray studies. This suggests that the gene expression 
signature of depression is complex and further research on identifying the cell-specific 
patterns of expression across relevant brain areas is needed. 
Transcriptomic signature of depression at the periphery 
Given that blood and brain cells share 81.9% of the transcriptome (Liew et al., 2006), 
peripheral blood profiling gives us an opportunity to study some of the aspects of brain 
functioning in the absence of human neural tissue. Various types of peripheral blood cells 
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have been investigated in depression and gene expression studies, such as mononuclear 
cells (PBMCs) (Belzeaux et al., 2012, Liu et al., 2014, Segman et al., 2010), lymphocytes 
(Yi et al., 2012), CD4+ T cells (Wang et al., 2015), as well as dexamethasone (Menke et 
al., 2012) and lipopolysaccharides (LPS) (Spijker et al., 2010) stimulated, and 
unstimulated whole blood.   
Out of the combined pool of reported 752 DEGs, only 21 DEGs were replicated in an 
independent cohort. None of them have been replicated more than once across all 
reported studies. Moreover, only 8 out of 21 (38.1%) replicated DEGs showed a 
consistent direction of expression, whereas 11 were expressed in the opposite direction 
(52.3%), and for 2 genes the information about directionality was not available (9.5%) 
(Figure 2.3). This inconsistency creates a major obstacle for developing a peripheral 
blood biomarker panel for depression. 
The Top Diseases and Functions analysis (IPA) of the 21 overlapping DEGs identified in 
depression vs. healthy controls in the periphery highlighted the functional role of these 
genes in processes related to the cell cycle, cancer, cardiovascular disease, cellular 
assembly and organisation, cellular function and maintenance, amino acid metabolism, 
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Figure 2.3. Replicated differentially expressed genes identified in periphery cells in 
depression. Red dotted lines represent upregulation; blue downregulation; and, grey for 
directionally of expression not reported.  
 
 
Abbreviations: MDD – Major Depressive Disorder, PBMCs – peripheral blood mononuclear cells, PBLs – 
peripheral blood leukocytes 
Studies: 1Belzeaux et al. (2012), 2Garbett et al. (2015a), 3Jansen et al. (2016), 4Liu et al. (2014), 5Menke 
et al. (2012), 6Mostafavi et al. (2014), 7Segman et al. (2010), 8Spijker et al. (2010), 9Wang et al. (2015), 
10Yi et al. (2012). 
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Isolated cells vs. whole blood in biomarker research 
Using the measure of replication at the single gene level, we found that overall the results 
from isolated cell types had a better replication rate than results obtained using whole 
blood. This may partly be related to differential power, i.e. isolated cells with more specific 
signals yield high power for the same sample size, in comparison with whole blood, with 
multiple signals from different cell types.  The heterogeneity of depression also reduces 
statistical power. For instance, depression transcriptomes obtained from PBMCs showed 
overlap for 6 (Segman et al., 2010) and 7 (Belzeaux et al., 2012) DEGs across all studies 
with only 9 depression cases. On the other hand, the first deep RNA-seq of whole blood 
of 463 MDD cases and 459 healthy controls (Mostafavi et al., 2014) showed only 2 
overlapping genes from the list of the top DEGs, but failed to reach threshold for 
significance, DEGs (SEMA3, replicated by Garbett et al. (2015a) and IFIT3, replicated 
after Segman et al. (2010)). Although we show that transcriptomes obtained from isolated 
cells provide results with higher replicability, increased risk of spontaneous modifications 
in gene expression during cell isolation process should be considered when interpreting 
the results. 
Rather unexpectedly, the largest collection of replicated DEGs (9 out of 21) belongs to 
gene expression profiling study of dermal fibroblasts (Garbett, Vereczkei et al. 2015). 
Human dermal fibroblasts, due to their genetic and chemical stability during division in 
cell culture, are believed to be an experimental model for psychiatric research free of 
medication and lifestyle effects (Kalman et al., 2016) and have previously been used 
successfully for identifying cell cycle abnormalities in schizophrenia (Wang et al., 2010). 
This suggests that dermal fibroblasts may be fruitfully utilized as an accessible 
experimental model in depression gene expression research. 
Transcriptome signature of depression 
38 
 
Comorbidities of depression 
Depression is known for its high comorbidity with chronic somatic diseases, such as 
asthma, diabetes and cardiovascular disease.  It may also occur in pregnancy and post 
pregnancy periods. Emerging research suggests that the comorbidity may arise due to 
overlapping mechanisms between different medical conditions. For this reason, we 
included and compared the overlap between the only two transcriptome studies 
investigating comorbid phenotypes with our list of replicated depression-related DEGs, (i) 
depressive asthma (Wang et al., 2015) and (ii) postpartum depression (Segman et al., 
2010). Wang et al. (2015) hypothesized that asthma and depression were linked via 
overlapping molecules/pathways mediated by CD4+ T-cells, and therefore isolated them 
and performed transcriptome profiling. Among 156 genes identified as differentially 
expressed between depressive asthma and healthy controls, we found that 6 genes 
(ZNF333, PIK3R1, ZCCHC2, GNTAB, LMNA, and ABL1) overlapped with the findings 
from other studies on pure MDD phenotype; among 73 DEGs between postpartum 
depression and healthy controls, 5 DEGs (HIST1H4A, HIST1H4L, GSTT1, ASPM, and 
IFIT3) overlapped with pure depression phenotype findings; moreover, one gene, 
SERPING1, showed overlap between depressive asthma and postpartum depression. 
These support the hypothesis of overlapping mechanisms involved in pathophysiology of 
depression and non-psychiatric diseases.  
Stimulated blood cells challenge 
Challenged blood cells potentially have a better ability to overcome the noise of variation 
in expression in basal blood, which is of critical importance in the case of such a 
heterogeneous phenotype as depression (Elowitz 2002). However, studies on stimulated 
cells, which are expected to show better signal-noise discrimination, showed the smallest 
number of replicated DEGs. Using in vivo dexamethasone stimulation of glucocorticoid 
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receptors (GR) in males aged 18-65 (18 MDD cases), Menke et al. (2012) were able to 
demonstrate the GR-mediated changes in gene expression between depressed patients 
and healthy controls. They suggested that altered GR functioning could potentially be 
used as a molecular biomarker of depression. However, only one gene (SSH2) out of 19 
identified as a biomarker panel by Menke et al. (2012)  was recently replicated in a larger 
cohort of depressed patients (Jansen et al., 2016).  
Interestingly, one of the key GR binding proteins coded by the STAT3 gene was 
significantly differentially expressed (upregulated) in both PBMCs (Belzeaux et al., 2012) 
and unstimulated whole blood (Jansen et al., 2016), but did not reach significance in the 
dexamethasone stimulated study. 
The ex-vivo lipopolysaccharide (LPS) stimulation of whole blood suggested 12 top DEGs 
as a signature of depression (Spijker et al., 2010). However, only two genes, LMNA and 
CAPRIN1, were replicated by Wang et al. (2015) and Yi et al. (2012), respectively. 
Interestingly, LMNA was replicated in the depressive asthma phenotype study by Wang 
et al. (2015). Given that LMNA is associated with the most common type of 
cardiomyopathy, i.e. dilated cardiomyopathy (Lu et al., 2011), a disease of the heart 
muscle which primarily affects the left ventricle, a link between depression, asthma, and 
cardiovascular diseases is suggested. 
Interplay between brain and periphery in depression 
In an attempt to answer the question whether there is any interplay between the brain 
and periphery in depression at the replicated DEG level, we compared the lists of 
replicated DEGs for both brain and peripheral tissues. None of the replicated genes 
overlapped across both lists. This might suggest that there is no interaction between the 
CNS and periphery in depression at the replicated gene level. However, when we 
Transcriptome signature of depression 
40 
 
compared the results from top disease and functional annotation, we observed that both 
lists were overrepresented with cardiovascular system abnormality terms. We further 
investigated this using Top Functions and Disease Network tool (IPA), and found that 25 
out of 57 genes (43.9%) were replicated in the different brain areas in relation to 
depression (GRIA1, GRIA2, GRIA4, GABRA1, GABRA5, GABRB1, GABRG2, GABRG1, 
GABRD, HTR2C, HTR2A, HTR1A, SLC1A2, SNAP25, SAT1, MAPT, JUN, NR3C1, 
CREB1, MOG, NTRK2, PTK2B, AQP4, ADRA2A, S100B) also appeared to play a role in 
cardiovascular diseases, like coronary artery disease, peripheral vascular disease, 
hypertrophic response of cardiomyocytes, as well as permeability of vascular system and 
function of blood brain barrier (Figure 2.4). Furthermore, 6 out of 21 (28.6%) replicated 
depression-related DEGs in peripheral tissues (STAT3, LMNA, MYH9, SERPING1, 
PIK3R1, ABL1) were also involved in cardiovascular conditions, like dilated 
cardiomyopathy 1A, myopathy of heart, quality of cardiomyocytes, injury of heart, 
Slovenian type heart-hand syndrome, delay in initiation of leakage of capillary vessels, 
dilated cardiomyopathy with hypergonadotropic hypogonadism as well as permeability of 
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Figure 2.4. The 25 replicated genes identified as differentially expressed in depression 
at the genome-wide level in the brain and involved in the pathophisiology of 
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Figure 2.5. The 6 replicated genes identified as differentially expressed in depression at 
the genome-wide level in peripheral tissues and involved in the pathophisiology of 
cardiovascular diseases (Top Diseases and Functions Network analysis, IPA). 
 
These findings support the hypothesis that depression and cardiovascular diseases may 
share molecular pathways (Bondy, 2007), and suggests that there are complex molecular 
interactions between brain cortical and subcortical areas and peripheral tissues in a 
depression/cardiovascular comorbid phenotype. These findings may have clinical value, 
as the link between the two conditions at the molecular level may potentially lead to the 
development of drugs that provide treatment for both cardiovascular conditions and 
depression. 
DISCUSSION 
We reviewed the peripheral and brain genome-wide gene expression studies on 
depression.  To the best of our knowledge this is the first attempt to systematically 
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catalogue all reported differentially expressed genes in depression.  We observed 57 
replicated differentially expressed genes (DEGs) across different brain regions (based on 
15 studies) and 21 replicated DEGs in peripheral tissue (based on 10 studies).  Twenty-
eight of the brain DEGs were replicated in the same region.  There was no overlap 
between the replicated genes in the brain and the periphery.  Despite the replication, the 
directionality of dysregulation was highly inconsistent. 
Our results suggest that brain transcriptomes are in better agreement across studies than 
transcriptomes derived from peripheral tissues. However, this might simply reflect the fact 
that brain tissues (both genome-wide and candidate genes) in relation to depression are 
better investigated than peripheral tissues.   
The heterogeneity of the disease, dynamic nature of gene expression and the 
methodological differences between the studies all contribute to the observed low 
replication rate, which is the major obstacle for further progress in elucidating the 
mechanisms of depression. There are numerous technical factors that can potentially 
contribute to the observed inconsistencies across studies; however, this can be 
explained, at least partially, by biological factors. Given that mRNA abundance was 
measured in various cell types across multiple biological systems, the level and direction 
of gene expression may naturally differ by their functionality as different cell types perform 
different functions, and, therefore, the level of mRNAs can vary accordingly. Moreover, 
the state of disease changes over time, which is not necessarily reflected in a cross-
sectional analysis at a single time point. A major question yet to be resolved is how a 
particular gene in a specific cell type contributes to the global picture of the disease and 
whether there is an interaction between the brain and periphery in depression. 
There are several biological theories of the pathophysiology of depression, including 
altered hypothalamic–pituitary–adrenal axis (HPA) activity, monoamine deficiency, 
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neurotoxic and neurotrophic processes, reduced GABAergic activity, dysregulation of 
glutamate system, alteration of neuroimmune and cytokine activity, and impaired 
circadian rhythm (for review, see (Hasler, 2010)). Below we discuss how these findings 
relate to the major hypotheses of depression and suggest a new candidate to explain 
pathophysiological mechanisms of depression. 
EVIDENCE SUPPORTING THE MAJOR HYPOTHESES OF DEPRESSION 
Altered HPA axis activity 
Glucocorticoids are involved in regulation of many organs and systems in the body, 
including various brain regions and molecular mechanisms, including monoaminergic 
neurotransmission and the immune and metabolic systems. Despite numerous findings 
suggesting that altered HPA activity plays a role in the pathogenesis of depression 
(Schatzberg et al., 2014, Vreeburg et al., 2009, Hardeveld et al., 2014), examination of 
the effect of pharmacological modulations of the neuroendocrine system as 
antidepressant therapy has been limited (Maric and Adzic, 2013). Our findings highlight 
the glucocorticoid receptor, NR3C1 (see Table 2.1), which operates as a transcription 
factor in the regulation of gene expression (Lu and Cidlowski, 2005), as being 
dysregulated across the brain, i.e. downregulated in primary motor cortex (Sequeira et 
al., 2006) and upregulated in dorsolateral prefrontal cortex (BA8/9, BA46) (Sibille et al., 
2004). However, inconsistency in directionally of dysregulation together with lack of brain 
region-specific replications suggests only partial support for altered HPA-axis activity and 
this hypothesis of depression. 
Deficiency of monoamines 
The monoamine-deficiency hypothesis states that the pathophysiological basis of 
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depression is a depletion of the neurotransmitters serotonin, norepinephrine or dopamine 
in the CNS. In this review, we show replicated evidence that dysregulation of serotonin 
receptors A1, 1B, 2A, 2C (HTR1A, HTR1B, HTR2A, HTR2C) predominantly in the 
dorsolateral prefrontal cortices (BA8/9, BA46) and hippocampus is involved in the 
pathophysiology of depression (Duric et al., 2013, Sibille et al., 2004). The ADRA2A gene, 
coding for alpha-2A adrenergic receptor, which localizes post-synaptically to 
noradrenergic terminals and promotes the function of norepinephrine, was consistently 
downregulated in the dorsolateral prefrontal cortex (BA8/9), pars orbitalis (BA47) (Sibille 
et al., 2004) and pars triangularis, part of the inferior frontal gyrus and part of Broca's area 
(BA45) (Klempan et al., 2009). While two studies were in agreement on directionality of 
dysregulation of ADRA2A across the brain, there is no brain area-specific replication so 
far. Although there are recent findings that a dopamine genetic risk score can predict 
depressive symptoms (Pearson-Fuhrhop et al., 2014), we cannot provide support that 
dopaminergic-related gene expression is dysregulated in depression. While almost all 
established antidepressant drugs target the monoamine system, pointing towards the 
monoamine-deficiency hypothesis as the most clinically relevant theory of depression, 
the resistance to these drugs, the delayed treatment effects and only partial support of 
this hypothesis at the level of replicated findings suggest that the dysregulation in 
monoamine system alone cannot explain the full spectrum of pathophysiological events 
in depression. 
Altered neural plasticity and neurogenesis 
There is consistent evidence that untreated depression leads to brain volume shrinkage 
in advanced age (Dotson et al., 2009) as well as in middle-aged depression patients 
(Grieve et al., 2013). Numerous findings have collectively proposed increased 
glucocorticoid and glutamatergic neurotoxicity and decreased neurotrophic factors and 
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neurogenesis as possible mechanisms explaining brain volume loss in depression. 
However, the understanding of molecular events leading to structural changes and 
neurodegeneration remains elusive. Brain-derived neurotrophic factor (BDNF) has 
attracted considerable interest as the major known regulator of synaptic plasticity in the 
brain. Although we did not find evidence for dysregulated transcription of BDNF mRNA in 
depressed patients, the BDNF receptor – the Tyrosine receptor kinase B protein coded 
by NTRK2 – has been consistently found to be dysregulated across the cortex in 4 
independent studies (see Table 1); upregulated in the anterior prefrontal cortex (BA10) 
(Malki et al., 2015) and hippocampus (Sequeira et al., 2007), and downregulated in the 
dorsolateral prefrontal cortex, pars orbitalis (BA47) (Sibille et al., 2004) and temporal 
cortex (BA21) (Aston et al., 2005). Another candidate for supporting the neurotrophic 
hypothesis of depression is fibroblast growth factor receptor 3, coded by FGFR3, which 
plays an important role in controlling cell growth and development. The FGFR3 has been 
replicated in three studies, downregulated in the cortex (Kang et al., 2007, Evans et al., 
2004) and the subcortical locus coeruleus (Bernard et al., 2011). Therefore, there is 
partial support for the neurodegenerative hypothesis of depression. 
Reduced GABAergic activity 
GABA is the major inhibitory neurotransmitter in the brain that modulates ongoing activity 
of neuronal networks. GABA re-uptake from the synaptic cleft is one the mechanisms to 
regulate GABA activity. Eight subunits for GABA receptors (GABRA1, GABRA5, GARB1, 
GABRD, GABRG1, GABRG2, GABRR1, and GABBR2) have been found to be 
consistently dysregulated, predominantly upregulated, across multiple brain areas 
including BA6, BA8/9, BA44, BA45, and BA46 (Table 1). SLC6A1 - GABA transporter 
type 1, which functions to remove GABA from the synaptic cleft (Hirunsatit et al., 2009), 
has also been replicated as being downregulated in BA47 (Table 1). These findings 
mostly support the GABAergic hypothesis of depression. However, since the functionality 
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of GABA receptors is determined by specific subunit configurations (Anisman et al., 
2012), the highly complex mosaic of possible interactions creates a myriad of possible 
effects on brain activity. What the relationships between GABA receptor subunits altered 
in depression are, and how the brain area-specific patterns of GABA receptor/transporter 
dysregulations are related to depression remain questions to be investigated in further 
research. 
Dysregulation of glutamatergic system 
Glutamate is the major excitatory neurotransmitter in the brain that regulates synaptic 
transmission and plasticity by activating ionotropic glutamate receptors, AMPA and 
NMDA. We found evidence that all four genes coding for AMPA receptor subunits 
(GRIA1, GRIA2, GRIA3, GRIA4) were replicably upregulated across multiple brain areas 
(see Table 1) with one exception – GRIA3, coding for AMPA receptor subunit 3, which 
was found to be upregulated in dorsolateral prefrontal cortex (BA46) by Choudary et al. 
(2005) and downregulated by Sequeira et al. (2009) and Klempan et al. (2009). The 
glutamate metabotropic 3 receptor (GRM3) has been replicated as being downregulated 
in temporal cortex (BA20) and BA47 in suicides with major depression (Sequeira et al., 
2009, Klempan et al., 2009)  The function of SLC1A3 – glutamate aspartate transporter - 
is the termination of excitatory neurotransmission in CNS. The SLC1A3 was 
downregulated in the locus coeruleus, known to be involved in the physiological response 
to stress (Bernard et al., 2011). Another glutamate transporter that clears the 
neurotransmitter from the extracellular space at synapses, which is necessary for proper 
synaptic activation and the prevention of neuronal damage from excessive activation of 
glutamate receptors - SLC1A2, has been replicated in the dorsolateral prefrontal cortices 
(BA8/9, BA47), anterior cingulate cortex (BA24) and locus coeruleus (Table 2.1). 
However, the directionality of SLC1A3 dysregulation is inconsistent across different brain 
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regions as well as within the same brain area. Although these findings provide support 
for the glutamate system hypothesis of depression, the brain area-specific mechanisms 
of action and their effects on depressive behaviours require further investigation. 
Disturbed neuroimmune and cytokine activity 
There is growing evidence suggesting that cytokine-mediated neuroimmune disruptions 
contribute to the behavioural symptoms of depression (Loftis et al., 2010, McAfoose and 
Baune, 2009, Mills et al., 2013). Although we did not find support for the most promising 
candidates of the cytokine hypothesis of depression, like IL1B, IL6, and TNFα at the level 
of replicated genome-wide gene expression findings, it is worth noting that many genes 
from our replicated genes list are known to be involved in various aspects of immune 
responses. Using GO search (ImmPort database) we identified that (1) four replicated 
genes - FGFR3, ENPP2, PTP4A2, and CREB1 – are involved in the innate immune 
response; (2) three genes – CREB1, MOG, and JUN are heavily involved in various toll-
like receptor signalling pathways; (3) LEPR, which belongs to the gp130 family of cytokine 
receptors, is involved in cytokine-mediated signalling. These collectively suggest that 
altered immunological activation may play a role in depression via various pathways, 
possibly interacting with other pathological mechanisms of depression. 
Dysregulation of melatonergic system 
The melatonergic hypothesis of depression states that dysregulation of melatonin plays 
a principal role in sleep disturbances in depressed patients. Since serotonin is the 
precursor of melatonin, two systems – melatonergic and monoaminergic - become tightly 
tied together, providing new avenues for future research. Although this review cannot 
directly support the melatonergic hypothesis of depression, as we did not observe 
differential expression of membrane MT1/MT2 melatonin receptors, through which 
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melatonin exerts its action, nor for specific clock genes Per1 and Per2, we can provide 
indirect evidence for this hypothesis.  Transcription factor CREB1 - CAMP responsive 
element binding protein 1, which mediates norepinephrine-related mechanisms of 
melatonin secretion (Maronde et al., 2011), was dysregulated in depression compared to 
controls across the brain, being downregulated in the dorsolateral prefrontal cortex 
(BA8/9, BA47) (Sibille et al., 2004) and upregulated in the anterior prefrontal cortex 
(BA10) (Tochigi et al., 2008). However, it is not known why CREB1 is dysregulated in 
opposite directions in different brain areas and how it is related to depression. 
Novel candidate of pathophysiology of depression 
Replicated findings at the genome-wide gene expression level provide partial support for 
all major theories of depression. This clearly argues against a single theory and suggests 
that depression is etiologically a highly heterogeneous disorder. Moreover, replication of 
the genes that are not yet known to have a direct relationship with any of the existing 
theories of depression may navigate towards new molecular players in understanding the 
biology of depression. One of the most exciting findings is dysregulation of PXMP2 in 
dorsolateral prefrontal, anterior cingulate and temporal cortices. Peroxisomal membrane 
protein 2, coded by PXMP2 gene, is a channel-forming protein in a mammalian 
peroxisomal membrane (Figure 2.6). Peroxisomes are cell organelles primarily involved 
in lipid metabolism and reduction of reactive oxygen species (ROS), specifically hydrogen 
peroxide, which are critical for the normal functioning of the brain (Antonenkov and 
Hiltunen, 2012, Wanders and Waterham, 2006). Although oxidative stress been 
previously found to be implicated in depression, which is partially reflected by our finding 
highlighting replicated downregulation of LEPR and S100B in the brain and periphery, to 
the best of our knowledge, neither peroxisome functioning in general nor dysregulation of 
PXMP2 in particular, have ever been investigated in relation to mood disorders, including 
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depression. Taking into account findings pointing towards shared pathways between 
metabolic disorders and depression (Foley et al., 2010) and robust replication of this gene 
at the genome-wide gene expression level in depression, we suggest that dysregulation 
of PXMP2 may play a role in depressive disorder via the peroxisome lipid and ROS 
metabolism pathway. 
Figure 2.6. Peroxisome and the role of PXMP2 in lipid and reactive oxygen species 
(ROS) metabolism (KEGG pathway). 
 
Limitations 
Although replication of findings is a way to systematise the most robust findings at the 
single gene level, the approach itself can be viewed as a limiting factor for the findings 
that have not yet been replicated. Non-replicated results, especially those of high 
significance, are likely to have a biological value but cannot be included in this review of 
replicated findings. To overcome this limitation, more studies are needed. 
In the current review, we examined replication of gene expression results in the periphery 
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and the brain.  This approach has an obvious limitation as there are more parameters to 
consider, like phenotype definition (e.g. age of onset, diagnosis, method of recruitment, 
use of medication), sample characteristics including race, age and sex, microarray 
platform and statistical algorithms used. To include all those variables, a more hierarchical 
approach is needed.  
Another important limitation of this study is missing or incomplete information reported in 
the article. Given that we examined the genes derived from differential expression 
analysis only, we were expecting to find the full lists of DEGs either in the main body text 
or in the supplement materials. However, reporting only the top DEGs (with the lowest p-
value) is a common practice for transcriptome studies. A related limitation is that the 
choice DEGs was based on an arbitrary p-value threshold selected by the authors, which 
may differ between studies. To overcome these limitations authors are encouraged to 
provide the complete list of differentially expressed genes along with corresponding fold-
change and p-values.  
The small sample sizes are the common limiting issue for the microarray and RNA-seq 
studies due to the cost and difficulties in obtaining samples, particularly for brain studies. 
Global collaborative efforts at the consortia level in data collection, advancements in data 
analysis and good communication practices may help us to better understand the 
pathophysiological mechanisms of depression. 
Future directions 
Given that depression is a complex disease with overlapping activity across many 
systems, the key pathophysiological mechanisms can be obscured when investigated by 
measuring the relative difference in mRNA abundance between cases and controls. 
Growing interest in investigation using coexpression (Zhang and Horvath, 2005) and 
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differential coexpression (Zheng et al., 2014) network analyses, which measure the 
coordinated coexpression patterns between the genes, can provide a far more detailed 
and complete picture of the pathophysiology of depression. The observation that 
differentially expressed genes reside at the periphery of the co-expression networks in 
depression (Gaiteri et al., 2010a, Gaiteri et al., 2014) suggests that differential expression 
technique is not an optimal method to detect the key regulatory genes. This observation 
is consistent with the heterogeneous nature of disease and may partially explain the 
limited therapeutic effect of currently available antidepressant drugs, as pharmacological 
modulation of one or even a set of genes with low connectivity are likely to have minimal 
effect on key regulators. Network-based methodologies as part of systems biology 
approach are promising innovations that can provide new insights into molecular 
processes underlying the pathophysiology of depression, which potentially can lead to 
development of clinical biomarkers required for diagnosis, drug development and 
improved treatment of depression.  
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FROM A SINGLE GENE TO A NETWORK OF COMPLEX INTERACTIONS 
In the first chapter, the gene expression signature of depression based on a large body 
of previously obtained findings in both brain and peripheral tissues covering 16 brain 
regions and five cell types from the peripheral nervous system was examined.  We found, 
that out of 1,334 genes reported as differentially expressed across 25 transcriptome 
studies of depression, only 57 genes in the brain and 21 in the peripheral tissues were 
replicated, highlighting large inconsistencies across the studies. An overlap in genetic 
expression between the brain and peripheral tissues was also observed which strongly 
implicated a link between depression and cardiovascular disease.  
This study suggests that depression is associated with dysregulated expression of 
multiple genes (at least several hundreds), supporting multiple theories of the underlying 
biological mechanisms of depression. In-silico functional characterisation of ‘replicated’ 
genes using Ingenuity Pathway Analysis (IPA) indicated that these genes are involved in 
many biological functions, such as cell cycle, cellular function and maintenance, cellular 
death and survival. Given the nature of biological systems, these individual genes are 
unlikely to act in isolation: instead, they interact with each other forming complex 
molecular networks. These interacting genes can be involved in various biological 
processes, therefore affecting multiple molecular pathways, the dysregulation of which 
may lead to depression. Examining the global network of co-expressed genes at the 
genome-wide level will help in understanding which known molecular pathways are 
dysregulated within depression therefore providing the insights into the molecular 
underpinnings of the disorder. 
In the next chapter, we explore which patterns of co-expressed genes are associated with 
depression and whether these patterns are functionally meaningful. This work consists of 
four major steps: (1) investigation into the network structure of peripheral blood 
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transcriptome using an unsupervised data mining technique, Weighed Gene Co-
expression Network Analysis (WGCNA), (2) identification of which clusters/modules of 
tightly co-regulated genes are associated with MDD disease status, (3) examination of 
which molecular pathways appear to be altered in depression using in-silico functional 
characterisation of MDD-related clusters, and  (4) replication of the findings on an 
independent cohort.  
This study has the potential to improve our understanding of biological underpinnings of 
depression, pinpoint specific biological markers and suggest which molecular pathways 
are dysfunctional in depression. 












Co-expression network analysis of peripheral blood transcriptome 
identifies dysregulated protein processing in endoplasmic reticulum 




The molecular factors involved in the pathophysiology of major depressive disorder 
(MDD) remain poorly understood. One approach to examine the molecular basis of MDD 
is co-expression network analysis, which facilitates the examination of complex 
interactions between expression levels of individual genes and how they influence 
biological pathways affected in MDD. Here, we applied an unsupervised gene-network 
based approach to a prospective experimental design using microarray genome-wide 
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gene expression data derived from the peripheral whole blood of older adults. We utilised 
the Sydney Memory and Ageing Study (sMAS, N=521) and the Older Australian Twins 
Study (OATS, N=186) as discovery and replication cohorts, respectively. We constructed 
networks using Weighted Gene Co-expression Network Analysis (WGCNA), and 
correlated identified modules with four subtypes of depression: single episode, current, 
recurrent, and lifetime MDD.  Four modules of highly co-expressed genes were 
associated with recurrent MDD (N=27) in our discovery cohort, with no significant findings 
for a single episode, current or lifetime MDD. Functional characterisation of these 
modules revealed a complex interplay between dysregulated protein processing in the 
endoplasmic reticulum (ER), and innate and adaptive immune response signalling, with 
possible involvement of pathogen-related pathways.  We were underpowered to replicate 
findings at the network level in an independent cohort (OATS), however; we found a 
significant overlap for 9 individual genes with similar co-expression and dysregulation 
patterns associated with recurrent MDD in both cohorts. Overall, our findings support 
other reports on dysregulated immune response and protein processing in the ER in MDD 
and provide novel insights into the pathophysiology of depression. 
INTRODUCTION 
Major depressive disorder (MDD) is a leading cause of disability worldwide and is one of 
the major contributors to the overall global burden of disease spanning all age groups 
(Ferrari et al., 2013, Whiteford et al., 2015, Vos et al., 2016). While MDD is relatively 
uncommon among older adults, epidemiological studies suggest that clinically significant 
depressive symptoms affect between 7% and 49% of community-dwelling older adults, 
substantially affecting the quality of life in later years (Riedel-Heller et al., 2006). MDD is 
highly heterogeneous with regards to its clinical phenotypes (Fried, 2017), course of 
symptoms (Posternak et al., 2006), responses to treatment (Uher and Pavlova, 2016), 
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and longer-term functional outcomes (Prisciandaro and Roberts, 2008).  Major biological 
hypotheses of MDD have included altered hypothalamic–pituitary–adrenal (HPA) axis 
activity (Pariante and Lightman, 2008), deficiency of monoamines (Hirschfeld, 2000), 
altered neural plasticity and neurogenesis (Jacobs et al., 2000), oxidative stress (Maes 
et al., 2011), dysregulation of GABAergic, glutamatergic (Luscher et al., 2010, Pan et al., 
2018) and melatonergic (Srinivasan et al., 2009) systems, and dysregulated 
neuroimmune pathways (Wohleb et al., 2016, Leday et al., 2018).  
High-throughput methodologies which allow screening for a large number of biological 
substrates for molecular differences between MDD patients and healthy controls in 
hypotheses-free paradigms are a promising avenue towards improving our understanding 
of the disorder. Several genome-wide association studies (GWAS) in MDD have indicated 
that the genetic architecture of MDD is complex, with many polymorphisms of small effect 
contributing to the clinical phenotype in middle-aged adults (Cai et al., 2015, Okbay et al., 
2016, Hek et al., 2013, Wray et al., 2017, Hyde et al., 2016) as well as in late-life 
depression (Tsang et al., 2017). Studying global gene expression is an emerging and 
continually growing field that can shed light on the molecular underpinnings of depression 
that can lead to the development of biology-based diagnostic tools and novel 
pharmacological therapies. A recent systematic review of 25 transcriptome studies found 
that over 1200 genes have been reported as differentially expressed in MDD compared 
to controls in the brain, and peripheral, tissues (Ciobanu et al., 2016). Replicability of 
these findings, however, has been minimal, which may be attributed to differences in 
methodological and statistical applications, small sample sizes, false positives, and the 
inherent dynamic and cell-specific nature of gene expression. In addition, clinical 
heterogeneity has been recognized as a major limiting factor for robust characterisation 
of gene expression alterations in MDD. For example, the first RNA sequencing study of 
463 lifetime MDD cases, consisting of a mixture of individuals with current and remitted 
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MDD, found no differentially expressed genes between cases and controls (Mostafavi et 
al., 2014). In contrast, stratification of the phenotype into “current” and “remitted” MDD 
yielded 18 genes differentially expressed between control and current MDD groups 
(FDR<0.05) (Jansen et al., 2016). These findings have yet to be replicated. Thus, 
studying transcriptomic patterns among more homogeneous subgroups of MDD patients 
has the potential to improve the identification of a biomolecular signature of depression.  
A challenge in interpreting gene expression data is that ‘candidate’ genes do not function 
in isolation but rather interact in complex networks which can affect clinical phenotypes. 
Weighted gene co-expression network analysis (WGCNA) is a hypothesis-free systems 
biology approach that identifies ‘modules’ of co-regulated, and therefore functionally 
related, genes in a given phenotype (Langfelder and Horvath, 2008), extending classic 
bivariate approaches.  
In this study, we aimed to investigate the relationship between global gene co-expression 
profiles and MDD subgroups. Utilising a 6-year prospective community-dwelling sample 
of relatively healthy elderly people from the sMAS, we applied WGCNA, and explored the 
correlation of co-expressed modules with four phenotypes: (a) a lifetime diagnosis of 
MDD, (b) a single episode of MDD diagnosed during the study, (c) current episode of 
MDD, and (d) recurrent MDD diagnosed during the study. We then sought to replicate our 
findings in a second, independent cohort drawn from the Older Australian Twins Study 
(OATS), Australia.  
METHODS 
Discovery cohort 
The Sydney Memory and Aging Study (sMAS) was initiated in 2005 to examine the clinical 
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characteristics and prevalence of mild cognitive impairment and related syndromes, 
including depression, in a relatively healthy aged population aged 70-90 years at 
recruitment (N=1,037) (Sachdev et al., 2010). The phenotype data were collected at four 
time points with 2-year intervals between assessments. Blood samples for gene 
expression analyses were collected at Wave 4 (N=521), six years after baseline data 
collection. 
Replication cohort 
To conduct the replication analyses we utilised the Older Australian Twins Study (OATS) 
(N=623).The primary aim of OATS is to investigate healthy brain ageing in older twins 
(65+ years) (Sachdev et al., 2009). Depression data were collected at three time points 
with 2-year intervals between assessments. Blood samples for gene expression analyses 
were collected at Wave 3, four years after baseline (N=186).  
Informed consent was obtained for all participants and study procedures were explained 
prior to study commencement. 
MDD definition 
MDD was assessed by two well-validated self-report, and two clinical interview-based, 
measures of depression including the Geriatric Depression Scale (GDS-15) (cut-off ≥ 6) 
(Yesavage et al., 1982), the Patient Health Questionnaire (PHQ-9) (cut-off ≥ 10) (Kroenke 
K and R., 2002), the Neuropsychiatric Inventory (NPI) (depression sub-scale) (Cummings 
et al., 1994), and the Mini International Neuropsychiatric Interview (M.I.N.I.) (Sheehan et 
al., 1998). To make use of all measures available, a “minimum by two” approach for 
defining MDD was employed. Accordingly, MDD cases were defined as participants who 
were identified as clinically depressed by at least two of the above depression measures 
at any one study Wave, according to DSM-IV criteria. Using this approach, four subgroups 
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of depression were formed: a) lifetime diagnosis of MDD, b) a single episode of MDD, c) 
current diagnosis of MDD and d) recurrent MDD (details in Appendix A). 
Gene expression data acquisition and pre-processing 
Total RNA from whole blood collected in PAXgene tubes after overnight fasting was 
extracted using the PAXgene Blood RNA System (PreAnalytiX, QIAGEN). The RNA 
samples with RIN ≥ 6 were used in subsequent analyses (Gallego Romero et al., 2014). 
Purification, amplification, labelling, and microarray hybridization were carried out using 
the Illumina Whole-Genome Gene Expression Direct Hybridization Assay System 
HumanHT-12 v4 (Illumina Inc., San Diego, CA, USA) according to standard manufacturer 
protocols. Quality control (QC) and pre-processing of raw gene expression intensity 
values extracted from GenomeStudio (Illumina) were performed within the R statistical 
environment. The pre-processing steps included: (1) background correction by Maximum 
Likelihood Estimation (MLE) algorithm using Model-based Background Correction for 
Beadarray (MBCB) R package, (2) the Variance-Stabilising Transformation (VST), (3) 
quantile normalisation, and (4) two-stage filtering by detection p-value (p<0.01 in ≥50% 
of samples) and by coefficient of variation under threshold of 0.01. Data were adjusted 
for batch and RINs effects using Empirical Bayes-moderated linear regression 
implemented in empiricalBayesLM function (WGCNA package); control for non-biological 
latent noise was performed using sva function (Leek et al., 2012) (details in Appendix A). 
Co-expression network analysis 
WGCNA was performed with the WGCNA R package, as previously described 
(Langfelder and Horvath, 2008). In short, this method selects the threshold for 
constructing the network based on the scale-free topology of gene co-expression 
networks. Using biweight mid-correlation, which is a robust alternative of Pearson’s 
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correlation (Langfelder and Horvath, 2012), we computed the networks for several 
thresholds and selected the threshold β=6, which led to a network with scale-
free topology. The network consisted of multiple modules of functionally related genes on 
the basis of their expression patterns. Module eigengenes (MEs), i.e., the first principal 
components of the standardized gene expression profile of a given module, were tested 
for correlation with binary measures of depression subtypes versus the rest of the cohort. 
The MEs were used to define measures of module membership (MM) by correlating the 
gene expression profile of each gene in a module with the ME of a given module. The 
gene with the highest MM was defined here as the top hub gene of a given module. Gene 
significance (GS) was computed as hybrid robust-Pearson’s correlation (Langfelder and 
Horvath, 2012) between gene expression and MDD status. Module Membership (MM) vs. 
Gene Significance (GS) measure was used to assess how representative each gene is 
of the module and its importance for MDD. 
Cell-type specific gene expression  
We examined whether known cell type-specific markers of expression (Aran et al., 
2017) were driving depression-related gene expression signatures by calculating 
relative proportions of cell type-specific markers in defined MDD-related modules 
(details in Appendix A). 
Functional analyses 
To functionally characterise modules of interest we used two strategies: (1) examined 
the significance of pathway enrichment in a gene list of each module with a modified 
Fisher’s exact test (FDR < 0.5) using the Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) (Huang da et al., 2009b, Huang da et al., 2009a) with the 
genes which were included in the WCGNA as background, and (2) performed Signalling 
Pathway Impact Analysis (SPIA) (Tarca et al., 2009) implemented in the SPIA R 
package. SPIA uses the information from differentially expressed genes and their fold 
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changes (derived using limma R package (Ritchie et al., 2015) for each module 
separately), as well as pathways topology in order to assess the significance of the 
pathways. We used the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa 
and Goto, 2000) database to run the SPIA algorithm. These functional analyses were 
performed for the modules correlated with recurrent MDD phenotype only (details in 
Appendix A) 
Replication study 
Data from 186 unrelated OATS participants (one twin from each pair, randomly selected) 
were used for replication analyses. To assess comparability between sMAS and OATS 
gene expression datasets, we computed Pearson’s correlations between ranked 
expressions and ranked connectivity for probes that were expressed in both data sets 
(Miller et al., 2010). To conduct replication analyses we (1) extracted the OATS data for 
the transcripts that represented the sMAS depression-related modules, (2) computed 
MEs for these pre-constructed modules in the replication cohort, (3) correlated these MEs 
with a binary phenotype of recurrent MDD, and (4) tested for statistical significance of the 
overlap between two groups of recurrent MDD-correlated genes in two datasets (details 
in Appendix A). 
RESULTS 
Cohort characteristics 
The sMAS sample consisted of 521 individuals aged over 76 (age range 76.4-95.9, mean 
age 83.7±4.5), 255 males and 266 females. Utilising the prospective nature of this study, 
four subgroups of MDD were defined. Statistical tests of independence showed that there 
were no differences between cases and controls for age, sex or BMI in neither of MDD 
patient subgroups (Table 3.1).  
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Table 3.1. Summary of MDD patient subgroups and statistical test of independence for 




Weighted gene co-expression network analysis 
After pre-processing, 11 018 probes corresponding to 9 041 genes were used for 
downstream analyses. Using WGCNA we constructed a co-expression network for 521 
samples and identified 24 distinct modules of various sizes (details in Appendix A).  
Four gene co-expression modules are associated with recurrent MDD, but no module 
association was found for lifetime, single episode or current MDD 
No association between any of the identified module eigengenes and lifetime, single 
episode or current MDD was observed. However, the eigengenes of four modules 
(denoted by colour) were significantly associated with recurrent MDD: 1) turquoise (r = -
0.12, p = 0.007), 2) tan (r = 0.1, p = 0.02), 3) black (r = 0.09, p = 0.04), and 4) lightcyan 
(r = 0.09, p=0.04) (Figure 3.1).  However, only turquoise module remained significant after 
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using Benjamini-Hochberg procedure at 0.2 FDR for 24 tests. The lightcyan module was 
also associated with sex (r = -0.13, p = 0.03). The MEs of turquoise, tan, and black 
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Figure 3.1. Heatmap plot of correlations between the module eigengenes (ME) of 
Turquoise, Tan, Black, Lightcyan modules and single episode of depression (SD), current 
(CD), recurrent (RD), and lifetime depression (LD), age, sex and BMI. Associated p-
values are indicated in parenthesis with significant values bolded. 
 
 
Relationship between MM and GS for recurrent MDD 
We found a highly significant positive correlation between MM and GS measures for all 
four modules, indicating that those individual genes that were statistically representative 
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Figure 3.2. Scatterplots depicting correlations between Module Membership (MM) and 
Gene Significance (GS) for Turquoise, Tan, Black, and Lightcyan modules, eigengenes 




In total, 1 241 probes were nominally associated with recurrent MDD across four modules 
(GS, p < 0.05); 761 probes remained significant after transcriptome-wide correction for 
multiple testing (FDR at 0.2) (Online Supplementary Tables S1, S2, S3, S4). 
Immune cells-specific markers of expression for recurrent MDD-related modules 
We defined gene expression signatures for six immune cell types – B cells, CD4+ T cells, 
CD8+ T calls, monocytes, neutrophils and NK cells – using in-silico estimation method 
(Aran et al., 2017). We found that turquoise module is likely to be influenced by these 
immune cell types; only negligible number of cell-specific markers was found in tan, black 
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and lightcyan modules. 
The effect of smoking on the findings 
To examine the potential effect of smoking on our results, we checked whether our 
modules of interest contain any genes the expression of which can be effected by 
smoking (Vink et al., 2017, Huan et al., 2016). We found that the Turquoise module 
contained several smoking-related genes (CLDND1, MM=0.78; MTSS1, MM=0.5; PASK, 
MM=0.3). However, we observed that these genes were not associated with recurrent 
MDD status and had moderate to low MM value;  none of the hub genes (with MM>0.9) 
checked across four modules have been previously found associated with smoking, 
suggest that smoking is unlikely to have a large effect of these findings. 
Enrichment and signalling impact pathway analyses  
Enrichment analyses highlight downregulation of genes involved in protein processing in 
Endoplasmic Reticulum (ER) in recurrent MDD 
Using DAVID we identified the biological pathways that were significantly over-
represented in each of the four modules. The two most relevant pathways associated with 
turquoise module were: protein processing in ER (FDR = 2.8e-06) and COPII (Coat 
Protein 2) Mediated Vesicle Transport (FDR = 2.7e-06). We also found significant 
enrichment for mRNA Splicing, antigen processing: ubiquitination & proteasome 
degradation, ubiquitin mediated proteolysis, and macroautophagy pathways in turquoise 
module (Table 3.2). Given that over 79% of transcripts in turquoise module were 
downregulated (2250 downregulated, 595 upregulated), and the correlation between ME 
and recurrent MDD was negative (r = -0.12, p = 0.007) we concluded that downregulation 
of turquoise module may play an important biological role in recurrent MDD. The black 
module was enriched with the hemoglobin's chaperone pathway (FDR = 0.008). There 
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was no pathway enrichment for tan and lightcyan modules at the FDR ≤ 5% level. 
Table 3.2. Pathway enrichment analysis on the modules associated with recurrent MDD 
in older adults 
 
 
Pathway enrichment analyses were performed using DAVID. As a background gene set, we utilised 9 041 
genes used for network construction. 
NP – the number of genes in the pathway, NM – the number of module genes featured in the pathway, FE 
– fold enrichment 
 
SPIA identifies dysregulation of biological pathways involved in innate and adaptive 
immune response, protein processing in ER and host-defence response to infectious 
pathogens in recurrent MDD 
To further detail how dysregulation of individual genes within each module affects specific 
pathways we selected module probes with GS p<0.05 (963 in turquoise, 117 in tan, 99 in 
black, 62 in lightcyan) and conducted SPIA. This analysis showed what biological 
pathways were affected by module genes that were differentially expressed in recurrent 
MDD. We found that 13 biological pathways were dysregulated in recurrent MDD at FDR 
≤ 5%: 12 in turquoise module and 1 in tan module; there were no pathways identified for 
black and lightcyan modules (Table 3.3). In turquoise module, the following pathways 
were activated: Fc gamma R-mediated phagocytosis, Shigellosis, mTOR signaling 
pathway, Antigen processing and presentation, Herpes simplex infection, Insulin 
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signaling pathway, Pathogenic Escherichia coli infection, RNA degradation, Epstein-Barr 
virus infection, Protein processing in ER, and Apoptosis pathways; while T cell receptor 
signaling pathway was inhibited. SPIA was also consistent with the over-representation 
analysis (Table 3.2) and further detailed that protein processing in ER pathway was 
activated in recurrent MDD (FDR adjusted global p-value = 0.04). Natural killer cell 
mediated cytotoxicity was the only affected (inhibited) pathway in tan module.  
 
Table 3.3. Signaling Pathway Impact Analysis (SPIA) on the modules associated with 
recurrent MDD in older adults. 
          
 
NP - the number of genes on the pathway; NDE - the number of DE genes per pathway; tA - the observed 
total perturbation accumulation in the pathway; pNDE - the probability to observe at least NDE genes on 
the pathway using a hypergeometric model; pPERT - the probability to observe a total accumulation more 
extreme than tA only by chance; pG - the p-value obtained by combining pNDE and pPERT; pGFdr - the 
False Discovery Rate adjusted global p-values; Status - the direction in which the pathway is perturbed 
(activated or inhibited). A web link to the KEGG website that displays the pathway image with the 








After QC and pre-processing following the same criteria as in the discovery analyses in 
sMAS, 11 685 probes for 186 individuals aged 69 and over from the OATS cohort (age 
range 69.4 – 93.5, mean age 75.9±5.3, 72 males and 114 females) were utilised for 
replication. High correlations for ranked expression (cor=0.99, p<e-200) and connectivity 
(cor=0.87, p<1e-200) and high module preservation calculated for 10 654 probes 
expressed in both datasets indicated these cohorts were comparable (details in Appendix 
A). 
Significant overlap between MDD-related genes in discovery and replication cohorts 
We computed MEs for turquoise, tan, black, and lightcyan modules in OATS and 
examined their correlations with a binary phenotype of recurrent MDD (N = 7 cases), age, 
sex, and BMI. Although, there was no association between the MEs and recurrent MDD 
in the replication dataset (Table S1.6), the directions of associations were consistent with 
the discovery results (Figure 3.1). Despite the lack of replication at the eigengene level, 
we observed a significant overlap of 9 individuals genes across four modules (p<0.03) 
that showed association with recurrent MDD in both cohorts (p<0.05): 7 genes in 
turquoise module (CTSC, ORMDL1, NARG1L, B4GALT4, GTF2H1, AGAP6, and 
THEMIS), 1 gene in tan module (IL5RA), and 1 gene in lightcyan module (SNX22), 
whereas no genes replicated in black module. These 9 genes showed moderate to high 
correlation with the ME of the relevant module respectively (0.3>MM<0.9) of similar 
strength of correlations across both cohorts. The directionality of dysregulation (GS) was 
also consistent for 8 out 9 genes across both cohorts (Appendix A, Table S1.7). There 
was no correlation between ME and age, sex, or BMI, suggesting that our replicated 
findings are independent of the effect of these potential confounders (Appendix A, Table 
S1.6). 




We explored the gene co-expression patterns in peripheral whole blood related to lifetime 
history of MDD, single episode, current, and recurrent MDD subtypes in older adults. 
While no significant association between gene expression and lifetime depression, single 
episode, or current depression was found, interesting results were obtained for recurrent 
MDD that forms a subgroup of depression with higher severity. Consistent with previous 
genetic findings that depression is a disorder of multiple genes of small effects, we 
identified four modules of highly co-expressed genes (a total of > 3000 genes) of which 
the eigengenes were significantly associated with recurrent MDD. We found that eleven 
biological pathways, namely Fc gamma R-mediated phagocytosis, Shigellosis, mTOR 
signaling pathway, Antigen processing and presentation, Herpes simplex infection, 
Insulin signaling pathway, Pathogenic Escherichia coli infection, RNA degradation, 
Epstein-Barr virus infection, Protein processing in ER, and Apoptosis pathways, were 
activated; and two pathways, T cell receptor signaling and Natural killer cell mediated 
cytotoxicity, were inhibited in recurrent MDD.  While we could not replicate association 
between the eigengenes and recurrent MDD in the independent cohort, which is likely 
due to insufficient statistical power, there was a significant overlap of recurrent MDD-
related individual genes: 9 genes (CTSC, ORMDL1, NARG1L, B4GALT4, GTF2H1, 
AGAP6, THEMIS, SNX22, and IL5RA) were associated with recurrent MDD with highly 
preserved co-expression and dysregulation patterns between the two cohorts.  
There are several notable results that we could not replicate.  
Downregulated ribosomal protein (RPS6KB1) in Fc gamma R-mediated phagocytosis 
and mTOR signalling  
The top biological pathway associated with recurrent MDD was Fc gamma R-mediated 
phagocytosis, which plays an essential role in host-defence mechanisms through the 
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uptake and destruction of infectious pathogens. Activation of this pathway was 
represented by downregulated RPS6KB1 and ARPC5 and upregulated WASF2 and 
ASAP1. It is worth noting that dysregulation of these genes was consistent in both 
discovery and replication cohorts, however, we failed to replicate the association of these 
genes with recurrent MDD at the accepted level of significance. The top gene involved in 
activation of Fc gamma R-mediated phagocytosis was ribosomal protein S6 kinase B1 
(RPS6KB1), which encodes a protein that responds to mTOR signalling to promote 
protein synthesis, cell growth, and cell proliferation.  RPS6KB1 was one of the hub genes 
in turquoise module in both sMAS (MM = 0.83) and OATS (MM = 0.89), indicating its 
important coordinating role in downstream processing. Consistent with our blood findings, 
RPS6KB1 was previously found downregulated in the PFC (Brodmann’s area 10) in 
patients who experienced depression for an average of 9.6 (± 3.6) years and died from 
suicide (Jernigan et al., 2011). Findings that dysregulation of RPS6KB1 is detectable in 
the brain and observable in peripheral blood, provide evidence that RPS6KB1 may be a 
potential biomarker for depression. Interestingly, RPS6KB1 was also recently proposed 
as a novel antidepressant target; it has been shown that enhanced RPS6KB1 activity in 
the medial prefrontal cortex produced antidepressant-like effects and resilience to chronic 
stress, whereas decreased RPS6KB1 activity produced pro-depressive behaviour in rats 
(Dwyer et al., 2015).   
Activated pathogen-related pathways  
Activation of Fc gamma R-mediated phagocytosis pathway along with activation of 
infectious pathogen-related pathways, such as Shigellosis, Herpes simplex infection, 
Pathogenic Escherichia coli infection, and Epstein-Barr virus infection in infectious 
disease-free recurrently depressed individuals may indirectly indicate a possible link 
between past pathogenic infection and recurrent MDD. Such a link has been previously 
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observed in epidemiological research. A large nationwide, prospective cohort study found 
that any history of hospitalisation for infection increased the risk of mood disorders, 
including depression, in later life by 62% (Benros et al., 2013). Pathogens are known to 
be able to influence host response processes, long after a viral load was undetectable 
(Traylen et al., 2011). Importantly, it has been shown that latent viruses can reactivate 
their replication in response to stress (Coskun et al., 2010) and ageing (Padgett et al., 
1998, Thomasini et al., 2017). Furthermore, SIRT1, a longevity-promoting gene, which is 
known to have an antiviral role (Kim et al., 2016), and was previously associated with 
depression in a GWAS (rs12415800, p=1.92e-08) (Cai et al., 2015), was also 
downregulated in recurrent MDD in our study (r = -0.11, p = 0.01). Moreover, SIRT1 was 
one of the hub genes in turquoise module (MM = 0.86), suggesting an important 
regulatory role in depression in older adults. Although speculative, our study suggests 
that there is a link between activation of pathogen-related pathways and depression in 
later life. 
Dysregulated protein processing pathways in the ER and innate and adaptive immune 
responses  
Emerging evidence suggests that dysregulated protein processing in the ER, leading to 
accumulation of misfolded proteins and causing ER stress, plays an important role in the 
pathophysiology of depression (Gold et al., 2013, Gold, 2015). In our study, we found that 
11 ER genes were dysregulated in recurrent MDD (STT3B, DNAJB11, DNAJC10, 
TRAM1, DERL1, SSR1, NPLOC4, UBQLN2, MAPK9, UBE2D2, UBE2D3) suggests 
impaired protein processing in the ER.  
We also found that several immune response-related pathways, such as antigen 
processing and presentation, T cell receptor signalling, apoptosis, and NK cell-mediated 
cytotoxicity are dysregulated in recurrent MDD. It is well known that impaired protein 
processing in the ER leads to ER stress. To prevent ER stress-related cell damage, the 
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ER uses unfolded protein response signalling to influence immune responses such as 
antigen presentation and immunoglobulin synthesis (Janssens et al., 2014). 
Substantiating this, antigen processing and presentation pathway was found to be 
activated by upregulated KIR2DL1, KIR2DS5 (killer cell immunoglobulin-like receptors), 
CTSB (amyloid precursor protein secretase), and downregulated CTSS (involved in the 
degradation of antigenic proteins to peptides for presentation on MHC class II molecules) 
in recurrent MDD. 
Our findings are in line with the largest transcriptomic study of MDD (Jansen et al., 2016), 
which identified that NK cell-mediated cytotoxicity pathway is implicated in MDD. 
Specifically, the authors found that TNFRSF10C was associated with a change in MDD 
status over 2-years, i.e. while upregulated in current MDD, the mean expression 
decreased more in recovered MDD than in the controls. Consistent with these findings, 
we show that upregulated TNFRSF10C and KIR3DL2 can induce the inhibition of NK cell-
mediated cytotoxicity pathway in recurrent MDD. We also support recent findings on 
changes in immunological profile in MDD (Leday et al., 2018). Authors proposed the 
transcriptional biomarkers panel, consisting of 165 genes differentially expressed 
between MDD cases and controls. We observed that 24 genes from this panel belong to 
the recurrent MDD-associated modules in our study (Supplementary materials, Table 
S15).  
The notable strength of this study is the utilisation of various clinical subtypes of 
depression in conjunction with a longitudinal assessment of participants. However, use 
of blood, the small size of depression subgroups, reliance on self-report for diagnosis, 
and a single time point for gene expression are the major limiting factors in our study. 
Using a population design for our analyses (i.e. each subgroup of MDD was contrasted 
against the rest of the population irrespective their depression status) can be viewed as 
a limitation since the control group could include people with a history of depression; 
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however, this might be of value in that it allows to compare different depression groups 
against each other (e.g. current vs recurrent vs lifetime). WGCNA as a non-supervised 
exploratory technique might be useful for this approach as this method does not require 
prior categorisation of the samples by phenotype, which allowed us increasing robustness 
of the findings by including all the samples available. In contrast, it is worthwhile to use a 
control group without history of any form of MDD albeit the resulting smaller sample size. 
To evaluate this approach using a control group without any form of depression, we 
conducted additional analyses utilising a reduced sMAS sample (N=465) consisting of 
recurrent MDD cases (N=27) and healthy controls only (N=438). We observed a large 
agreement between the results for both types of analyses: four modules were associated 
with recurrent MDD in a case/control design (Turquoise r=-0.12, p=0.01; Tan r=0.1, 0.04; 
Black r=0.09, p=0.045; Lightcyan r=0.09, p=0.046) in comparison to a population design 
(Turquoise r=-0.12, p=0.007; Tan r=0.1, 0.02; Black r=0.09, p=0.04; Lightcyan r=0.09, 
p=0.04) (Figure 3.1). Another important limitation of this study is that not all potential 
confounders were examined. Thus, while both our cohorts represent part of a relatively 
healthy community-dwelling aged Australian population, multiple medical comorbidities, 
inevitably accompanying ageing processes, and smoking that is known to affect gene 
expression (Vink et al., 2017, Huan et al., 2016), may have influenced the results. Given 
the ageing cohorts utilised in our analysis, we cannot rule out the possibility that our 
findings reflect a combined effect of MDD status and the ageing process itself.  
CONCLUSIONS 
This study supports the epidemiological link between the legacy of infectious diseases 
and their role in dysregulated biological pathways implicated in later life depression. 
Replication of our findings and further research utilising a network approach in a larger 
primary clinical cohort stratified for subtypes of depression is warranted. Specifically, 
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future research on the long-term effects of interaction between past infectious diseases 
and depression in later life is recommended. 
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FROM BIOLOGICAL NETWORKS TO MACHINE LEARNING PREDICTIONS 
In the third chapter, the peripheral blood genome-wide gene expression signature of 
depression using the co-expression network approach was investigated. It was found that 
over 3,000 highly co-expressed genes were dysregulated in depression, which supports 
previous findings of depression being a highly heterogeneous disorder associated with 
multiple genes each with a small effect size. Using WGCNA, we identified these genes 
as forming four relatively unrelated clusters of highly co-expressed genes within the blood 
transcriptome network. Collectively, these genes are involved in several molecular 
pathways, such as protein processing in endoplasmic reticulum and adaptive and innate 
immune responses, which were found to be dysregulated in the disorder. Although these 
findings provide a comprehensive view of possible biological mechanisms underlying 
depression, it failed to replicate network-level findings on an independent cohort (largely 
due to a limited statistical power). Therefore, a possible translation of these findings into 
clinical settings is limited. To evaluate whether the mRNA findings in recurrent MDD can 
be potentially utilised as therapeutic targets or to inform better diagnostic decisions in 
clinical practice, there is a need to explore whether predictive markers of MDD can be 
identified when studying complex gene interactions  Previous chapters 2 and 3, 
determined linear associations between mRNA levels and depression. However, in light 
of the non-replicated findings it is highly unlikely for gene interactions in relation to MDD 
to be in a linear fashion. Therefore, application of statistical tools which are only able to 
capture linear interactions are not sufficient to uncover the complexity of molecular 
dysregulation in depression. To advance the field in this area requires the application of 
novel methodologies that extend beyond fitting a linear function onto transcriptome data. 
To this end, we applied machine learning techniques which accounts for both linear and 
non-linear interactions between mRNA expression levels and depression. 
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In the next chapter, the predictive capacity of blood transcriptome in recurrent MDD using 
the same elderly cohort (sMAS) will be evaluated. Using fuzzy forests (FF) approach, a 
novel machine learning algorithm, we develop a predictive model that assesses the 
predictive capacity of gene expression levels in recurrent MDD. Fuzzy forests were 
designed to overcome limitations seen in machine learning literature related to a large 
feature space relative to sample size in the presence of correlated features, which are 
known characteristics of transcriptome data that can limit the performance of the 
classifier. This study will help in identifying the top molecular predictors of recurrent MDD 
that may potentially serve as predictive markers for the disease. 
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ABSTRACT 
At present, no predictive markers for Major Depressive Disorder (MDD) exist, and there 
is limited understanding of the biological underpinnings of depression. The search for 
such markers is challenging due to clinical and molecular heterogeneity of MDD, the lack 
of statistical power in studies and suboptimal statistical tools applied to multidimensional 
Transcriptome signature of depression 
84 
 
data.  Machine learning is a powerful data mining approach that has been proven 
successful in biomedical research. Transcriptomic data are highly multidimensional with 
the presence of correlated features organised in a network-like structure. To develop a 
meaningful predictive model using this type of data, a large number of observations are 
required; however the typical transcriptomic dataset is of a relatively small sample size. 
Multidimensional space with correlated features, coupled with a lack of observations, 
posits a challenge for machine learning classification. In an attempt to overcome these 
limitations, we adopted a novel Fuzzy Forests approach that takes advantage of the co-
expression network structure between genes aiming to identify predictive markers for 
recurrent MDD in the elderly at the blood gene expression level. Utilising transcriptome 
data from 521 individuals in the Sydney Memory and Aging Study (sMAS), we developed 
a model that correctly classified 63% of recurrently depressed individuals in the test 
dataset. We found that the most predictive marker, the gene TFRC, which encodes 
transferrin receptor, is downregulated in recurrent MDD and may represent a predictive 
marker for recurrent MDD. 
INTRODUCTION 
Currently investigations into biological underpinnings of MDD remain challenging; 
however it is paramount for developing reliable diagnostic tools and effective treatments. 
Despite decades of research, elucidation of the exact molecular mechanisms is in its 
infancy  (Cai et al., 2015, Okbay et al., 2016, Hek et al., 2013, Wray et al., 2018, Hyde et 
al., 2016, Jansen et al., 2016). MDD as a heterogeneous disorder is a complex dynamic 
system from both clinical (Cramer et al., 2016) and biological (Sibille and French, 2013) 
perspectives. The biological complexity of MDD can be accounted for by studying altered 
gene expression patterns in affected individuals compared to unaffected. These 
dysregulated patterns  can serve as a dynamic marker of the disorder. 
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As far as molecular biology is concerned, genes do not act in isolation; instead, they 
interact within each other akin to complex networks that might be disrupted in depression. 
In our previous study, we explored what genome-wide gene co-expression patterns are 
associated with depression. We applied Weighted Gene Co-expression Network Analysis 
(WGCNA) to transcriptomic data from 521 community-dwelling individuals aged over 65. 
We studied four subtypes of depression derived from the data collected at four time points 
with 2-year intervals between assessments: single episode, current MDD, recurrent MDD, 
and lifetime MDD. Although we were not able to detect a signal for the single episode, 
current or lifetime MDD, we found that four clusters containing 1,241 of highly interacting 
genes are associated with recurrent MDD status. Using in-silico Enrichment and 
Signalling Pathway Impact Analysis (SPIA) we found that this gene pool was biologically 
meaningful with 13 known molecular pathways significantly dysregulated in recurrent 
MDD in the elderly (Ciobanu et al., 2018b). While these findings were consistent with 
previous observations, and provided new insights into aetiology of depression, we sought 
to further explore the complex relationship between recurrent MDD, as the more severe 
subtype of depression, and transcriptome alterations.  
The typical biostatistical approach is to fit linear function between variables and the 
outcome. Although this approach is powerful in many scenarios, it can be suboptimal for 
multivariate transcriptome data. Machine learning (ML) provides an alternative view for 
data analysis, allowing for complex linear and non-linear interactions between the 
features to be explored. ML explicitly focuses on learning statistical functions from 
multidimensional data sets to make generalizable predictions about affected individuals.  
Random forests (RF) is an established technique for classification and feature selection, 
owing to its unique advantages in dealing with relatively small sample size, high-
dimensional feature space, and complex data structures. While RF is able to capture the 
true importance of features in settings where the features are independent, it is 
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established that RF is biased when features are correlated with one another and the 
correlation structure is not known a priori (Nicodemus and Malley, 2009), which is a typical 
scenario for transcriptome data. Fuzzy forests (FF) an extension of a RF algorithm, is 
designed to reduce this bias. FF is a novel algorithm which  takes advantage of the 
network structure between features and relies on WGCNA to create relatively 
uncorrelated clusters of highly correlated features (Zhang and Horvath, 2005).  FF uses 
recursive feature elimination RF to select features from separate clusters (Díaz-Uriarte 
and Alvarez de Andrés, 2006). The final RF is fit using the surviving features. The selected 
features are then used to construct a predictive model (Conn et al., 2015, Conn et al., 
2016).  
Although FF is based on WGCNA, these methodologies represent two different analytical 
strategies. WGCNA is primarily concerned with identifying important genes assumed to 
be involved in the same biological processes, which is useful in understanding biological 
underpinnings of depression. However, given that depression is a biologically 
multifactorial disorder, it is likely that hundreds to thousands of genes are involved in the 
disease, making it diagnostically impractical. RF aims to find a small number of genes 
sufficient for a good prediction of the response variable. While WGCNA is based on fitting 
a linear function into data, RF is non-parametric and non-linear. Athough this makes it 
difficult for interpretation it is more useful for identifying prediction markers and thereby 
clinical translation. Combining the two strategies in FF framework may help to overcome 




The Sydney Memory and Aging Study (sMAS) was initiated in 2005 to examine the clinical 
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characteristics and prevalence of mild cognitive impairment and related syndromes, 
including depression, in a non-demented population aged 70-90 years at recruitment 
(N=1,037) (Sachdev et al., 2010). The phenotypic data were collected at four time points 
with 2-year intervals between assessments. Blood samples for gene expression analyses 
were collected at Wave 4 (N=521), six years after baseline data collection. 
MDD was assessed by two well-validated self-report, and two clinical interview-based, 
measures of depression including the Geriatric Depression Scale (GDS-15) (cut-off ≥ 6) 
(Yesavage et al., 1982a), the Patient Health Questionnaire (PHQ-9) (cut-off ≥ 10) 
(Kroenke K and R., 2002), the Neuropsychiatric Inventory (NPI) (depression sub-scale) 
(Cummings et al., 1994a), and the Mini International Neuropsychiatric Interview (M.I.N.I.) 
(Sheehan et al., 1998). MDD cases were defined as participants who were identified as 
clinically depressed by at least two of the above depression measures at any one study 
Wave, according to DSM-IV criteria. A recurrent MDD subgroup consisted of 27 
individuals as published in (Ciobanu et al., 2018b). 
Gene expression data pre-processing 
Whole blood gene expression data for 521 participants were generated from PAXgene 
tubes using the Illumina Whole-Genome Gene Expression Direct Hybridization Assay 
System HumanHT-12 v4 (Illumina Inc., San Diego, CA, USA) according to standard 
manufacturer protocols. After rigorous QC, filtering, and adjustments for known (RINs, 
age, sex) and latent non-biological variables, gene expression data for 11,018 probes 
were available for downstream analyses (Ciobanu et al., 2018b).  
Data partitioning and balancing  
Our data represent a population study design with extremely unbalanced classes of 
individuals with recurrent MDD and those without. Since the aim of any classification 
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algorithm is to minimize the overall error rate, it posits a challenge for ML algorithms to 
correctly predict the minority class. Our solution was to train the model on balanced 
dataset, containing an equal proportion of positive and negative instances, and test it on 
unbalanced dataset that better reflects population distribution. To balance our training set 
(70% of the whole dataset), we used Synthetic Minority Over-sampling Technique, 
SMOTE, a hybrid method allowing for down-sampling the majority class and 
synthesizing new data points in the minority class using k-nearest algorithm, where k 
was set to 5 (Chawla et al., 2002). The never seen before training set (30% of the 
whole dataset) was left in its original distribution.  
RESULTS 
Training and test data 
After partitioning the full dataset, our training consisted of two groups: 19 recurrently 
depressed individuals (group [1]) and 346 individuals without recurrent MDD (group [0]) 
(0.05 vs 0.95), which is highly unbalanced. Using SMOTE, a combined method of over-
sampling the minority (MDD) class and under-sampling the majority (non-MDD) class, we 
balanced training data to 38 observations in each group (Figure 4.1). The test data 
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Figure 4.1. Balancing training dataset using SMOTE. A. Unbalanced dataset; B. 
Balanced dataset. 
Modules of co-expressed genes and FF model performance 
To determine the power of the adjacency function, we estimated network topology for 
various soft-thresholding powers. Based on these analysis, we used the scale-free 
topology criterion β = 6 (more details in Supplementary materials, Figure S1). Minimum 
module size, minModuleSize, was set to 100. Using WGCNA within the FF, we 
constructed a co-expression network consisting of 23 modules of co-expressed genes. 
Following the FF workflow, we applied recursive feature elimination RF to select features 
from separate modules. The last RF was performed on the genes from the survivors list. 
After parameter tuning, the best performance was achieved using the following 
hyperparameters: min_ntree = 500, final_ntree = 500, mtry factor = 5, ntry_factor = 5, 
drop_fraction = 0.25, keep_fraction = 0.05, number_selected = 1 (details in the Appendix 
A). This final model was tested on the test dataset achieving sensitivity of 63%, specificity 
of 66% and balanced accuracy of 63% for the top predictive feature – gene TFRC (ILMN 
_1674243) assigned to the module 2. (Figure 4.2). 
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Figure 4.2. Module membership distribution plot visualizing the relative importance of the 
modules for recurrent MDD. The blue bars represent the percentage of selected features 
in a particular module. The top predictive feature of recurrent MDD, gene TFRC, was 
assigned to the module 2. 
 
TFRC is implicated in recurrent MDD – consistent findings from co-expression network 
analysis, fuzzy forests machine learning algorithm and differential expression analysis.   
As described above, FF approach captures both non-linear and linear interactions 
between the genes to predict the outcome. Although we cannot directly estimate how 
much each type of interaction contributes to the final model, we sought to determine the 
effect of linear relationship between TFRC levels and recurrent MDD using differential 
expression analysis for the identified candidate gene, and, therefore, to establish the 
directionality of dysregulation of TFRC in recurrent MDD in our data. In our previous 
study, we investigated patterns of transcriptome dysregulations in recurrent depression 
using linear modelling implemented in co-expression network analysis (Ciobanu et al., 
2018b) and found that TFRC was assigned to a cluster of co-expressed genes, the 
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eigengene of which was associated with recurrent MDD (p=0.007). At the individual gene 
level, there was a significant difference of a small effect (at the FDR 20%) in the TFRC 
expression in recurrent MDD compared to those without this diagnosis in the sMAS cohort 
(logFC = -0.14), suggesting that TFRC is downregulated in people diagnosed with 
recurrent MDD. Although we could not replicate this finding in the independent replication 
cohort the Older Australian Twins Study (OATS) at the accepted level of significance, 
which was largely due to the limited sample size, it is worth noting that directionality of 
dysregulation was consistent with the primary findings (logFC = -0.01)  (details in Ciobanu 
et al. (2018b), Appendix A).  
DISCUSSION 
Downregulated transferrin receptor, TFRC, as a potential predictive marker for recurrent 
MDD 
In this study, we applied a novel ML algorithm on blood transcriptome data in order to 
identify a biological predictive marker in recurrent MDD. Using FF we developed the 
model that was able to correctly classify 63% of recurrently depressed elderly individuals 
on a test dataset. We found that the transferrin receptor gene, TFRC, was the top 
predictor of recurrent MDD in our cohort, suggesting that TFRC can potentially serve as 
a predictive marker for recurrent MDD. This finding was consistent with our previous study 
using this cohort, where downregulated TFRC was assigned to the module of 
interconnected genes the eigengene of which was associated with recurrent MDD 
(Ciobanu et al., 2018b). Taken together, we observed that three separate methodologies, 
namely WGCNA, FF, and differential expression produced comparative results, pointing 
towards TFRC as being involved in recurrent MDD. TFRC was also previously found 
dysregulated in the brains of MDD patients suffering from disrupted circadian rhythm (Li 
et al., 2013).However, it is unlikely that TFRC is the only gene that has a predictive 
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capacity given the molecular complexity of depression. Therefore, our model cannot be 
considered comprehensive. Instead a model capturing a larger pool of genes is likely to 
have a better predictive performance which could be achieved with a larger sample size. 
This will ensure the model is trained on sufficient number of observations to learn a true 
pattern of interactions between multiple genes.  
Transferrin receptor gene, TFRC, the gatekeeper of cellular iron uptake 
Transferrin receptor is a type II transmembrane glycoprotein expressed by all nucleated 
cells of the body. TFRC is an important modulator of iron homeostasis recognised as the 
gatekeeper of cellular iron uptake (Porto and De Sousa, 2007). Expression of TFRC is 
regulated at both the transcriptional and post-transcriptional levels by the cellular iron 
status: in a cellular iron-deficient state, TFRC expression increases, whereas in the 
presence of excess iron, TFRC expression decreases (Walker and Walker, 2000, 
Khumalo et al., 1998, Kawabata, 2018). Downregulated mRNA TFRC in blood, therefore, 
may indicate a disrupted iron homeostasis in depression (Brandao et al., 2005, Rostoker 
et al., 2015).  
The role of transferrin receptor in immunity 
Transferrin receptor plays a role in many immune-related processes, such as antigen 
processing and presentation, natural killer cell mediated cytotoxicity and T cell receptor 
signalling (Figure 4.3); these pathways were also previously found disrupted in 
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Figure 4.3. The TFRC immune-related functional relationships. The networks were 
constructed using ImmuNet software (Gorenshteyn et al., 2015). 
 
 
In our previous study, we found that multiple genes were associated with dysregulated 
immune system-related processes and activation of four pathogen-related pathways 
(Shigellosis, Herpes simplex infection, Pathogenic Escherichia coli infection, and Epstein-
Barr virus infection) in recurrent MDD, providing support for the role of previously 
observed complex interaction between pathogens and host’s immune response in 
depression (Carter, 2013, Ciobanu et al., 2018b). Furthermore, an emerging body of 
evidence indicates that many viruses and parasites use the transferrin receptor, for 
cellular entry into host cells (Weinberg, 1996). Downregulated TFRC coupled with 
dysregulated immune-related pathways therefore may indicate interplay between altered 
pathogen and host response mechanisms in recurrent MDD. Although we report on the 
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ability of our model to predict recurrently depressed individuals, these results should be 
treated with caution. While we identified TFRC as the most predictive gene for recurrent 
depression in the elderly our test sample was fairly small, relative to the feature space 
and could be a source of poor generalizability. While we corrected our data for age, sex, 
RINs and latent non-biological variables, we were unable to account for medications 
taken, comorbidities, and other environmental confounders that can be numerous in the 
elderly cohort. Furthermore, the serum levels of transferrin receptor were not assessed 
in this study. 
Using fuzzy forests framework, we identified that the most predictive gene, TFRC, can 
predict recurrent depression in the elderly with an accuracy of 63%. This finding, coupled 
with our previous observation that blood TFRC mRNA downregulated in recurrent MDD 
individuals as compared with those without, may potentially serve as a recurrent MDD-
specific predictive marker and provide some insights into pathophysiology of depression. 
Although our study is exploratory in nature providing preliminary results which require 
further exploration, the use of ML in biological psychiatry is an emerging field which will 
promote clinical translation and inform personalised psychiatry in the future.  
AN EMERGING NEED TO FOCUS ON IMMUNE DYSREGULATION IN DEPRESSION 
In the previous chapters, depression-relevant alterations of transcriptome using various 
approaches were explored, including traditional statistical approaches based on fitting a 
linear function into data, such as differential expression analysis (Chapter 2) and WGCNA 
(Chapter 3). Furthermore the machine learning approach enabled predictions to take into 
account linear as well as non-linear interactions between the genes and phenotype of 
interest (Chapter 4). While we did not find an absolute agreement between the findings, 
a common theme has emerged. Immune dysregulation was a highlight in all three studies, 
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suggesting that focusing on this aspect of transcriptome dysregulation might provide us 
with further insights into pathophysiology of depression.  
In Chapter 5, the research focus is on immune related biological pathways that we 
previously found dysregulated in recurrent depression. First, a comprehensive overview 
of previous findings on immune alterations in depression at gene expression level for both 
brain and periphery is presented. Next, in the experimental part of this chapter, the 
differential gene expression of immune genes that are known to be involved in immune-









Dysregulation of immune-related pathways in depression  
ABSTRACT 
Immune dysregulation is one of the most consistent findings in the biology of depression 
research. While many ‘immune’ genes were previously found implicated in depression, 
including upregulated pro-inflammatory cytokines IL1B, IL6, TNF, and INF, and 
transcription factors FN-kB and CREB1 identified in both the brain and  the periphery, the 
results are inconsistent across studies. Furthermore, at the transcriptome level, 
dysregulation of immune-related pathways at the periphery beyond the commonly studied 
cytokines was consistently found in multiple studies including our own. However, the 
exact mechanisms of peripheral immune dysregulation in depression are still largely 
unknown. In this study, we (1) provide a comprehensive overview of immune 
dysregulation in depression at gene expression level in both brain and periphery, and (2) 
using our previous exploratory findings on 13 immune-related pathways being 
dysregulated in recurrent MDD (Chapter 3), we examine the role of these pathways in 
recurrent MDD at individual gene level on independent cohort (the Older Australians Twin 
Study, OATS). To target the immune pathways, we selected all known genes (KEGG) 
involved in these 13 pathways (N = 1,302) and conducted a differential expression 
analysis on these candidates between individuals with recurrent MDD (N = 186). We 
found that two Illumina probes corresponding to CD14 were significantly downregulated 
in recurrent MDD (FDR < 0.05). This suggests that CD14 can potentially serve as a 
peripheral marker of immune dysregulation in recurrent MDD.  




Gene expression of inflammation in depression presents as a relatively novel and 
promising approach to uncover the pathophysiology of depression and to possibly provide 
useful clinical information for predicting treatment response and for decision-making 
processes in depression treatment. Quantifying the abundance of mRNA molecules 
known to be involved in immune-related pathways in a single cell or in a population of 
cells provides essential information on the biological activity and functions of immune 
system. Studying gene expression alteration in genes that are involved in immune-related 
biological pathways in depression can be viewed as complementary to a gene discovery 
approach, both aiming at understanding the molecular mechanisms of depression. There 
is a body of research that investigates gene expression alterations in depression in the 
brain as well as in the periphery at genome-wide level (when all genes are assessed) as 
well as using gene targeted (when several candidate genes are assessed) approaches. 
These studies have substantially improved our understanding the biology of depression; 
in particular, it is now clear that the immune system plays a role in its aetiology. However, 
to the best of our knowledge, there were no depression-related pathway-targeted studies 
aiming to assess all genes known to be involved in a particular molecular pathway, which 
is essential to better understanding the role of the immune system in depression. In this 
study, we aim to answer two questions: (1) what genes known to be involved in specific 
pathways are dysregulated in depression and (2) do these genes perform in isolation in 
one pathway, or have a pleiotropic effect on multiple immune pathways? First, we provide 
a comprehensive overview of known alterations in expression of immune-related genes 
in the brain and in the periphery (this overview was published as a part of a book chapter 
(Ciobanu and Baune, 2018), the full chapter can be accessed via 
https://doi.org/10.1016/B978-0-12-811073-7.00011-8), and secondly, using a pathway-
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targeted approach, we examine the expression levels of all genes known to be involved 
in 13 immune-related pathways that were found associated with depression. 
Gene expression patterns of immune dysregulations in the brain 
Studying the gene expression patterns in post-mortem brain tissues of individuals who 
suffered from depression provides us with valuable information about molecular changes 
occurring in depressed brains compared to healthy controls. Such studies have 
substantially advanced our understanding of the pathophysiological mechanisms of 
depression. Gene expression signatures derived from various brain regions collectively 
point towards molecular processes involving inflammatory pathways, cell survival, 
apoptosis and oxidative stress (Bakunina et al., 2015). 
Structural and functional neuroimaging studies in humans suggest that the limbic system 
(predominantly, amygdala (Ciobanu and Baune, 2018) and hippocampus) and the 
prefrontal cortex serve as primary brain areas responsible for disturbances in emotion 
processing and mood regulation in depression (Wise et al., 2014). Gene expression 
studies on human brain tissue, utilizing both candidate genes and genome-wide 
approaches, provide some support for dysregulated immune signalling within the brain, 
however the results lack consistency across the studies, which makes it challenging to 
specify how altered markers of inflammation found in different brain areas contribute to 
depression.  For instance, the most commonly reported circulating markers of 
inflammation, pro-inflammatory cytokines IL1B, IL6, TNF or INF were upregulated within 
various areas of prefrontal cortex (PFC), such as the dorsolateral prefrontal cortex, 
DLPFC (BA9) (Kang et al., 2007) and the anterior PFC (BA10) (Shelton et al., 2011, Malki 
et al., 2015) of depressed individuals, in the primary ventral regions of the prefrontal 
cortex (BA 44, 45, 46, 47) of depressed suicide victims (Klempan et al., 2009), in the 
orbitofrontal area (BA11) of adult suicide victims (Tonelli et al., 2008), in BA8 (part of the 
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frontal cortex involved in the management of uncertainty) and the anterior PFC (BA10) of 
teenage suicide victims (Pandey et al., 2012). However, none of these genes were 
replicated within the same brain area. Immune and apoptosis signalling along with 
synaptic and glutamatergic signalling pathways were also found disrupted in the 
hippocampal subfields DG and CA1 of middle-aged subjects diagnosed with MDD (Duric 
et al., 2013). An interesting study proposing synchronised dysregulation of expression in 
depression across different brain areas found a shift in coordinated gene expression 
levels between the amygdala and cingulate cortex for 100 to 250 individual genes, 
including IL1 and CREB1 in male MDD patients (Gaiteri et al., 2010b). Furthermore, 
several transcription factors known to be involved in immune response were found 
dysregulated in the depressed brain. For example, alterations in expression levels of 
CREB1, a transcriptional factor known to be involved in a wide variety of biological 
processes including immune response, is one of the most consistently replicated findings, 
however, the directionality of dysregulation is not consistent across different brain areas. 
For instance, Sibille et al. (2004) found that CREB1 is downregulated in the DLPFC (BA9 
and BA47) of depressed suicide subjects (noting that it did not survive correction for 
multiple testing), while Tochigi et al. (2008) observed upregulation of CREB1 in the 
anterior PFC (BA10) of non-suicide depressed subjects. This discrepancy may be 
explained by the presence of a suicide component in one study and its absence in 
another, pointing towards a differential role of CREB1 in depression and suicide. 
Alternatively, it may indicate that CREB1 is downregulated in the DLPFC and upregulated 
in the anterior PFC in depression.  Another transcription factor FOXD3, which functions 
as a transcriptional repressor, was found upregulated in the DLPFC together with 
TNFRSF11B, INFA6, and INFR1 (Kang et al., 2007). Moreover, it seems that post-
transcriptional regulation by short non-coding microRNAs, affecting both the stability and 
translation of mRNAs, are also involved in depression. Thus, utilising RNA-sequencing 
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data derived from DG granule cells, it has been found that posttranscriptional regulation 
by miR-182, which is involved in a broad range of biological processes including 
regulation of immune response, significantly contributed to disrupted signalling in the 
hippocampus (DG) in depression (Kohen et al., 2014b) (Table 5.1).  
Although all these findings suggest that brain dysregulation of immune genes, involving 
IL1B, IL6, TNF, INF, CREB1, FOXD3, and miR-182 might play a role in depression, they 
do not provide solid evidence, as the majority of those individual players of immune 
signalling have not been replicated. To further explore the level of replication of the 
findings in gene-expression studies,  we re-analysed data from 15 brain transcriptomic 
studies in depression and identified only seven genes of the immune response showing 
minimal replication (i.e. they were found dysregulated within the depressed brain but in 
different brain areas): FGFR3, ENPP2, PTP4A2 (innate immune response), CREB1, 
MOG, JUN (toll-like receptor signalling pathways), and LEPR, which belongs to the gp130 
family of cytokine receptors (cytokine-mediated signalling (Ciobanu et al., 2016). These 
findings point to a possible involvement of immune factors going beyond the typically 













Table 5.1. Studies on the dysregulation of immune genes and oxidative stress factors in 
brain tissues in depression  





It has been suggested that inflammation is tightly linked with oxidative stress in 
depression, which may lead to cell death and further inflammation, creating a vicious 
circle, and a mechanism which is not well understood (Bakunina et al., 2015). A recent 
integrative brain analysis of rat and human prefrontal cortex transcriptomes revealed that 
80% of dysregulated genes were functionally associated with a key stress response 
signalling cascade, involving NF-kB, AP-1 (activator protein 1) and ERK/MAPK, 
suggesting inflammation-mediated oxidative stress and further dysregulation of 
neuroplasticity and neurogenesis in the prefrontal cortex in MDD (Malki et al., 2015). 
Furthermore, oxidative stress, measured by expression levels of four antioxidant 
oxidative defence enzymes, A+B) superoxide dismutases (SOD1 and SOD2), C) catalase 
(CAT) and D) glutathione peroxidase (GPX1), which were significantly lower in depressed 
individuals, found to contribute to telomere shortening in oligodendrocytes of the 
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prefrontal cortex (BA10) (Szebeni et al., 2014). These findings provide evidence for a 
possible aetiological link between inflammation, oxidative stress, telomere shortening and 
white matter abnormalities previously observed in depression. 
Although many individual players of the immune and the oxidative stress pathways have 
been found altered in brain tissue of patients diagnosed with depression, an inconsistency 
on the direction and brain areas of dysregulated genes precludes firm conclusions on 
specific immune-related pathways dysregulated in the brain in depression. The current 
state of knowledge suggests that multiple brain areas are possibly involved in depression-
related immune dysregulation in a complex manner. 
Overlap of gene expression markers of inflammation across psychiatric disorders  
Given that a transdiagnostic assessment may reveal common biological features 
between depression, schizophrenia and bipolar disorder, the comparative assessment of 
gene expression levels can shed some light on shared and distinct pathophysiological 
mechanisms of these disorders, which can potentially provide a molecular basis for 
developing diagnostic guidelines. Molecular comparisons of different brain areas in 
schizophrenia, bipolar disorder and MDD at a transcriptome level suggested that (1) the 
prefrontal cortex in all three disorders have distinct gene expression signatures with 
shared upregulation of genes encoding proteins for transcription and translation (Iwamoto 
et al., 2004) and that (2) the activation of immune/inflammatory response in the 
hippocampus is present in all disorders.  However, despite these similarities across 
disorders, several differences in the specifics of the dysregulated transcriptomes were 
found. For MDD, abnormal activation of the first component of the complement cascade 
C1q (hub genes in co-expression analysis C1QA, C1QB and C1QC) and IL1B (Kim et al., 
2016) were observed in the hippocampus, while a dysregulation of the immune-related 
response in the thalamus, including B cell receptor signalling, was specific to 
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schizophrenia, as it was not found in depression (Chu et al., 2009) (Table 5.1).  
Taken together, there is a plethora of findings pointing towards inflammation and oxidative 
stress-related events in depressed brains, including upregulation of pro-inflammatory 
cytokines, transcriptional and post-transcriptional regulators of immune signalling in the 
prefrontal cortex and hippocampus. Emerging evidence also suggests a possible causal 
link between inflammation, oxidative stress and structural changes in the brain in 
depression. However, it is premature to propose a distinct inflammatory/oxidative stress 
transcriptomic signature of depression as of yet, as replication of these findings is minimal 
at present. Further exploration of transcriptomes across different brain areas at a single 
cell type level and peripheral blood has a great potential to discover how inflammation-
induced molecular changes lead to structural abnormalities and impair neural circuits 
involved in emotional and cognitive processing in depression. 
Peripheral Gene expression patterns of immune dysregulation  
Studying gene expression markers of depression in peripheral tissues is a promising 
approach to identify biomarkers that are potentially translatable into clinical practice for 
diagnostic and prognostic purposes. Dysregulated transcripts identified at candidate gene 
and genome-wide levels provide us with new insights into biological mechanisms of 
depression. However, similar to gene expression studies in post-mortem brain, the 
findings in peripheral tissues lack consistency. In a recent systematic review, we re-
analysed the results obtained from 10 transcriptomic studies in depression and showed 
that only 2.8% of genes (21 out of 752) identified as significantly differentially expressed 
in the periphery between depressed patients and healthy control subjects were replicated. 
Although a low level of replication at an individual gene level is discouraging, we made 
the observation that various factors of the immune response were consistently 
dysregulated. Among these 21 replicated genes, three were involved in the immune 
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system: IFIT3, which is involved in the type 1 interferon signalling pathway was found 
upregulated in MDD and downregulated in postpartum depression; STAT3, a 
transcription factor that mediates cellular responses to interleukins and SEMA3C, which 
is also known to be involved in the immune response, were found upregulated in MDD 
(Ciobanu et al., 2016).  This provides further evidence for an involvement of peripheral 
inflammation in the pathophysiology of depression.  
At this stage it is unknown how well the peripheral markers are predictors for brain 
inflammation (and vice versa). Despite a substantial overlap between brain and peripheral 
blood transcriptomes (Liew et al., 2006), the extent at which peripheral inflammation is a 
reflection of CNS inflammation in depressed individuals is not fully understood. One of 
the challenges in biomarker research for psychiatric disorders is to agree on the ‘best’ 
peripheral tissue source. While separated cell types or stimulated blood provide better 
resolution of signal compared to unstimulated blood, dysregulation of inflammatory and 
other immune-related genes is detectable even in unstimulated whole blood. For 
example, elements of disrupted immune signalling were found in unchallenged 
monocytes (Carvalho et al., 2014), PBMCs (Belzeaux et al., 2010, Savitz et al., 2013, 
Segman et al., 2010), dermal fibroblasts (Garbett et al., 2015b), whole blood after 
lipopolysaccharide (LPS) stimulation (Spijker et al., 2010), as well as in unstimulated 
whole blood (Jansen et al., 2016) from MDD patients. Although the aforementioned 
studies not only differ in cell type, but also in type of depression (postpartum, melancholic, 
induced by INF-α treatment), type of study design (targeted vs. genome-wide), and 
among cohort characteristics (age groups, medications), there was some agreement in 
findings on gene expression markers of inflammation between the studies .For instance, 
by studying a panel of 47 inflammatory-related genes Carvalho et al. (2014) found that 
one of two identified clusters, consisting primarily of pro-inflammatory mediators (IL1A, 
IL1B, IL6, PTX3, PDE4B, PTGS2, and TNF), were upregulated in monocytes of 47 
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patients with melancholic depression. This was somewhat consistent with genome-wide 
findings of a dysregulated functional network centred on differentially expressed TNF in 
PBMCs from 21 current and re-current moderately to severely affected MDD cases 
(Savitz et al., 2013). However, the latter study underscored that differentially expressed 
immune players were functionally linked with non-differentially expressed NF-kß, TGFß, 
and extracellular signal-regulated kinase (ERK), indicating that differential expression 
analysis might be a suboptimal option for detecting complex gene-gene interactions in 
depression. In another study, one of the TNF receptors, TNFRSF1 together with 
interferon-induced proteins IFIT1, IFIT2, and IFIT3 and 8 other genes involved in immune 
response (HELLS, HIST2H2B, GBPI, IGJ, SERPING, LOC44203, CXCL10, EREG) were 
found differentially expressed in PBMCs of 9 patients with postpartum depression 
(Segman et al., 2010). In contrast, among 40 studied candidate genes including TNF, 
IL1B, IL2, IL4, IL6, IL8, and IL10, only the anti-inflammatory cytokine IL10 was statistically 
significantly elevated in PBMCs of 11 individuals suffering from a severe melancholic 
depressive episode (Belzeaux et al., 2010). To overcome low signal to noise ratio of gene 
expression in basal blood, Spijker et al. (2010) used LPS challenged whole-blood cells 
from 21 individuals with a single MDD episode. They observed LPS-induced gene 
expression, among which there were several cytokines, such as TNF, NF-kB, IL1, IL6, 
and IL10. Although none of these genes displayed a differential expression level between 
MDD patients and control subjects, six out seven genes in a proposed diagnostic 
signature of depression are related to the immune system and deal with cellular 
proliferation (CAPRIN1, PROK2, ZBTB16) and differentiation (CLEC4A, KRT23, 
PLSCR1). Environmental influences, like lifestyle and medication use, can confound gene 
expression findings. Dermal fibroblasts were proposed as an alternative experimental 
model to study depression-specific gene expression alterationsas this cell type isless 
dependent of environmental influences (Garbett et al., 2015a). The authors argue that 
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after several rounds of fibroblasts’ division in the cell culture, many epigenetic changes 
disappear over time, leaving a more “pure” genetic model at hand. Findings in fibroblasts 
were consistent with previously described observations in other cell types, pointing to 
disrupted molecular pathways related to cell-to-cell communication that are known to play 
a role in the adaptive and innate immune system. A set of 13 PR-qPCR validated immune-
related genes was suggested to be associated with life style-independent and 
medication-free status in depression (CD74, HLA-DRA, HLA-DQB1, IL11, HLA-DPA1, 


















Table 5.2. Studies on the dysregulation of immune genes in peripheral tissues  
 





While we report on some agreement of gene expression markers of inflammation in the 
periphery across studies, the majority of immune-related genes have not been replicated. 
One of the major factors that may have led to the disagreement between the studies is 
low statistical power. Small sample sizes, ranging from only 9 to 47 depression cases 
(Table 5.2), is one of the main limiting factors affecting statistical power to detect and 
replicate dysregulated transcripts. To overcome this limitation,  (Jansen et al., 2016) 
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performed the largest to date study on 882 patients with current MDD. Using both 
differential expression and co-expression clustering (WGCNA) (Zhang and Horvath, 
2005) methods and accounting for 16 demographic and technical covariates, they 
identified that MDD is characterised by upregulated  IL-6 signalling (IL6R, STAT3, 
MAPK14, RXRA) and downregulated NK cell activation (GZMB, KLRK1, PRF1, SH2D1B, 
KLDR1, NFATC2, IL2RB, CALM1, NCALD). Longitudinal analysis at 2-year follow-up 
showed that the levels of expression for 15% of genes out of the 129 genes identified in 
cross-sectional analyses were reversed in those who remitted after a previous depression 
episode. This indicates that transient gene expression patterns are detectable in 
peripheral blood and the results provide support for the potential success in the 
development of whole-blood gene expression-based biomarkers of depression. These 
results were also meta-analysed with a recent RNA-seq study, in which alone no 
significant association with depression on 463 self-reported MDD cases accounting for 
39 covariates were found. Binding the two largest datasets derived from microarrays and 
RNA-sequencing technologies together, resulted in 12 differentially expressed genes at 
FDR˂0.1 between MDD cases and healthy controls, 7 of which are known to be involved 
in activated immune signalling and oxidative stress (CALM1, FCRL6, APOBEC3G, 
RAP2B, PIPOX, PRR5L, and KLRD1), providing further support for the often reported 
peripheral inflammation in depression. 
Taken together, an intensive search for peripheral gene expression biomarkers of 
inflammation in depression at both the candidate gene and transcriptome levels identified 
some promising candidates, including IL1B, TNF, IL6, INF, CREB1 and NF-kB, the field 
is far away from claiming an immune signature of depression. Further understanding of 
gene expression alterations in depression with a particular focus on immune-related 
pathways will help us to better understand the role of immune system in depression.  
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In our previous study, employing co-expression network approach, we found that 13 
biological immune-related pathways are significantly altered (activated or inhibited) in 
older adults suffering with recurrent MDD. However, the exact mechanisms of this 
dysregulation requires further investigation. Targeting these immune related pathways at 
individual gene level to determine what genes are differentially expressed in depression 
is complementary to candidate gene and transcriptome-wide approaches. In this study, 
we select a pathway-targeted subset of biologically relevant genes that can provide us 
with more granular understanding on immune dysregulation in depression. To select a 
subset of targeted immune genes for further analyses, we (1) extracted the full list of 
genes that are known to be involved in a given pathway, (2) removed redundant 
information about genes involved in multiple pathways, and (3) conducted differential 
gene expression analysis between individuals with recurrent MDD and those without 
using the OATS cohort of elderly community-dwelling individuals. 
METHODS 
Candidate gene selection and mapping gene names to Illumina probes 
The 13 KEGG pathways associated with recurrent MDD in the elderly are listed in the 
Table 5.3. In total, there were 1,869 genes involved in these pathways with 30.3% (576) 
of them involved in multiple pathways. After removing duplicated values 1,302 individual 
genes across 13 KEGG pathways remained for further analysis. For viewing KEGG 
pathway diagrams with “depression” genes marked up, refer to Supplementary Materials 
for (Ciobanu et al., 2018b). The 1,302 genes of interest were mapped to the 2,085 
corresponding Illumina HumanHT-12 v4 probes.  
 
 



























Shigellosis hsa:05131 65 Activated 0.006 
mTOR signalling pathway hsa:04150 153 Activated 0.006 
Natural killer cell mediated cytotoxicity  hsa:04650 131 Inhibited 0.008 
Antigen processing and presentation hsa:04612 77 Activated 0.01 
Herpes simplex infection hsa:05168 492 Activated 0.01 
Insulin signalling pathway hsa:04910 137 Activated 0.03 
Pathogenic Escherichia coli infection hsa:05130 55 Activated 0.03 
RNA degradation hsa:03018 79 Activated 0.04 
Epstein-Barr virus infection hsa:05169 201 Activated 0.04 
Protein processing in endoplasmic reticulum hsa:04141 165 Activated 0.04 
Apoptosis hsa:04210 136 Activated 0.04 
T cell receptor signalling pathway hsa:104660 101 Inhibited 0.046 
Pathway name, KEGG ID, and Total N (total number of genes known to be involved in a given pathway) 
refer to the KEGG database; Status in MDD (activated or inhibited), MDD N (number of genes found 
differentially expressed in MDD), and FDR (at 5%) refers to the previous findings (Ciobanu et al., 2018b). 
 
Cohort characteristics 
To conduct the differential expression analyses on immune related genes in recurrent 
MDD we utilised the Older Australian Twins Study (OATS). The primary aim of OATS is 
to investigate healthy brain ageing in older twins (65+ years) (Sachdev et al., 2009). 
Depression data were collected at three time points with 2-year intervals between 
assessments. Blood samples for gene expression analyses were collected at Wave 3, 
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four years after baseline. The total sample size available for further analyses N=186 
(recurrent MDD = 7). Informed consent was obtained for all participants and study 
procedures were explained prior to study commencement. Further details on cohort 
characteristics can be found in (Ciobanu et al., 2018b). 
MDD definition 
MDD was assessed by two well-validated self-report, and two clinical interview-based, 
measures of depression including the Geriatric Depression Scale (GDS-15) (cut-off ≥ 6) 
(Yesavage et al., 1982), the Patient Health Questionnaire (PHQ-9) (cut-off ≥ 10) (Kroenke 
K and R., 2002), the Neuropsychiatric Inventory (NPI) (depression sub-scale) (Cummings 
et al., 1994), and the Mini International Neuropsychiatric Interview (M.I.N.I.) (Sheehan et 
al., 1998). The recurrent MDD cases were defined as participants who were identified as 
clinically depressed by at least two of the above depression measures, according to DSM-
IV criteria, at more than one study Wave. 
Gene expression data pre-processing 
Gene expression data for 186 whole blood samples collected in PAXgene tubes were 
generated using the Illumina Whole-Genome Gene Expression Direct Hybridization 
Assay System HumanHT-12 v4 (Illumina Inc., San Diego, CA, USA) according to 
standard manufacturer protocols. After rigorous QC (RIN<6), pre-processing, filtering, 
and adjustments for known (RINs, age, sex) and latent non-biological variables, 11,685 
probes for 186 individuals aged 69 and over from the OATS cohort (age range 69.4 – 
93.5, mean age 75.9±5.3, 72 males and 114 females) were available for downstream 
analyses.  
Differential gene expression analysis 
To assess differential gene expression, DGE, between individuals diagnosed with 
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recurrent depression and those without this diagnosis, we fit gene-wise linear modelling 
implemented in limma R package. The linear modelling was performed in a row-wise 
fashion, with regression coefficients and standard errors estimating the comparisons of 
interest. The fitted model and contrast matrix were used to compute log2-fold-changes 
and t-statistics for the contrasts of interest. For each coefficient in the contrast, empirical 
Bayes moderated t-statistics and their associated P-values were computed to assess the 
significance of the observed expression changes.  
RESULTS 
For the 1,302 individual genes that were identified using KEGG database there were 963 
Illumina corresponding probes (750 unique genes) in our OATS gene expression dataset 
available for DGE analysis. The 102 probes (90 unique genes) differentially expressed at 
nominal p < 0.05 (Appendix C). After FDR correction for multiple testing, two probes 
corresponding to two splice variants of the CD14 gene (ILMN1740014 and ILMN239644) 
remained significant at FDR 5%. Both probes were downregulated with comparable effect 
(logFC = - 0.7 and - 0.64 accordingly). Five more genes, namely LSM2, ACTB, 
ATP6V1B2, CFP and PAK 1, can be considered significantly dysregulated at relaxed FDR 
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Figure 5.1. Differentially expressed genes in recurrent MDD. The volcano plot displaying 
log fold changes on the x-axis versus a measure of statistical significance on the y-axis 
(here the significance measure is the posterior log-odds of differential expression (B-
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Table 5.4. The top 6 differentially expressed genes in recurrent MDD 
Official 
symbol 
Illumina probe ENTREZ Official gene 
name 
logFC p-value FDR 





CD14 ILMN_2396444 929 CD14 
molecule 
-0.64 3.19E-06 0.002 







0.26 0.0006 0.16 
ACTB ILMN_2152131 60 actin beta -0.29 0.0007 0.16 
ATP6V1B2 ILMN_1787705 526 ATPase H+ 
transporting V1 
subunit B2 
-0.34 0.0009 0.17 
CFP ILMN_1658121 5199 complement 
factor 
properdin 
-0.3 0.001 0.18 
PAK1 ILMN_1767365 5058 p21 (RAC1) 
activated 
kinase 1 
-0.3 0.002 0.22 
   
DISCUSSION 
In our previous study (Chapter 3) using co-expression network analyses we reduced 
dimensionality of transcriptome data in a functionally relevant manner and identified 
immune- and pathogen-related pathways associated with recurrent depression. To gain 
further insight into immune dysregulation in recurrent MDD at gene expression level we 
employed a targeted candidate pathway approach. After selection of 13 immune-related 
pathways associated with recurrent depression in the elderly, we found two mRNA 
variants that encode for the CD14 molecule to be significantly downregulated in 
individuals with recurrent MDD compared to those without (FDR < 0.05) in independent 
cohort. This finding confirms previous observations that innate immune response-
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activating signal transduction mechanisms are altered in depression and suggests that 
CD14 may represent a novel putative biomarker for recurrent MDD. 
The role of CD14 in innate immune responses and oxidative stress 
Cluster of differentiation antigen 14 (CD14) is a glycosylphosphatidylinositol (GPI)-
anchored receptor known to serve as a co-receptor for several Toll-like Receptors (TLRs) 
both at the cell surface and in the endosomal compartment.  CD14 is mainly expressed 
in peripheral tissues, including whole blood; it also expressed in the brain (hippocampus, 
cortex, nucleus accumbens etc.) although in a much smaller quantity 
(https://gtexportal.org/home/gene/CD14). CD14 is known as a critical upstream regulator 
of the host's inflammatory response to pathogenic challenge; it influences the intensity 
and duration of inflammation to finely modulate NF-κB activity. While CD14 is a 
multifunctional molecule that participates in many immune-related biological pathways 
(Figure 5.2), current thinking emphasizes the role of CD14 in facilitating recognition of 
pathogens to initiate and orchestrate innate immune-mediated signalling events (Sahay 
et al., 2009, Zanoni and Granucci, 2013). 
The role of CD14 in oxidative stress is emerging. Recent studies show that CD14 has an 
impact on Reactive Oxygen Species (ROS) production when primed by Escherichia coli 
lipopolysaccharides in human leukocytes in vitro (Kabanov, 2019); activation of CD14-
dependent innate immune response was also found causal to neuronal oxidative damage 
and dendritic degeneration in vivo (Milatovic, 2004). Therefore, if the expression of CD14 
is compromised, activation of an intracellular signalling pathway NF-kB and inflammatory 
cytokine production that are responsible for facilitating the innate immune system would 
be impaired leading to damage by ROS (Liu et al., 2012, Lau et al., 2015). Together with 
our finding on a role of the peroxisome lipid and ROS metabolism pathway in depressive 
disorder (Chapter 2), the results on altered CD14 expression in recurrent MDD suggest 
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that dysregulated CD14-dependent innate immune cascade leading to accumulation of 
ROS-induced damage plays a role in recurrent MDD and could represent a recurrent 
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Figure 5.2. Interaction network for CD14. Network nodes represent proteins. Enrichment 
for top 10 GO terms is presented  
 
The network was generated using STRING software https://string-db.org 
 




The role of CD14 in age-related alterations in innate immune response and ROS 
production 
Aging is associated with dysregulation of multiple components of the immune system that 
results in a decrease of adequate response to pathogens and increase in susceptibility to 
infections (Metcalf et al., 2015, Weiskopf et al., 2009). Furthermore, oxidative stress is a 
hallmark of ageing (Liguori et al., 2018). Considering that CD14 is an important modulator 
of both pathogen-activated innate immune response and production of ROS, our findings 
on dysregulated CD14 within the elderly can be partially attributed to the aging process 
itself. However, it can also indicate that within the elderly population depression could be 
stratified according to particular innate immune and oxidative stress mechanisms 
coordinated by CD14.  
While the population design employed in this study (individuals with recurrent MDD vs 
those without) may suggest that the results obtained have a stronger potential to be 
translated into actionable clinical insights, the unbalanced ratio of those affected 
(minority) with those not (majority) used in differential expression analysis can potentially 
produce unreliable results. Therefore, replication of these findings on a larger cohort 
employing case-control study design is required. 
CONCLUSIONS 
Considering a central coordinating role of CD14 in orchestrating the host’s inflammatory 
response to pathogenic challenge and association of downregulated CD14 with recurrent 
MDD in the elderly, our results suggest that CD14-mediated immune response is impaired 
in recurrent MDD. However, replication of these results on a larger cohort is warranted in 
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addition to cellular based experiments. 
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A NOVEL CANDIDATE PATHWAY FRAMEWORK  
Navigating our way towards a greater understanding of the pathophysiological 
mechanisms in depression requires a combined focus on the forest (global focus, 
transcriptome-wide view) and focus on the trees (local focus, individual genes view). It’s 
becoming clear that whilst it is important to identify individual players via for example 
differential gene expression analyses, that can be utilised as biomarkers and therapeutic 
targets, this cannot be done without taking a global perspective on a whole system of 
complex interactions between the genes. Co-expression network (WGCNA) and 
differential gene expression represent two different but complimentary analytical 
strategies. While co-expression network takes a global systems approach to identifying 
disrupted biological pathways in a disease, differential gene expression is a powerful 
method to pinpoint individual players. Combining these two methodologies in a workflow 
provides a much more comprehensive analytical approach to gain novel insights into the 
underlying biological mechanisms of MDD.  
We propose a novel candidate pathway framework that incorporates both global and local 
perspectives. The framework consists of the three major steps: (1) transcriptome co-
expression network construction (WGCNA) to identify biological pathways associated 
with depression (an example can be found in Chapter 3), (2) identification of all genes 
known to be involved in given candidate pathways using pathway database (KEGG), (3) 
differential gene expression analysis of genes involved in candidate pathways on an 
independent cohort (limma, R) (an example can be found in Chapter 5). Figure 5.3 
outlines the major steps of the candidate pathway framework. 
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Figure 5.3. A candidate pathway framework 
 
This framework allows for a comprehensive investigation of transcriptome signature in 
depression from a complex network of interactions at genome-wide level to individual 
genes and includes replication process on an independent cohort. Using proposed 
candidate pathway framework, we were able to identify pathogen- and immune-related 
molecular pathways implicated in recurrent MDD (Chapter 3) and identified CD14 as one 
of the central players that appear to be responsible for orchestration of these pathways 
(Chapter 5). This suggests that a candidate pathway framework is useful for detecting 
relevant signals in highly multidimensional transcriptome data with poor signal-to-noise 
ratio and can be further utilised for studying gene expression signatures of depression or 








Summarising the findings and outlining future directions 
 
 
Elucidating transcriptome signature of depression is critical for understanding biological 
underpinnings of depression. In general, transcriptome research in MDD Over the last 10 
years of has been challenging due to multiple limiting factors of technical and biological 
nature, which we extensively discuss throughout this manuscript. In particular, for this 
study some technical aspects and experimental limitations will be discussed. 
There are a number of highly significant confounders, which would potentially influence 
the replicability of expression levels of specific genes, and therefore, the interpretability 
of the results obtained in this work. Of pivotal relevance is the pharmacological treatment 
of patients included in each study, and the potential impact of confounding of 
pharmacological treatment received by MDD patients. It is quite possible that differences 
in gene expression between MDD patients and healthy controls reported in previously 
published studies (examined in Chapter 2) are influenced by those which are regulated, 
consequently, of the treatment received, and that differences in DEGs observed between 
studies may reflect different treatments received by patients in each study. Differences in 
treatments may also explain the lack of replicability across the studies observed (Ciobanu 
2016).  Our main experimental cohorts, namely sMAS and OATS, utilised in Chapters 3, 
4 and 5 for transcriptome data analyses in MDD also suffered from a lack of information 
regarding pharmachological treatments taken by patients prior to blood collection, which 
might have affected the obtained results. Future transcriptome studies should consider 
pharmacological treatment at the stage of study design to facilitate adjustment for this 
important confounder at data analysis step.   
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In addition, the different sensitivities of the methods used to capture gene expression (i.e. 
microarray vs RNA-seq) can have an effect on the results obtained. For example, when 
using microarray data, low abundance genes are usually filtered out before the analysis 
due to lack of sensitivity to reliably detect them, while RNA-seq has higher sensitivity for 
low abundance genes and these genes can be included in statistical analysis. 
Furthermore, microarrays cannot capture alternative mechanisms of functional gene 
regulation (e.g. alternative splicing isoforms or non-coding transcripts not typically 
captured by microarray), while RNA-seq technology can, which may also be relevant in 
the molecular mechanisms of depression.  
To overcome some of the limitations observed in the previous studies (Chapter 2) that 
may have affected the progress in the field, we applied several novel statistical and 
machine learning techniques, such as co-expression network (Chapter 3), fuzzy forests 
(Chapter 4), and candidate pathway (Chapter 5) on two large population cohorts of older 
adults. We found that (1) immune dysregulation characterised by thirteen pathogen- and 
immune-related molecular pathways appear to have an important role in recurrent MDD 
(Ciobanu et al., 2018b), the downregulated TFRC can predict recurrent MDD in the 
elderly, and therefore can potentially be used as a predictive marker of the disease for 
the specific subgroup of patients (Chapter 4, paper under review), and (3) CD14-
coordinated innate immune signalling is associated with recurrent MDD and can 
represent a potential novel therapeutic target (Chapter 5).  Future directions are outlined 
for the importance of emerging methodologies and suggest several approaches that have 
a potential to facilitate biological findings into actionable clinical insights. Figure 6.1 














In summary, while supporting previous findings on the immune system being involved in 
depression, our work provides converging evidence that pathogen-related immune 
dysregulation plays a role in recurrent MDD in older adults and highlights two candidate 
genes (TFRC and CD14) as potential peripheral markers of the disorder.  
The next section outlines how advanced analytical strategies can enhance biological 
psychiatric research for stratification of subgroups via molecular signatures and treatment 
response biotypes.  This will further advance our understanding of disorder mechanisms 
and accelerate transition into an era of personalized treatments in psychiatry. 
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GENE CO-EXPRESSION NETWORK AND MACHINE LEARNING APPROACHES TO TRANSLATE 
BIOLOGICAL FINDINGS INTO ACTIONABLE CLINICAL INSIGHTS 
Despite the success of collaborative international efforts to identify genetic variants 
involved in depression, the biological underpinnings of complex psychiatric traits, 
including depression, remain elusive. Increasing evidence suggests that depression is 
the result of complex interactions between genomic variations, epigenetic modifications, 
and other regulatory mechanisms involved in gene expression. Therefore, the 
transcriptome, representing a nexus of genetic and environmental interactions, can be 
seen as an essential biological layer of information for studying molecular dysregulations 
in mental disorders. Transcriptomics can be used for diagnostic purposes to differentiate 
disease from healthy controls, differentiate disease stages and identify subgroups of 
patients exhibiting different biological signatures within diagnosis. It also allows 
measuring the influence of drugs on the transcriptome, which can be useful in getting 
insights on molecular mechanisms of drug’s action and in predicting treatment response. 
Using co-expression network analysis-based methods, disease-relevant clusters of co-
regulated genes can be identified and further integrated with genetic and epigenetic data 
for a comprehensive investigation of biological underpinnings of depression. In this 
chapter, we provide an essential guide to the co-expression network approach as an 
important statistical tool that can enrich the understanding of disrupted molecular 
processes in psychiatric disorders. Furthermore, given the complex system structure 
inherent in psychiatric disorders, including depression, statistical learning frameworks 
that can translate these findings into actionable clinical insights are required. A number 
of emerging methodologies that address this problem are explored, including weighted 
gene co-expression network analysis, differential co-expression analysis, biclustering, 
and regularised machine learning.  
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Emerging evidence suggests that interactions between both genes and the 
environment can have a large impact on the phenotypic variability of psychiatric disorders 
(Kubota et al., 2012). Given that gene expression is a product of genetic effects, 
environmental influences and epigenetic modifications, studying alterations of mRNA 
levels in disease represents a promising approach to further our molecular understanding 
of depression. However, a major challenge has remained. How is it that we go about 
measuring and identifying the expression of which genes are altered in disease specific 
cells, tissues and brain regions?  
Early studies measuring the differential expression of candidate genes pointed towards 
many potential targets for depression. However, the replication of these findings has been 
limited due to methodological differences, inconsistencies in the diagnostic measures 
used, and underpowered study designs (Drago et al., 2007). Nevertheless, advances in 
high-throughput technologies have helped facilitate a shift from hypothesis-driven 
approaches, to less biased data-driven methodologies. A substantial body of research 
has applied microarray and RNA-seq technologies to investigate disease-associated 
genome-wide expression alterations in both brain and peripheral tissues. This work has 
been demonstrated in schizophrenia (Sanders et al., 2017, Cattane et al., 2015), bipolar 
disorder (for review, Seifuddin et al. (2013)), and MDD (for review, (Ciobanu et al., 2016)). 
While these findings have improved our understanding of the pathophysiological 
mechanisms in psychiatric disorders, replication of identified candidates has remained a 
challenge. One proposed reason for the lack of consistent results between studies is 
attributed to the molecular complexity of psychiatric disorders, which commonly, is further 
compounded by the small sample sizes often employed in this research. The capacity to 
detect multiple small effects from single molecules at the transcriptome-wide level places 
large sample size requirements on a study. Given the complex genetic architecture of 
psychiatric illness and the functional interdependencies between genes, emergent clinical 
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phenotypes are likely to reflect the interactions within a complex network of molecular 
processes. Therefore, capturing the most important genes that orchestrate the molecular 
cascades leading to psychiatric pathophysiology is of utmost importance. However, given 
the methodological constraints discussed above in traditional analysis, alternative 
methodologies are needed to further progress the field. A range of these methodologies 
will be discussed below. 
 DIAGNOSIS OF DEPRESSION 
Co-expression network analysis to differentiate disease from healthy controls 
Gene co-expression network analysis is a technique used to quantify the linear co-
expression of multiple genes in relation to disease diagnosis. This methodology allows 
for effective dimensionality reduction of transcriptome data (decreasing the number of 
independent variables in a dataset), as well as, clustering of interacting genes associated 
with a phenotype. It can be argued that if two (or more) genes are co-expressed, then the 
mechanisms regulating their expression must be either the same, or at least similar. 
Therefore, it is inferred that co-expressed genes are functionally related, and if associated 
with a disease status, are important contributors to a clinical phenotype.  
Weighted gene co-expression network analysis 
Gene clustering is a technique used in co-expression analysis that allows for the 
identification of sub-networks of convergent biological pathways. The Weighted Gene Co-
expression Network Analysis (WGCNA) is one of the most established techniques used 
in gene clustering. This technique utilises both  microarray and RNA-seq data (Zhang and 
Horvath, 2005). WGCNA organizes transcriptome data by defining genes as nodes and 
the relationships between nodes as edges. Biological networks tend to have a 
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hierarchical structure, such that their nodes can be clustered together into fewer 
modules of highly interconnected genes.  Inter-modular connectivity reflects a higher-
order structure of biological relationships within a gene network, while intra-modular 
connectivity can identify which genes behave as central hubs in the modules. In co-
expression networks, hubs are highly connected genes; therefore, being a hub is an 
indication of the importance of a gene in a module. Hubs are likely to be key molecular 
drivers that determine co-expression. Evidence also suggests that they may help to 
interpret a module as they likely reflect its predominant biological role. 
WGCNA has been successfully applied in many areas of medical research, including 
psychiatry. For example, WGCNA  has been used to differentiate disease cases from 
healthy controls and identify brain based immune system dysregulation in schizophrenia 
(Mistry et al., 2013), postsynaptic density implicated in the pathogenesis of bipolar 
disorder (Akula et al., 2015), peripheral inflammation in depression (Malki et al., 2013) 
and transcriptional and splicing dysregulation as underlying mechanisms of neuronal 
dysfunction in autism spectrum disorder (ASD) (Voineagu et al., 2011). Co-expression 
network analysis has also been applied to explore overlap and specificity across different 
disorders compared to healthy controls. For example, comparing gene co-expression 
patterns between adult and childhood attention-deficit hyperactivity disorder (ADHD), 
autism spectrum disorder (ASD), major depressive disorder (MDD) and healthy controls, 
it has been found that immune system dysregulation is involved in both MDD and adult 
ADHD and is inversely correlated with a disease status (de Jong et al., 2016). Using 
WGCNA, neuron differentiation and development pathways in cerebral cortex have been 
discovered as potential contributors to the etiologies for both schizophrenia and bipolar 
disorder (Chen et al., 2013);   while distinct molecular signatures have been found for 
ASD and intellectual disability (ID) (Parikshak et al., 2013). Recent work from Gandal et 
al. (2016) utilised WGCNA to compare molecular phenotypes across 5 major psychiatric 
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disorders, including autism (ASD), schizophrenia (SCZ), bipolar disorder (BD), 
depression (MDD), and alcoholism (AAD). From this comparison, authors were able to 
identify a clear pattern of shared and distinct gene-expression perturbations across all 
conditions. It has been found that neuronal gene co-expression modules were 
downregulated across ASD, SCZ, and BD, and astrocyte related modules were 
predominantly upregulated in ASD and SCZ.  
Differential co-expression network analysis to study differences among gene 
interconnections 
Differential co-expression analysis is a tool that is used to investigate the differences 
among gene interconnections. This is achieved by calculating the expression correlation 
change of each gene pair between conditions. Genes that are differentially co-expressed 
between different conditions are more likely to be regulators, thus, are likely to explain 
differences between phenotypes (Amar et al., 2013). By comparing the regulatory 
differences between cases and controls, specific differential networks of genes can be 
identified in psychiatric disorders. This methodology can be utilized to better understand 
the dynamic changes in gene regulatory networks in psychiatric illness, as well as 
comparing network properties across disorders. Thus, Xu et al. (2015) showed that 
mechanisms underlying MDD and subsyndromal symptomatic depression (SSD) were 
actually different. Authors found that there was no overlap between the MDD and SSD 
differentially regulated genes. Furthermore, the authors also found that Venlafaxine 
appeared to have a significant effect on the gene expression profile of MDD patients but 
no significant effect on the gene expression profiles of SSD patients. For more information 
on differential co-expression network analysis, see Hsu et al. (2015). 
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 DIAGNOSIS OF PATIENTS SUBTYPES 
Biclustering for identifying subgroups of patients  
Although gene co-expression clustering algorithms have proven useful for studying the 
molecular complexity of psychiatric disorders, the dominant clustering methodology 
discussed above is limited in its ability to detect gene expression patterns that are specific 
to subgroups of patients. An alternative approach called biclustering may be able to 
overcome this limitation. Biclustering is an alternative method for detecting differentially 
co-expressed genes between subgroups of patients, allowing for patient stratification into 
unique biological sub-groups. Biclustering algorithms perform clustering without the need 
for prior sample group classification, a beneficial characteristic given the uncertainty of 
diagnostic boundaries across psychiatric disorders. Using this approach, Cha et al. (2015) 
explored shared molecular basis of five neurodegenerative diseases (Alzheimer's 
disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic 
lateral sclerosis) and three psychiatric disorders (SCZ, BP, and ASD). The authors found 
that 4,307 genes were co-expressed in multiple brain diseases, whilst 3,409 gene sets 
were exclusively specified in individual brain diseases. Using the same approach in the 
field of oncology, Fiannaca et al. (2015) were able to identify unique molecular subgroups 
of breast cancer tumours based off of patients’ miRNA expression profiles. Interestingly 
enough, all patients presented with the same clinical profiles. These findings are 
beneficial for clinical practice as they may allow for the molecular stratification of both 
diagnosis and treatment of disease, thus, allowing clinicians to tailor treatment strategies 
to individual patients. At present, biclustering methods show promise to help further 
elucidate the complexity and biological heterogeneity of complex psychiatric traits. For an 
extensive overview of the different biclustering algorithms available, refer to (Pontes et 
al., 2015).  
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 PERSONALISED TREATMENTS 
Gene co-expression networks for understanding treatment response biotypes 
Understanding the biological basis of why some patients respond to certain therapies 
and others do not is essential for advancing personalised care in psychiatry. Due to the 
ability of gene co-expression analysis to approximate the complex interactions of 
biological information, it can be argued that this technique may help to inform the 
isolation of unique treatment response biotypes. Systematic characterisation of changes 
in gene co-expression patterns in responders vs. non-responders may provide biological 
grounds for developing predictive models that help to minimise therapeutic uncertainty. 
Furthermore, it may help to reveal novel mechanisms of action that remain unidentified 
in commonly used psychiatric drugs. Support for this notion has already been 
demonstrated in the field of oncology to delineate responders and non-responders to 
cancer treatment (Hsiao et al., 2016, Yang et al., 2014). In the field of psychiatry, co-
expression network analysis of peripheral blood has identified  immune-related pathways 
as important predispositions to antidepressant treatment response in MDD (Belzeaux et 
al., 2016). Blood-derived gene expression signature was found predictive of clozapine 
monotherapy in psychosis (Harrison et al., 2016). Furthermore, several gene co-
expression modules in patient-derived lymphoblastoid cell lines were discovered as 
lithium-responsive, indicating widespread effects of lithium on diverse cellular signalling 
systems including apoptosis and defence response pathways, protein processing and 
response to endoplasmic reticulum stress in bipolar disorder (Breen et al., 2016). As 
these studies suggest, applying co-expression based network methods across different 
disorders and medications can help to yield important insights on the molecular 
interactions regulating treatment response in complex psychiatric traits. 
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 DISEASE MECHANISMS 
Gene co-expression network for integrative analyses in psychiatry 
Due to the multiple testing burden, large samples sizes are required to detect disrupted 
genes and pathways when multiple biological processes are analysed in unison (Chari et 
al., 2010). Gene co-expression network analysis may help to facilitate this goal by 
providing an endpoint for the quantification of such processes. For example, Parikshak et 
al. (2013) found that by intersecting co-expression modules with GWAS loci, they were 
able to identify ASD genes that tightly coalesced with modules implicated in distinct 
biological functions during human cortical development, including early transcriptional 
regulation and synaptic development. Furthermore, when modules of a network are 
combined with epigenetic information, we can substantially enrich our understanding of 
the epigenetic interplay between both genes and the environment in psychiatric disorders 
(Gibney and Nolan, 2010). As such, integrated transcriptome and methylome data 
derived from peripheral blood was able to identify 43 risk genes that discriminated youth 
patients and high-risk for bipolar disorder patients from controls (Fries et al., 2017), further 
demonstrating the utility of integrative analyses in the identification of biomarkers for 
disease risk. 
Combining more than two layers of biological data is a largely unexplored avenue 
in psychiatric research (Bersanelli et al., 2016). However, Ciuculete et al. (2017) 
investigated the interplay between 37 psychiatric-related genetic risk variants as well as 
shifts in both methylation and mRNA levels in 223 adolescents distinguished as being at 
risk for the development of psychiatric disorders. Using this approach, the authors were 
able to detect five SNPs (in HCRTR1, GAD1, HADC3 and FKBP5), which were 
associated with eight CpG sites. Three of these CpG sites, cg01089319 (GAD1), 
cg01089249 (GAD1) and cg24137543 (DIAPH1), manifest in significant gene expression 
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changes and overlap with active regulatory regions in chromatin states of brain tissues. 
Although these findings are preliminary, further studies employing multi-stage integrative 
analysis may help to advance the field and provide novel insights on how genetic variants 
may modulate risks for the development of specific psychiatric diseases (Ritchie et al., 
2015). 
Shared molecular mechanisms between disorders: implications for treatment response 
There is growing understanding that many psychiatric diseases share underlying 
biological mechanisms. The cross-disorder group from the Psychiatric Genomics 
Consortium (PGC) has provided empirical evidence for the shared genetic etiology of five 
psychiatric disorders, including, schizophrenia, bipolar disorder, major depressive 
disorder (MDD), autism spectrum disorder (ASD) and attention-deficit/hyperactivity 
disorder (ADHD) (Lee et al., 2013). Recently, (Lotan et al., 2014) curated all GWAS 
findings for ADHD, anxiety disorders, ASD, bipolar disorder, MDD, and schizophrenia, 
finding that 22% of identified genes overlapped across two or more disorders. An overlap 
in underlying biology between different conditions was also observed at the level of gene 
expression. For example, using microarrays, Iwamoto et al. (2004) compared gene 
expression profiles across different brain regions in bipolar disorder, MDD and 
schizophrenia. What they found is that although these mental disorders were molecularly 
distinctive, there was a relatively large overlap of the gene expression profiles in all three 
disorders. Using RNA-seq, further support was provided for these findings by Darby et al. 
(2016), finding that hippocampus and orbitofrontal cortex transcriptomes were consistent 
across diagnostic groups. These fundings may also help to explain why the same 
medication exerts its effects on patients diagnosed with different disorders.  
Although we have outlined many studies that have successfully exploited co-
expression network approaches in psychiatric research, this methodology is yet to be fully 
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embraced by the field. New methods and algorithms for gene expression analyses are 
growing. Including the use of co-expression networks in conjunction with machine 
learning methodologies (Lareau et al., 2015). In the following section the role of machine 
learning in both genetics and gene expression for developing predictive models for 
diagnostic purposes as well as for treatment response will be further explored. 
 FUTURE METHODS: MACHINE LEARNING 
Machine learning (ML) exists at the intersection of computer science, mathematics, and 
statistics and is proving to be one such methodology that can handle the modelling of 
large, complex systems datasets (Iniesta et al., 2016). Given the brevity of this chapter, 
only a very brief explanation will be provided (see Iniesta et al. (2016) for a more extensive 
review). Firstly, supervised ML algorithms learn from data and improve their performance 
through experience. This is achieved through learning a set of features (SNPs, gene 
expression data) that relate to a label. The label can be either binary (response/non-
response) or multiclass (low-response/moderate-response/high-response). Supervised 
ML can also be used for regression, where a continuous outcome such as psychiatric 
illness severity can be predicted (Hastie et al., 2009). In contrast, unsupervised ML 
algorithms identify clusters in data derived from a distance metric (such as Euclidean 
distance) that potentially contain unique characteristics related to an outcome of interest 
(Ghahramani, 2004).  In this section, we will focus on supervised ML models. 
Gene selection and complex trait prediction 
There are two main problems that ML may help to resolve in both gene expression and 
genome-wide association studies. Firstly, given the large p small n problem (𝑝 ≫ 𝑛), a 
methodology is needed that can not only reduce the dimensionality of a genetic feature 
space, but do so in a way that can lead to a clinically meaningful prediction of a complex 
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trait. For example, using a patient’s gene expression data, can we predict whether or not 
a patient will respond to drug A) or drug B)? In differential expression analysis (DEA), 
univariate statistical tests are often performed to discover quantitative changes in 
expression levels between case and control phenotypes (Gupta et al., 2012). However, 
according to Okser et al. (2014), regularized ML models have demonstrated an improved 
ability to select SNPs and differentially expressed genes that are most predictive of 
complex traits. In ML, a process called regularization penalises a models’ complexity, 
thus, enabling prediction in individuals outside of a training data set. A beneficial 
characteristic of this approach is that they search out the most predictive combinations of 
variants, rather than just individually predictive variants like in univariate statistical tests. 
It is therefore not surprising that variants that do not attain genome-wide significance in 
univariate tests, often contribute to the predictive capacity of multi-locus ML models 
(Abraham et al., 2013, Evans et al., 2009). Furthermore, evidence is beginning to suggest 
that genetic markers with highly significant and replicated odds ratios derived from 
genome wide association studies (GWAS) may actually be poor classifiers of disease 
(Jakobsdottir et al., 2009). This is not to suggest that findings from GWAS studies are not 
useful; they provide valuable information for establishing etiological hypotheses. What it 
may suggest is that regularized ML models may be more beneficial for the derivation of 
clinically translatable pathways and variants that evade detection in classical statistical 
methods when 𝑝 ≫ 𝑛. Therefore, the use of regularized ML models may lead to greater 
prediction of disease and overall utility in translational psychiatry. 
Support for this hypothesis has been demonstrated by (Wei et al., 2013) in their ML based 
prediction of Crohn’s disease. Using regularized (lasso) logistic regression, they trained 
a prediction model whist also minimising a feature space of 10,799 SNPs. Their final 
model contained 573 SNPs and obtained an area under the curve (AUC) of 0.86. They 
then compared this model to a traditional log odds model. For dimensionality reduction, 
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they estimated association significance and odds ratios for each variant by using two folds 
of data. They took all variants where 𝑝 < 0.01 and pruned correlated variants by setting 
the linkage disequilibrium threshold to 𝑟2
1
4
 0.8. The final feature space contained 15,158 
SNPs and obtained an AUC of 0.73, a score 13% lower than the penalized logistic 
regression model whilst containing a feature space that was more than 25 times the size. 
Thus, achieving both sub-optimal predictive performance and decreased computational 
tractability relative to the regularized ML model. 
Applications for gene expression 
The use of ML methodologies for both dimensionality reduction and prediction of complex 
traits in gene expression studies is less prevalent, however, some support for this 
methodology has been attained. For example, (Tan and Gilbert, 2003) trained a decision 
tree classifier with probes from 6,817 genes to predict cancerous colon tumours, attaining 
an accuracy score of 95% to discern between each type of tumour. Furthermore, using 
bagged decision trees, they were also able to differentiate between two different types of 
lung cancer with 93% accuracy. Whether such findings are possible in complex 
psychiatric traits such as major depression is questionable, yet the methodology is 
theoretically applicable; and as demonstrated; appears to outperform univariate statistical 
tests and classical methods for both dimensionality reduction and prediction of complex 
traits when 𝑝 ≫ 𝑛. In support of this, preliminary evidence suggests that the use of an ML 
based methodologies in complex psychiatric trait prediction may be possible, yet much 
larger studies are still needed. For example, using a prospective design, Guilloux et al. 
(2014) collected blood samples from a discovery cohort of 34 adult MDD patients with co-
occurring anxiety and 33 matched non-depressed controls. Data was collected at 
baseline and after 12 weeks of combined citalopram and psychotherapy treatment. Using 
linear support vector machines trained on gene-expression data from 13 genes, they were 
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able to predict remission/non-remission of MDD with a cross validated corrected accuracy 
score of 76.2% (sensitivity = 86.1%, specificity = 59.3%). Much larger studies are still 
warranted across a range of complex traits and treatments; however, the initial proof of 
concept is encouraging. 
 CONCLUSIONS 
Studying interactions between genes in relation to psychiatric phenotype using co-
expression network analysis is a promising complementary approach to better 
understand molecular mechanisms of psychiatric disorders, which may lead to 
developing clinically translatable diagnostic and treatment response biomarkers. 
However, further research needs to also utilise machine learning algorithms to quantify 
diagnosis and treatment response prediction. We believe that these methods, combined, 
can help to advance a rapidly developing field of personalised psychiatry. 
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1. Demographics and case definition for the MAS and OATS 
 
1.1. Sydney Memory and Aging Study (MAS) 
 
The Sydney Memory and Aging Study (MAS) was initiated in 2005 to examine the clinical 
characteristics and prevalence of mild cognitive impairment (MCI) and related 
syndromes, including depression, and to determine the rate of change over time. At the 
baseline assessment from 2005 to 2007, 1037 non-demented individuals aged 70-90 
were recruited from two areas of Sydney, following a random approach to 8914 
individuals on the electoral roll. They underwent detailed neuropsychological assessment 
and donated a blood sample for clinical chemistry, proteomics and genomics. Participants 
were excluded if they had a previous diagnosis of dementia, psychotic symptoms or a 
diagnosis of schizophrenia or bipolar disorder, multiple sclerosis, motor neuron disease, 
developmental disability, progressive malignancy (active cancer or receiving treatment 
for cancer, other than prostate – non-metastases, and skin cancer), or if they had medical 
or psychological conditions that may have prevented them from completing assessments. 
Participants were excluded if they had a Mini-mental Statement Examination (MMSE) 
(Folstein et al., 1975)  score of <24 adjusted for age, education and non-English speaking 
background at study entry, or if they received a diagnosis of dementia after a 
comprehensive assessment. Participants were followed up with brief telephone reviews 
annually and detailed assessments biannually. More details on study design are 
published somewhere else (Sachdev et al., 2010).  
For the purposes of current work, we utilised the MAS as an exploratory cohort. 
Participants who had their venous blood collected for transcriptome analysis in Wave 4 
in MAS (N=521) were included in further analyses. The demographic characteristics of 
the sample are presented in Table S1. The mean age of the sample was 77.84 years at 
Wave 1, and 83.73 years at Wave 4. The sex ratio was F 255/M 266. Participants had a 
mean education of 11.8 years. Just over 99% of the participants were of Caucasian origin 





Table S1.1. Statistical tests of independence for Age, Sex and BMI between cases and 
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controls for four MDD patient subgroups in MAS cohort  



































LD 84.2±4.9 83.6±4.4 t(519)=1.0
2, p=0.3 







SD 83.7±4.6 83.7±4.6 t(519)=0.9, 
p=0.3 





27.3±4.4 26.8±4.2 t(519)=0.8, 
p=0.4 
CD 84.8±4.9 83.6±4.4 t(519)=1.7, 
p=0.07 





27.6±4.3 26.7±4.2 t(519)=1.4, 
p=0.2 
RD 83.7±4.5 83.8±4.0 t(519)=0.1, 
p=0.9 





27.4±4.4 26.8±4.2 t(519)=0.7, 
p=0.5 
LD – Lifetime diagnosis of MDD, SD – Single episode of MDD, CD – Current MDD, RD – Recurrent MDD 
 
Depression in MAS was assessed by a battery of well-validated self-report and interview-
based measures of depression. This buttery included: Geriatric Depression Scale (GDS-
15), Neuropsychiatric Inventory (NPI) (depression sub-scale), Mini International 
Neuropsychiatric Interview (M.I.N.I.), and Patient Health Questionnaire (PHQ-9). Given 
that the measures availability differed across the waves and the data in some of the 
measures were sparse, we argue that integration of all available data in time point 
diagnosis of depression at each wave is a meaningful approach to overcome these 
limitations. To integrate all available data on different measures of depression across the 
waves we created a composite variables depression for each wave. These composite 
scores represent a summative diagnosis of depression using all available information 
about the clinical representation of depression for 521 individuals. The step-by-step 
process of creating the composite variables of depression is detailed below. 
 
 
The process of creating composite variables of depression consisted of three steps: 
1) Creating unified dichotomous variables of depression for each measure in each 
wave. 
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2) Creating a composite diagnosis of depression for each wave using “minimum by 
two” approach.  
3) Creating a lifetime MDD, single episode, current, recurrent MDD variables of 
depression 
 
Step 1. Creating unified dichotomous variables of depression for each measure in each 
wave.  
Measures included: 
 Geriatric Depression Scale (GDS-15) 
The Geriatric Depression Scale (GDS-15) is a 15-item self-report assessment used to 
identify depression in the elderly (Yesavage et al., 1982b). In the MAS we used the GDS-
15 with item 9 as described in Brink (1982, here item 12) instead of the more common 
one. In order to determine whether this would affect the classification of depression, a 
statistical analysis was carried out on two data sets from the same sample, one with the 
GDS-15 containing the version used in MAS, and the other with the more common 
version. Using the same cut-point for depression (score ≥ 6) the results showed a high 
level of agreement between the two classifications (kappa = .931) with a total of only 4 
false positives, and no false negatives, out of a sample of 354. 
To derive a dichotomous variable of GDS scoring we applied commonly used a cut-off of 
6; participants scored ≥6 were assigned to 1 (depressed by GDS-15) and 0 (not 
depressed) if scored <6. 
 Neuropsychiatric Inventory (NPI). Depression sub-scales. 
The Neuropsychiatric Inventory (NPI) was developed by Cummings et al. (1994b) to 
assess dementia-related behavioural symptoms. The ratings of the NPI produce one 
score per behavioural domain. This score reflects the degree of disturbance of a particular 
domain. In this study, we used NPI sub-scales of depression to screen for depressive 
behaviours in our sample. Although using an individual NPI sub-scales have been 
subjected to further testing for its clinical utility (Lai, 2014), depression sub-scale showed 
moderate correlation with well-established Montgomery-Asberg Depression Rating 
Scale (MADRS) and Cornell Scale for Depression in Dementia (CSDD) depression 
instruments (MADRS: r = 0.70; CSDD: r = 0.62) (Leontjevas et al., 2009). This indicates 
that the NPI depression sub-scales are suitable for research purposes. 
A participant was assigned to 1 (depressed by NPI depression sub-scale) if a diagnosis 
was confirmed and to 0, if the diagnosis of depression was not confirmed.  
 Patient Health Questionnaire (PHQ-9) 
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The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD 
diagnostic instrument for common mental disorders. The PHQ-9 is the depression module 
to assess depression severity; it scores each of the 9 DSM-IV criteria as “0” (not at all) to 
“3” (nearly every day).  A PHQ-9 score ≥10 (moderate to severe depression) was shown 
to have a sensitivity of 88% and a specificity of 88% (Kroenke et al., 2001) for major 
depression. In this study, we used the cut-off of ≥10 to identify participants with 
depression.  
 The Mini International Neuropsychiatric Interview (M.I.N.I.) 
The M.I.N.I. is a widely used psychiatric structured diagnostic interview instrument for the 
major Axis I psychiatric disorders in DSM-IV and ICD-10. The MINI is divided into modules 
identified by letters corresponding to diagnostic categories. Each diagnostic module 
consists of screening questions corresponding to the main criteria of the disorder. All 
questions are rated and clinical judgment used in coding the responses. At the end of 
each module, clinician indicate whether diagnostic criteria are met. In this study, to create 
a dichotomous variable of depression by M.I.N.I. we used the final diagnosis in the 
category of depression made by clinicians.  
 
Step 2. Creating a composite diagnosis of depression for each wave using “minimum by 
two” approach. 
In the second step, we summarised by how many measures of depression participants 
were diagnosed by interview-based or/and self-report measures at each wave. This 
summative measure reflected the level of diagnostic consensus across the measures 
within each Wave. Given that the measures availability differed across the waves and the 
data in some of the measures were sparse, we argued that integration of all available 
data in time point diagnosis of depression at each wave is a meaningful approach to 
overcome these limitations.  To make use of all measures available, a “minimum by two” 
approach for diagnosing MDD was defined. Accordingly, MDD cases were defined as 
participants who were identified as clinically depressed by at least two of the above 
depression measures, according to DSM-IV criteria at each Wave. 
 
Step 3. Creating lifetime MDD, single episode, current, recurrent MDD variables of 
depression 
In the third step, we created composite variables of MDD (lifetime, single episode, current, 
and recurrent) across the waves described in the main text and Table 1.  
The 3 steps approach applied to MAS phenotype data of depression resulted in 13.3% of 
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lifetime depression prevalence, which is in line with current estimations of global 
prevalence of depression in older adults (Fiske et al., 2009). 
 
1.2. Older Australians Twins Study (OATS) 
 
The Older Australian Twins Study is a longitudinal study investigating healthy brain 
ageing in older twins (65+ years). Healthy ageing is characterised by low levels of 
disability, high cognitive and functional capacity, and an active engagement in life. The 
most important ingredient of healthy ageing is a healthy brain, bereft of age-related 
diseases and dysfunction, including depression. OATS commenced in New South Wales 
in January 2007, in Queensland in December 2007, and in Victoria in February 2008. 
Since the OATS study started we have followed our twin volunteers up every two years 
to check on their psychological and physical health. Participants undergo rigorous 
medical and cognitive function tests, with many participants also providing blood samples 
and having a magnetic resonance imaging (MRI) scan of their brain. OATS assessed 623 
participants at baseline, 450 at the 2-year follow up, and 390 completed their 4-year 
follow-up (Sachdev et al., 2012). 
For the purposes of current work, we utilised the OATS as a replication cohort.  
186 unrelated OATS participants, which had their venous blood collected for 
transcriptome analysis in Wave 3 were randomly selected (one twin from each twin pair) 
for further analyses.  
Depression in OATS was assessed by self-report (GDS-15 and PHQ-9) interview-based 
measures (NPI, depression sub-scale) and SCID. All depression assessment measures 
of depression were consistent between MAS and OATS, except M.I.N.I./SCID. While in 
MAS was used M.I.N.I. OATS utilised SCID. 
The Structured Clinical Interview for DSM (SCID) is a semi-structured interview guide for 
making the major DSM diagnoses. It was administered by a clinician or trained mental 
health professional. 
Using the three steps methodology developed for MAS, we identified the subgroup of 





2. Details on data generation and analyses   




2.1. Purification of intracellular RNA  
To extract RNA form the whole blood we used the PAXgene Blood RNA System 
(PreAnalytiX, QIAGEN), which consists of a blood collection tube (PAXgene Blood RNA 
Tubes) and nucleic acid purification kit (PAXgene Blood RNA Kit). It is intended for the 
collection, storage, and transport of blood and stabilization of intracellular RNA in a closed 
tube and subsequent isolation and purification of intracellular RNA from whole blood. 
The whole blood of 536 MAS participants at wave 4 was collected into PAXgene Blood 
RNA Tubes for stabilization further processing after overnight fasting between 7 and 9 
am.  
The total RNA was successfully extracted from whole blood collected from 521 samples 
using PAXgene Blood RNA Kits following manufacturer’s protocol for manual purification. 
In short, 2.5 ml of whole blood was centrifuged to pellet nucleic acids in the PAXgene 
Tube. The pellet was washed and resuspended. The resuspended pellet was incubated 
in optimized buffers together with proteinase K to bring about protein digestion. After 
homogenising the cell lysate and removing residual cell debris, the supernatant of the 
flow-through fraction was transferred to a fresh microcentrifuge tube. Ethanol was added 
to adjust binding conditions, and the lysate was applied to a PAXgene spin column. 
During a brief centrifugation, RNA was selectively bound to the PAXgebe silica membrane 
as contaminants pass through. Remaining contaminants were removed in several wash 
steps. Between the first and second wash steps, the membrane was treated with DNase 
I to remove trace amounts of bound DNA. After the wash steps, RNA was eluted in elution 
buffer and heat-denatured. 
2.2. Whole-genome gene expression direct hybridization  
The gene expression data were generated using the Illumina Whole-Genome Gene 
Expression Direct Hybridization Assay System IlluminaHT-12 v4. The HumanHT-12 v4 
Expression BeadChip content provides genome-wide transcriptional coverage of well-
characterized genes, gene candidates, and splice variants, delivering high-throughput 
processing of 12 samples per BeadChip. Each array on the HumanHT-12 v4 Expression 
BeadChip targets more than 47,000 probes derived from the National Center for 
Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 (November 
7, 2009) and other sources. The gene expression data was generated in the Adelaide 
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Microarray Centre (SA Pathology, Adelaide, Australia) by qualified personnel following 
manufacturer’s protocols. In short, unlabelled total RNA extracted from the whole blood 
samples were biotin-labelled and amplified producing a pool of cRNA corresponding to 
the polyadenylated (mRNA) fraction. The labelled RNA strand was then hybridized to the 
bead on the BeadChip containing the complementary gene-specific sequence. After the 
overnight hybridization, the BeadChips were removed and then washed. To detect a 
signal, Cy3-SA was introduced to bind to analytical probes that have been hybridized to 
the BeadChip. This allowed for differential detection of signals when BeadChips were 
scanned. The fluorescence intensity was scanned at each addressed bead location using 
the scanner Illumina HiScan. The intensity of the signal should correspond to the quality 
of the respective transcript in the original sample. The raw intensity images were analysed 




2.3. Data quality control (QC) 
Quality control was performed in R environment using limma package. 
 
Figure S1.1. Housekeeping genes performance 




Figure S1.2. System background noise 
 
The probes in this control category correspond to Cy3-labeled oligonucleotides. Following 
successful hybridization, they produce a signal independent of both RNA quality and 
success of the sample prep reactions. 
 
 
Figure S1.3. Array hybridization control 
 
Signal generation control consists of two probes with complementary biotin-tagged 
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oligonucleotides. Successful secondary staining is indicated by a positive hybridization 
signal from these probes. 
 
Figure S1.4. Signal generation control 
 
2.4. Data pre-processing 
Background correction. Maximum Likelihood Estimation (MLE) algorithm 
To control for background noise, which is inherited in gene expression experiments, 
Illumina allocated more than 1000 control bead types to each array, which are not 
associated with gene-specific probes, i.e. have no corresponding targets in the genomes. 
Therefore, the control beads are not expected to hybridize to any genes in the RNA 
samples. They serve as a comprehensive measurement of background, representing the 
imaging system background noise as well as any signal resulting from non-specific 
binding of dye or cross-hybridization in an experiment (Xie et al., 2009). The signals and 
signal standard deviation of these probes were used to establish gene expression 
detection limits (GenomeStudio). A model-based background correction implemented in 
R package MBCB allows incorporating information from these negative controls, which 
removes the non-specific signal from total signal and improves the efficiency of 
background correction, leading therefore to more precise determination of gene 
expression and better biological interpretation of the data (Allen et al., 2009). The 
maximum likelihood estimation (MLE) method showed the best estimation efficiency over 
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the other methods available in MBCB package (non-parametric (NP), robust multi-array 
average (RMA), Bayesian (B)) (Xie et al., 2009). 
Variance-stabilising transformation (VST) 
Variance stabilization is critical for subsequent statistical interference from microarray 
data. Illumina microarray platform provides a large number of technical replicates on each 
array (over 30 spatially distributed at random locations beads per probe). We performed 
the variance-stabilizing transformation (VST) method takes advantage of these technical 
replicates to stabilize the variance better and more efficiently (Lin et al., 2008). The VST 
requires the information of the standard deviation, however, the BeadStudio output file 
provides the standard error of the mean of the bead intensities corresponding to the same 
probe. Therefore, correction is required. The corrected value will be x * sqrt (N), where x 
is the standard error of the mean and N is the number of beads corresponding to the 
probe. VST can be viewed as a generalized log2 transformation, fine-tuned for the noise 
characteristics of each array.  
Normalization (quantile) 
When preparing microarray data for downstream analyses, it is important to remove 
sources of variation between arrays of non-biological origin. Normalization is a process 
for reducing this variation. There are different methods for data normalization available; 
quantile normalization is one of the most commonly used methods due to its robustness 
and performance speed (Bolstad et al., 2003). 
 
Figure S1.5. Intensity boxplots (mean and SD) before pre-processing and after pre-
processing (background correction, transformation, normalization) 





Figure S1.6. Density plot of intensity before pre-processing and after pre-processing 
 
 
Filtering by detection value 
After filtering probes by a stringent criteria of detection p-value <0.01 in ≥50% of samples 















Filtering by coefficient of variation 
For the purpose of the gene co-expression analysis we are interested in the genes the 
expression of which vary across the samples, since low-expressed or non-varying genes 
usually represent noise. To filter out low-varying probes we used coefficient of variation. 
The coefficient of variation shows the extent of variability in relation to the mean of the 
sample and is defined as the ratio of the standard deviation to the mean. CV was 
computed for each probe across all samples. The threshold of 0.01 (red line) is used to 
filter out the probes with low variation. 1834 genes were filtered out giving us a final data 











Figure S1.7. Filtering by coefficient of variation. Red line represents a threshold of 0.01. 
 
Figure S1.8. Density plot of intensity of pre-processed and filtered MAS data 
 
Data adjustment for technical covariates 
Data was adjusted for batch and RINs effects using Empirical bayes-moderated linear 
regression implemented in empiricalBayesLM function (WGCNA package). 
To estimate latent non-biological variables we used sva function (sva R package) (Leek 
et al., 2012). The number of significant surrogate variables was 0 (in both, MAS and 
OATS datasets), therefore there was no need to adjust the data for these factors. 
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2.5. Weighed gene co-expression network analysis (WGCNA) 
WGCNA was performed using the WGCNA R package, as previously described 
(Langfelder and Horvath, 2008). In short, this method selects the threshold for 
constructing the network based on the scale-free topology of gene co-expression 
networks. Using  biweight mid-correlation, which is a median-based rather than mean-
based robust to outliers alternative of Pearson’s correlation implemented in bicor function 
(Langfelder and Horvath, 2012),  we computed the networks for several thresholds and 
selected the threshold β=6, which led to a network with scale-free topology (Figure S1.9).  
 
 
Figure S1.9. Scale independence and mean connectivity.  
Analysis of network topology for various soft-thresholding powers. The left panel shows 
the scale-free fit index (y-axis) as a function of the soft-thresholding power (x-axis). The 
right panel displays the mean connectivity (degree, y-axis) as a function of the soft-
thresholding power (x-axis). 
The network consisted of 24 modules of functionally related genes on the basis of their 
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expression patterns. The modules were labelled 1 through 24 in order of descending size, 
with sizes ranging from 2845 to 34 genes. The label 0 is reserved for genes outside of all 
modules (Table S1.2).  
 
 
Figure S1.10. Clustering dendrogram of genes, with dissimilarity based on topological 
overlap, together with assigned module colours. 
 
Table S1.2. Number of modules identified and the module sizes.  
 
 
To quantify the relationship between MEs and binary outcome variable (MDD status, 1 or 
0) we used bicor  function with the parameters robustX and robustY set to FALSE, with 
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reverses robust biweight midcorrelation to standard Pearson’s correlation (Langfelder 
and Horvath, 2012).Correction for multiple testing 
To correct obtained p-values for GS measure for transcriptome-wide multiple testing we 
used FDR at relaxed level of 0.2. The reason behind choosing this liberal threshold of 
FDT at 0.2 is based on previous literature suggesting that depression is a heterogeneous 
disorder with multiple genes of a small effect. Given the limited sample size of MDD 
cases, this study is underpowered to detect MDD-associated genes with a better 
precision. However, we believe that we were able to capture depression-relevant 
biological signal that can be validated in the future studies with larger sample sizes. 
There were 1,656 probes nominally associated with recurrent MDD (p < 0.05); after 
transcriptome-wide correction for multiple comparisons using Benjamini-Hochberg 
procedure, we identified 923 recurrent MDD-associated probes at FDR = 0.2; 82% of 
those (761 probes) belonged to the modules the MEs of which showed association with 
recurrent MDD. 162 probes belonged to other modules of the co-expression network. 
Table S1.3. Number of probes associated with recurrent MDD at FDR 0.2. DOWN 




Total N of probes 
 
DOWN, N (%) 
 
UP, N (%) 
Turquoise 614 565 (92%) 49 (8%) 
Tan 56 0 56 (100%) 
Black 58 0 58 (100%) 
Lightcyan 33 2 (6%) 31 94%) 
 
There were no probes associated with recurrent MDD in the replication study (OATS) 
after correction for multiple testing at FDR 0.2.  
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2.6. Type-specific markers of expression profiles in recurrent MDD-associated 
modules 
Whole blood is a complex tissue consisting of numerous cell types. To assess whether 
specific cell type/s driving the expression signature we found as relevant for recurrent 
MDD, we obtained known gene expression signatures for six major immune cell types 
and contrasted these to the modules of interest derived from our data. To define cell type-
specific gene expression signatures, we used the most recent in-silico estimations 
calculated from multiple data sources. Authors employed a curve fitting approach for 
linear comparison of cell types on harmonized 1822 pure human cell type transcriptomes 
from various sources, and introduced a novel spillover compensation technique for 
separating them (Aran et al., 2017). We combined cell-type specific markers obtained 
from 5 data sources (FANTOM, HPCA, IRIS, Blueprint, and Novershtern) for six major 
types of immune cells (B cells, CD4+ cells, CD8+ cells, monocytes, neutrophils, NK cells) 
into cell type-specific vectors, removed duplicated values (genes found in multiple 
datasets) and calculated proportion of these markers in each of four recurrent MDD-
related modules. The results are presented in Table S1.4 and Figure S1.11.  
Table S1.4. Number of cell type-specific markers found in recurrent MDD-related 
modules (N, number of markers in each cell type). 
 N Turquoise Tan Black Lightcyan 
B cells 135 22 (16.3%) 2 (1.5%) 1 (0.7%) 1 (0.7%) 
CD4+ T cells 160 49 (30.6%) 0 (0%) 0 (0%) 0 (0%) 
CD8+ T cells 116 23 (19.8%) 2 (0.9%) 0 (0%) 1 (0.9%) 
Monocytes 303 75 (24.8%) 4 (1.3%) 8 (2.6%) 5 (1.7%) 
Neutrophils 80 10 (12.5) 1 (1.3%) 0 (0%) 1 (1.3%) 
NK cells 100 23 (23%) 1 (1%) 1 (1%) 4 (4%) 
 




Figure S1.11. Visualisation of relative proportions of genes belonging to recurrent 
MDD-associated modules found in cell type-specific gene expression signatures. 
Given the results presented we suggest that the Turquoise module is likely to be 
influenced by immune cells-specific gene expression, especially by CD4+ T cells. For the 
Tan, Black and Lightcyan module we found that negligible number of cell-specific markers 
(up to 2.6%) appear in these modules, suggesting minimal influence from these cell types. 
2.7. Functional analyses 
The results of Enrichment (DAVID) and Signalling Pathway Impact Analyses (SPIA) are 
presented in the Supplementary Table S7 and Table S8 (online manuscript). Graphical 
representation of each identified pathway can be viewed via KEGG link provided in this 
table. By clicking on the KEGG link, the pathway graph with the genes that driving 
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2.8. Replication (OATS cohort) 
 
RNA purification, Illumina hybridisation, QC checks, pre-processing and filtering in 
replication cohort (OATS) were performed identically to what was done in the exploratory 
cohort (sMAS). Moreover, to reinforce high replicability, blood samples collection, RNA 
extraction and hybridisation were performed using the same protocols, by the same people 
in the same facilities across two studies.  
 
Assessing comparability of gene expression data  
 
 
Figure S1.12. General Network properties defined as correlations between ranked 













Module preservation  
Table S1.5. Module preservation in sMAS and OATS datasets quantified by Z summary 












































Table S1.6. Replication of MAS findings in OATS. Correlations between the module 
eigengenes (ME) of Turquoise, Tan, Black, Lightcyan modules and single episode (SE), 
current (CD), recurrent (RD), and lifetime depression (LD), age, sex and BMI in OATS 
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Table S1.7. Nine common genes identified across three modules in the discovery (MAS) 
and replication (OATS) cohorts as associated with recurrent MDD in older adults. Module 
Membership (MM) is computed as correlation of a given module gene with the 
eigenegene of a module. Gene significance (GS) is a correlation between module 




































cathepsin C Turquoise 0.38 -0.14  
(0.001) 
0.5 -0.17 (0.02) 
2 ORMDL1 
94101 
ORMDL sphingolipid biosynthesis 
regulator 1 
Turquoise 0.76 -0.13 
(0.003) 
0.85 -0.16 (0.03) 
13 NARG1L 
79612 
N(alpha)-acetyltransferase 16, NatA 
auxiliary subunit 
Turquoise 0.74 -0.12 
(0.008) 
0.75 -0.15 (0.046) 
3 B4GALT4 
8702 
beta-1,4-galactosyltransferase 4 Turquoise 0.39 -0.11 (0.02) 0.43 -0.16 (0.04) 
11 GTF2H1 
2965 
general transcription factor IIH subunit 1 Turquoise 0.34 -0.09 (0.04) 0.32 0.15 (0.046) 
10 AGAP6 
414189 
ArfGAP with GTPase domain, ankyrin 
repeat and PH domain 6 
Turquoise 0.46 -0.09 (0.04) 0.44 -0.15 (0.04) 
6 THEMIS 
387357 
thymocyte selection associated Turquoise 0.66 -0.09 (0.04) 0.75 -0.15 (0.04) 
3 IL5RA 
3568 
interleukin 5 receptor subunit alpha Tan 0.31 0.1 (0.03) 0.4 0.2 (0.007) 
15 SNX22 
79856 





2.9. Significance of the overlap between sMAS and OATS findings 
 
To test for statistical significance of the overlap between recurrent MDD-correlated probes 
in discovery (sMAS) and replication (OATS) cohorts we calculated the representation 
factor (RF) and the associated probability.  
The groups of probes associated with recurrent MDD were compared in sMAS and OATS 
found to have x probes in common (Table S).  
Representation factor (RF) 
The RF is the number of overlapping probes divided by the expected number of 
overlapping probes drawn from two independent groups.  
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RF > 1 indicates more overlap than expected of two independent groups; 
RF < 1 indicated less overlap than expected of two independent groups. 
 
Probability 
Exact hypergeometric test was used to calculate the probability of the overlap between 
sMAS and OATS recurrent MDD-related probes.  
Online tool: http://nemates.org/MA/progs/overlap_stats.cgi 
 




Table S1.8. Statistical significance of the overlap between recurrent MDD-related probes 




N of probes correlated with 














Turquoise 963 38 7 2.1 p < 0.04 
Tan  117 1 1 94.2 p < 0.01 
Black 99 0 0 NA NA 
Lightcyan 62 1 1 177.7 p < 0.006 
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Table S1.9. List of 24 genes belonging to recurrent MDD-associated modules that 
previously were found as differentially expressed between MDD cases and controls 




















MGST1 4257 Turquoise -0.02 0.66 0.60 0 0.08 0.083936767
TXN 7295 Turquoise -0.03 0.57 0.56 0 0.46 3.53E-28
CLEC4A 50856 Turquoise -0.08 0.08 0.27 0 0.59 3.46E-50
CKLF 51192 Turquoise -0.03 0.43 0.50 0 0.47 2.00E-30
S100A8 6279 Turquoise 0.01 0.75 0.63 0 0.50 4.53E-34
GABARAP 11345 Turquoise -0.07 0.09 0.27 0 0.47 1.11E-29
ZBTB4 57659 Turquoise 0.02 0.64 0.59 0 -0.33 4.80E-15
ASXL1 171023 Turquoise -0.01 0.88 0.67 0 -0.29 1.20E-11
MACF1 23499 Turquoise 0.01 0.86 0.66 0 0.40 1.17E-21
FNBP4 23360 Turquoise -0.06 0.15 0.33 0 0.61 4.51E-55
TBP 6908 Turquoise -0.08 0.06 0.24 0 0.34 1.40E-15
PDCD7 10081 Turquoise 0.00 0.93 0.68 0 0.14 0.000972626
SLC7A6 9057 Turquoise -0.05 0.25 0.40 0 0.35 7.47E-17
RPL22 6146 Turquoise -0.07 0.13 0.31 0 0.41 6.72E-23
ATP8B2 57198 Turquoise -0.07 0.11 0.30 0 0.17 0.000125648
NOL8 55035 Turquoise -0.05 0.25 0.40 0 0.63 6.11E-58
MTSS1 9788 Turquoise -0.03 0.43 0.50 0 0.54 4.39E-41
TMEM194A 23306 Turquoise -0.08 0.07 0.25 0 0.64 7.66E-62
ERMP1 79956 Turquoise -0.02 0.70 0.61 0 0.35 4.09E-16
NFATC3 4775 Tan 0.15 0.00 0.17 1 0.56 1.40E-43
PQLC1 80148 Black 0.05 0.24 0.39 0 0.60 3.20E-53
GDE1 51573 Black 0.06 0.15 0.33 0 0.64 2.15E-60
IMPDH1 3614 Lightcyan 0.09 0.03 0.21 0 0.73 3.88E-89
EPM2AIP1 9852 Lightcyan -0.04 0.36 0.47 0 -0.56 4.00E-45
q_value signif_at_FDR_0.2 MM p_MMGene_Symbol Entrez_ID Module GS_recurrent MDD p_GS_recurrent MDD
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Supplementary materials for the manuscript “Downregulated 
transferrin receptor in the blood predicts recurrent MDD in the 
elderly cohort: a fuzzy forests approach” 
 
Our motivation for choosing fuzzy forests algorithm 
Fuzzy forests is an algorithm that combines two frameworks: co-expression based 
hierarchical clustering implemented in WGCNA and ensemble classifier Random forests. 
First, data is clustered into relatively uncorrelated modules of highly correlated features 
within the modules. Then, the most important features are selected using random forests 
recursive feature elimination in each module separately. The last iteration of random 
forests includes all survived features across all modules to build a final predictive model. 
The motivation for choosing this algorithm is twofold. Firstly, transcriptome data is highly 
multidimensional with a large proportion of correlated features. Clustering prior fitting 
random forests into clusters help to alleviate multicollinearity problem to which random 
forests is known to be sensitive to. Secondly, fuzzy logic implemented in the algorithm 
reduces dimensionality to alleviate overfitting due to p>>n problem. Given that the dataset 
was heavily unbalanced, we balanced our testing data using random undersampling of 
the majority class as well as k-nearest oversampling implemented in SMOTE algorithm.  
 
Overview of WGCNA 
WGCNA was developed to detect the correlational structure in biological networks, 
assuming that genes with high correlations are likely to be involved in the same biological 
processes. The R package WGCNA, a well-documented implementation of the WGCNA 
framework, has shown a great success in many biological applications, including our 
previous work (Langfelder and Horvath, 2008). Briefly, to construct a network, we first 
define a similarity function. This similarity function is based on Pearson’s’ correlation 
calculated for each possible pair of genes in transcriptome. To define the connection 
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strength measure between the genes in the network, these correlations are weighted by 
taking the absolute value and rising to the power β. Network connectivity is defined as a 
sum of connection strengths for each gene, describing how strongly each gene is 
connected to the other genes in the network. Next, we calculate the topological overlap 
for each pair of genes and identify groups of genes with high topological overlap, where 
both genes in a pair are strongly connected to the same group of genes.  Hierarchical 
clustering is used to identify clusters, or modules, of interconnected genes (Zhang and 
Horvath, 2005).  
 
Figure S2.1. Scale independence and mean connectivity.  Analysis of network topology 
for various soft-thresholding powers. The left panel shows the scale-free fit index (y-
axis) as a function of the soft-thresholding power (x-axis). The right panel displays the 
mean connectivity (degree, y-axis) as a function of the soft-thresholding power (x-axis). 
 
Random forests (RF) and Variable Importance Measures (VIM) 
RF is an ensemble method that works by combining the predictions of an ensemble of 
classification (or regression) decision trees introduced by Breiman (2001). The principle 
of RF is to combine many binary decision trees built using several bootstrap samples 
obtained from the training sample. Each tree is grown on a separate bootstrap sample of 
the training data. About one third of observations that are not selected in a particular 
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bootstrap sample are out of bag (OOB) for each tree. By averaging prediction error over 
multiple trees and many bootstrap samples the estimated prediction error was obtained 
to assess model performance. 
If the goal is to build a predictive model using transcriptome data that can be utilized for 
diagnostic purposes, selection of the most relevant features out of multidimensional 
feature space is necessary. This requires an understanding of how each individual feature 
affects the model, which can be evaluated by Variable Importance Measures, VIMs.  We 
estimated VIMs by calculating the effect of random permutations of the values of an 
individual feature (standardized level of gene expression) on predictive accuracy of the 
target outcome on test data, i.e. VIMs estimate the average decline in predictive 
performance for each individual feature across multiple trees, therefore providing reliable 
measure of variable importance for the prediction of outcome. RF VIMs were calculated 
for the final model. Given that random forests are non-linear and non-parametric, VIMs, 
defined above, thus, naturally take into account non-linear interactions between the 
genes. Score of importance of a given variable was calculated as Mean Decrease 
Accuracy and Mean Decrease Gini coefficients.  
 
The effect of the number of pre-selected features for the final prediction model 
The number of features included in the final model is a manually specified the 
number_selected parameter. We observed that while the ranking order of the features 
were relatively stable for different numbers of features selected the performance of the 
model was greatly affected by the number_selected parameter. As an example, Figure 
S2.2 shows variable importance for the number_selected = 10 as measured by Mean 
Decrease Accuracy and Mean Decrease Gini indices. As can be seen, the TFRC is the 
top predictor of the target outcome, which alone predicted the outcome with sensitivity of 
63%; however, we were unable to achieve clinically meaningful sensitivity using multiple 
features.  




Figure S2.2. Variable importance plot for 10 most predictive features. The plot shows 
each variable on the y-axis, and their importance on the x-axis. 
 
Fuzzy forests algorithm 
FF, being an extension of random forests, is powerful algorithm that was proposed to deal 
with correlated, high dimensional data (Conn et al., 2015, Conn et al., 2016). FF works 
using piecewise approach. First, the network structure of the data and partition of features 
into distinct modules such that the correlation within each module is high and the 
correlation between modules is low is estimated using WGCNA (Zhang and Horvath, 
2005). FF reduces dimensionality of the data in two steps: a screening step and a 
selection step. The screening step uses recursive feature elimination random forests 
(RFE-RF) (Díaz-Uriarte and Alvarez de Andrés, 2006) independently on each module to 
screen out unimportant features assigned to the module by WGCNA. Given that we apply 
this algorithm to biological data, it is reasonable to assume that while modules are 
relatively independent from each other, there is potential for interaction between the 
modules. The selection step is the final iteration of RFE-RF, which was applied to all 
features from all modules that have been selected at the screening step. Thus, the 
potential correlation bias between the features is re-introduced, allowing, therefore, for 
interactions between features that were found to be important within individual modules. 
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Lastly, based on a specified number of a ranked variable importance list a final group of 
selected features is used to train a predictive model.  
To optimize the model performance, FF allows for tuning several parameters: 
drop_fraction (number of features to drop at each iteration), keep_fraction (number of 
features to retain at each iteration), number_selected (number of important features as 
the output of the final random forest), ntree_factor, min_ntree (minimum number of trees 
grown in each random forest), and final_ntree (number of trees grown in the final random 
forest containing all selected features). Since the number of features varies across 
random forests, for each random forest, parameters mtry (number of variables randomly 
sampled at each split) and ntree (number of trees to grow) were specified as a function 
of the current number of features:  
mtry = ceiling((p/3)*mtry_factor, 
where p is a number of features in a given module and mtry_factor = 5; 
The parameter ntree for each random forest is ntree_factor times the number of features: 
ntree = max(min_ntree, ntree_factor*p), 
where min_ntree = 5 and ntree_factor = 5. 
We set drop_fraction = 0.25 and  keep_fraction = 0.05; number_selected = 1, 3, 5, 10, 
20, 50, or 100 and min_ntree = 100, 500, 1000, 5000, 10000. 
The number_selected parameter, which is the number of features to be determined as 
the top predictors at the RF iteration, was set to 1, 3, 5, 10, 20, 50, 100. 
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  Appendix C 
Table S3.1. The top 100 pathogen- and immune-related genes in association with 
recurrent MDD 
       
ILMN_probe Gene symbol Entrez_ID logFC AveExpr P-value FDR 5% 
ILMN_1740015 CD14 929 -0.69448 9.90586 9.51E-07 0.000916 
ILMN_2396444 CD14 929 -0.6436 12.15393 3.19E-06 0.001535 
ILMN_2070300 LSM2 57819 0.263971 8.561128 0.000563 0.157371 
ILMN_2152131 ACTB 60 -0.29085 13.05806 0.000654 0.157371 
ILMN_1787705 ATP6V1B2 526 -0.33626 11.03821 0.000882 0.169787 
ILMN_1658121 CFP 5199 -0.30173 7.950343 0.00109 0.174956 
ILMN_1767365 PAK1 5058 -0.29518 8.469129 0.001564 0.215213 
ILMN_1700428 HLA-DOB 3112 0.310135 7.338196 0.002755 0.261859 
ILMN_1799134 KLRD1 3824 0.446587 8.018866 0.002999 0.261859 
ILMN_1729987 SRC 6714 -0.15924 7.190677 0.003263 0.261859 
ILMN_1782538 VIM 7431 -0.34665 11.5966 0.003358 0.261859 
ILMN_1728799 FBP1 2203 -0.26878 8.140827 0.004249 0.261859 
ILMN_1690546 PPP3CC 5533 0.178654 7.416294 0.004786 0.261859 
ILMN_1778977 TYROBP 7305 -0.30005 12.60216 0.004816 0.261859 
ILMN_1654396 ITGB2 3689 -0.29333 12.80852 0.004918 0.261859 
ILMN_1789074 HSPA1A 3303 -0.45897 9.398591 0.005326 0.261859 
ILMN_2386790 KLRC3 3823 0.17302 6.915689 0.005448 0.261859 
ILMN_1663160 ZNF337 26152 0.14795 7.634455 0.005534 0.261859 
ILMN_1799725 DOCK2 1794 -0.24106 9.758014 0.005846 0.261859 
ILMN_1740493 TRAF5 7188 0.17357 7.39066 0.006153 0.261859 
ILMN_2038777 ACTB 60 -0.30301 12.83257 0.006362 0.261859 
ILMN_2043816 ARPC5L 81873 0.147105 7.50646 0.006929 0.261859 
ILMN_2175912 ITGB2 3689 -0.28925 12.81918 0.006991 0.261859 
ILMN_1783709 RRAGA 10670 0.137455 8.49008 0.007355 0.261859 
ILMN_1738523 MYD88 4615 -0.19647 8.357946 0.0074 0.261859 
ILMN_1777220 VCP 7415 -0.14859 7.665732 0.007598 0.261859 
ILMN_1736577 ZNF688 146542 0.078748 7.044594 0.007691 0.261859 
ILMN_1743646 VASP 7408 -0.31046 8.125938 0.008101 0.261859 
ILMN_1785179 UBE2G2 7327 0.169525 7.738553 0.008508 0.261859 
ILMN_2156172 HK2 3099 -0.09421 7.041178 0.008652 0.261859 
ILMN_1677483 EXOSC1 51013 0.091585 7.206799 0.00895 0.261859 
ILMN_1797988 KLRD1 3824 0.385149 7.950138 0.008956 0.261859 
ILMN_1727284 CD4 920 -0.14903 7.437383 0.008973 0.261859 
ILMN_2058251 VIM 7431 -0.28734 10.76031 0.009289 0.263093 
ILMN_2310589 DIABLO 56616 0.114487 8.429549 0.009713 0.267237 
ILMN_1661554 DIAPH1 1729 -0.21661 7.877845 0.010864 0.280583 
ILMN_1670302 HK3 3101 -0.25128 8.298209 0.010915 0.280583 
ILMN_1710756 ENO1 2023 -0.23966 10.80819 0.011072 0.280583 
ILMN_1666269 CTSZ 1522 -0.21966 7.771136 0.013034 0.313932 
ILMN_1801105 PRKCD 5580 -0.25181 9.674262 0.014312 0.313932 
ILMN_1782704 CD19 930 0.364886 7.412291 0.014432 0.313932 
ILMN_1778360 PYGB 5834 -0.17446 7.535417 0.014624 0.313932 
ILMN_2399392 SIL1 64374 -0.07433 6.901988 0.014731 0.313932 
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ILMN_1814465 UBE2G1 7326 0.136778 7.388585 0.014741 0.313932 
ILMN_1738326 EIF4E2 9470 -0.12767 8.235022 0.015087 0.313932 
ILMN_2397954 PARP3 10039 0.117501 7.403345 0.01512 0.313932 
ILMN_1696187 PYGL 5836 -0.32474 9.275016 0.015322 0.313932 
ILMN_1779177 U2AF1L4 199746 0.085796 7.138459 0.016295 0.323588 
ILMN_1723486 HK2 3099 -0.15133 7.28403 0.016465 0.323588 
ILMN_1657483 SEC23B 10483 -0.11031 7.783979 0.017062 0.328612 
ILMN_3300358 ZNF84 7637 0.082691 6.942481 0.017796 0.329452 
ILMN_2312149 ZNF160 90338 0.074512 6.976155 0.018338 0.329452 
ILMN_2360784 RRBP1 6238 -0.18561 7.968479 0.018348 0.329452 
ILMN_1704404 PSMD13 5719 -0.06521 6.989597 0.018474 0.329452 
ILMN_2209748 DERL1 79139 0.177152 7.729297 0.019163 0.331618 
ILMN_1698419 NCOR2 9612 -0.15518 7.509525 0.019544 0.331618 
ILMN_2126706 LMNB1 4001 -0.09505 7.016712 0.019628 0.331618 
ILMN_1675674 UBE4B 10277 -0.13078 7.85877 0.020035 0.332654 
ILMN_1812403 BCAP31 10134 -0.16238 9.093416 0.020957 0.337308 
ILMN_1766275 PIK3CD 5293 -0.24303 8.722367 0.021585 0.337308 
ILMN_1758105 ZNF791 163049 0.107228 7.383606 0.021666 0.337308 
ILMN_1729915 PILRA 29992 -0.23221 8.236452 0.021774 0.337308 
ILMN_1762003 SEC62 7095 0.108246 7.140513 0.022067 0.337308 
ILMN_2367020 SEC61G 23480 0.200263 8.986863 0.023566 0.35459 
ILMN_2241953 PILRA 29992 -0.22745 8.102257 0.025831 0.38269 
ILMN_1807277 IFI30 10437 -0.24818 9.018814 0.027117 0.39566 
ILMN_1795822 DIS3L 115752 0.136976 7.701837 0.028234 0.401373 
ILMN_1812915 TNFRSF10B 8795 -0.34032 8.652337 0.02867 0.401373 
ILMN_1675788 ZNF175 7728 0.062265 6.902299 0.029211 0.401373 
ILMN_1777049 ZNF160 90338 0.157271 7.496851 0.029727 0.401373 
ILMN_1674160 BIN1 274 0.205495 8.66141 0.030745 0.401373 
ILMN_2334242 CREB1 1385 0.287781 9.812279 0.031245 0.401373 
ILMN_1680693 ZNF419 79744 0.080125 7.474288 0.031286 0.401373 
ILMN_1662451 FCER2 2208 0.217731 7.163268 0.031599 0.401373 
ILMN_1674038 CTSD 1509 -0.25868 8.23181 0.031892 0.401373 
ILMN_2321416 DIAPH1 1729 -0.2275 8.913148 0.032941 0.401373 
ILMN_2083469 IRS2 8660 -0.22138 7.577877 0.033198 0.401373 
ILMN_2313821 AIFM1 9131 -0.06945 7.348443 0.033505 0.401373 
ILMN_1744980 ZCCHC7 84186 0.153612 7.342094 0.033782 0.401373 
ILMN_2309245 BIN1 274 0.190631 8.510109 0.033928 0.401373 
ILMN_1653711 FZD2 2535 -0.08769 6.955879 0.033939 0.401373 
ILMN_1762825 CANX 821 -0.12807 7.835239 0.034293 0.401373 
ILMN_1678962 DFFB 1677 0.066668 7.052557 0.034694 0.401373 
ILMN_1660533 RPN1 6184 -0.15075 9.445104 0.035011 0.401373 
ILMN_1772113 U2AF1 7307 -0.08878 7.575507 0.035827 0.403685 
ILMN_1768194 BIRC2 329 0.073412 6.985571 0.036593 0.403685 
ILMN_1727402 HCLS1 3059 -0.22965 11.40675 0.036762 0.403685 
ILMN_1781290 RHOA 387 -0.19906 11.16215 0.036889 0.403685 
ILMN_1787026 SEC61G 23480 0.192212 9.250013 0.03857 0.414548 
ILMN_1678919 YOD1 55432 0.281611 7.356455 0.038743 0.414548 
ILMN_1801928 YWHAZ 7534 -0.17459 11.06982 0.040615 0.428025 
ILMN_1781996 NUDT16 131870 -0.06442 6.989968 0.040891 0.428025 
ILMN_1779735 C7ORF59 389541 -0.17879 9.873468 0.041546 0.430202 
ILMN_1685365 ZNF773 374928 0.075789 7.004205 0.042572 0.433188 
ILMN_1733324 ITGB3 3690 -0.1723 7.03312 0.042734 0.433188 
ILMN_2131861 SOCS2 8835 0.130674 7.24166 0.043526 0.4362 
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ILMN_1739792 RHOG 391 -0.24455 11.40908 0.046314 0.446003 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
  




ABRAHAM, G., KOWALCZYK, A., ZOBEL, J. & INOUYE, M. 2013. Performance and 
Robustness of Penalized and Unpenalized Methods for Genetic Prediction of 
Complex Human Disease. Genetic Epidemiology, 37, 184-195. 
AKULA, N., WENDLAND, J. R., CHOI, K. H. & MCMAHON, F. J. 2015. An Integrative 
Genomic Study Implicates the Postsynaptic Density in the Pathogenesis of Bipolar 
Disorder. Neuropsychopharmacology, 41, 886. 
ALLEN, J. D., CHEN, M. & XIE, Y. 2009. Model-Based Background Correction (MBCB): 
R Methods and GUI for Illumina Bead-array Data. Journal of cancer science & 
therapy, 1, 25-27. 
ALTMAN, D. G. 2006. Practical Statistics for Medical Research, Chapman \& Hall/CRC. 
AMAR, D., SAFER, H. & SHAMIR, R. 2013. Dissection of Regulatory Networks that Are 
Altered in Disease via Differential Co-expression. PLOS Computational Biology, 9, 
e1002955. 
AMBROSIO, G., KAUFMANN, F. N., MANOSSO, L., PLATT, N., GHISLENI, G., 
RODRIGUES, A. L. S., RIEGER, D. K. & KASTER, M. P. 2018. Depression and 
peripheral inflammatory profile of patients with obesity. 
Psychoneuroendocrinology, 91, 132-141. 
ANISMAN, H., MERALI, Z. & POULTER, M. O. 2012. Gamma-Aminobutyric Acid 
Involvement in Depressive Illness Interactions with Corticotropin-Releasing 
Hormone and Serotonin 
The Neurobiological Basis of Suicide, Boca Raton FL, Llc. 
ANTONENKOV, V. D. & HILTUNEN, J. K. 2012. Transfer of metabolites across the 
peroxisomal membrane. Biochim Biophys Acta, 1822, 1374-86. 
ANTYPA, N., SERRETTI, A. & RUJESCU, D. 2013. Serotonergic genes and suicide: a 
systematic review. Eur Neuropsychopharmacol, 23, 1125-42. 
ARAN, D., HU, Z. & BUTTE, A. J. 2017. xCell: digitally portraying the tissue cellular 
heterogeneity landscape. 18, 220. 
ASTON, C., JIANG, L. & SOKOLOV, B. P. 2005. Transcriptional profiling reveals 
evidence for signaling and oligodendroglial abnormalities in the temporal cortex 
from patients with major depressive disorder. Mol Psychiatry, 10, 309-22. 
BAKUNINA, N., PARIANTE, C. M. & ZUNSZAIN, P. A. 2015. Immune mechanisms linked 
to depression via oxidative stress and neuroprogression. Immunology. 
BAUNE, B. T. 2018. Chapter 35 - Future Perspectives on Immune-Related Treatments. 
In: BAUNE, B. T. (ed.) Inflammation and Immunity in Depression. Academic Press. 
BELZEAUX, R., BERGON, A., JEANJEAN, V., LORIOD, B., FORMISANO-TREZINY, C., 
VERRIER, L., LOUNDOU, A., BAUMSTARCK-BARRAU, K., BOYER, L., GALL, 
V., GABERT, J., NGUYEN, C., AZORIN, J. M., NAUDIN, J. & IBRAHIM, E. C. 
2012. Responder and nonresponder patients exhibit different peripheral 
transcriptional signatures during major depressive episode. Transl Psychiatry, 2, 
e185. 
BELZEAUX, R., FORMISANO-TRÉZINY, C., LOUNDOU, A., BOYER, L., GABERT, J., 
SAMUELIAN, J. C., FÉRON, F., NAUDIN, J. & IBRAHIM, E. C. 2010. Clinical 
variations modulate patterns of gene expression and define blood biomarkers in 
major depression. Journal of Psychiatric Research, 44, 1205-1213. 
BELZEAUX, R., LIN, C.-W., DING, Y., BERGON, A., IBRAHIM, E. C., TURECKI, G., 
TSENG, G. & SIBILLE, E. 2016. Predisposition to treatment response in major 
depressive episode: A peripheral blood gene coexpression network analysis. 
Journal of Psychiatric Research, 81, 119-126. 
Transcriptome signature of depression 
177 
 
BERNARD, R., KERMAN, I. A., THOMPSON, R. C., JONES, E. G., BUNNEY, W. E., 
BARCHAS, J. D., SCHATZBERG, A. F., MYERS, R. M., AKIL, H. & WATSON, S. 
J. 2011. Altered expression of glutamate signaling, growth factor, and glia genes 
in the locus coeruleus of patients with major depression. Mol Psychiatry, 16, 634-
46. 
BERSANELLI, M., MOSCA, E., REMONDINI, D., GIAMPIERI, E., SALA, C., 
CASTELLANI, G. & MILANESI, L. 2016. Methods for the integration of multi-omics 
data: mathematical aspects. BMC Bioinformatics, 17, S15. 
BOLSTAD, B. M., IRIZARRY, R. A., ASTRAND, M. & SPEED, T. P. 2003. A comparison 
of normalization methods for high density oligonucleotide array data based on 
variance and bias. Bioinformatics, 19, 185-93. 
BONDY, B. 2007. Common genetic factors for depression and cardiovascular disease. 
Dialogues Clin Neurosci, 9, 19-28. 
BRANDAO, M., OLIVEIRA, J. C., BRAVO, F., REIS, J., GARRIDO, I. & PORTO, G. 2005. 
The soluble transferrin receptor as a marker of iron homeostasis in normal subjects 
and in HFE-related hemochromatosis. Haematologica, 90, 31-7. 
BREEN, M. S., WHITE, C. H., SHEKHTMAN, T., LIN, K., LOONEY, D., WOELK, C. H. & 
KELSOE, J. R. 2016. Lithium-responsive genes and gene networks in bipolar 
disorder patient-derived lymphoblastoid cell lines. The Pharmacogenomics 
Journal, 16, 446. 
BREIMAN, L. 2001. Random Forests. Machine Learning, 45, 5-32. 
CAI, N., CHANG, S., LI, Y., LI, Q., HU, J., LIANG, J., SONG, L., KRETZSCHMAR, W., 
GAN, X., NICOD, J., RIVERA, M., DENG, H., DU, B., LI, K., SANG, W., GAO, J., 
GAO, S., HA, B., HO, H. Y., HU, C., HU, J., HU, Z., HUANG, G., JIANG, G., JIANG, 
T., JIN, W., LI, G., LI, K., LI, Y., LI, Y., LI, Y., LIN, Y. T., LIU, L., LIU, T., LIU, Y., 
LIU, Y., LU, Y., LV, L., MENG, H., QIAN, P., SANG, H., SHEN, J., SHI, J., SUN, 
J., TAO, M., WANG, G., WANG, G., WANG, J., WANG, L., WANG, X., WANG, X., 
YANG, H., YANG, L., YIN, Y., ZHANG, J., ZHANG, K., SUN, N., ZHANG, W., 
ZHANG, X., ZHANG, Z., ZHONG, H., BREEN, G., WANG, J., MARCHINI, J., 
CHEN, Y., XU, Q., XU, X., MOTT, R., HUANG, G. J., KENDLER, K. & FLINT, J. 
2015. Molecular signatures of major depression. Curr Biol, 25, 1146-56. 
CARDINALI, D. P., SRINIVASAN, V., BRZEZINSKI, A. & BROWN, G. M. 2013. Melatonin 
and its analogs in insomnia and depression. Journal of Pineal Research, 52, 365-
375. 
CARTER, C. J. 2013. Susceptibility genes are enriched in those of the herpes simplex 
virus 1/host interactome in psychiatric and neurological disorders. Pathogens and 
Disease, 69, 240-261. 
CARVALHO, L. A., BERGINK, V., SUMASKI, L., WIJKHUIJS, J., HOOGENDIJK, W. J., 
BIRKENHAGER, T. K. & DREXHAGE, H. A. 2014. Inflammatory activation is 
associated with a reduced glucocorticoid receptor alpha/beta expression ratio in 
monocytes of inpatients with melancholic major depressive disorder. Transl 
Psychiatry, 4, e344. 
CASSANO, P. & FAVA, M. 2002. Depression and public health: an overview. J 
Psychosom Res, 53, 849-57. 
CATTANE, N., MINELLI, A., MILANESI, E., MAJ, C., BIGNOTTI, S., BORTOLOMASI, 
M., CHIAVETTO, L. B. & GENNARELLI, M. 2015. Altered Gene Expression in 
Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood. 
PLoS ONE, 10, e0116686. 
CATTANEO, A., MACCHI, F., PLAZZOTTA, G., VERONICA, B., BOCCHIO-
CHIAVETTO, L., RIVA, M. A. & PARIANTE, C. M. 2015. Inflammation and 
neuronal plasticity: a link between childhood trauma and depression pathogenesis. 
Frontiers in Cellular Neuroscience, 9. 
Transcriptome signature of depression 
178 
 
CHA, K., HWANG, T., OH, K. & YI, G.-S. 2015. Discovering transnosological molecular 
basis of human brain diseases using biclustering analysis of integrated gene 
expression data. BMC Medical Informatics and Decision Making, 15, S7-S7. 
CHARI, R., THU, K. L., WILSON, I. M., LOCKWOOD, W. W., LONERGAN, K. M., COE, 
B. P., MALLOFF, C. A., GAZDAR, A. F., LAM, S., GARNIS, C., MACAULAY, C. 
E., ALVAREZ, C. E. & LAM, W. L. 2010. Integrating the multiple dimensions of 
genomic and epigenomic landscapes of cancer. Cancer metastasis reviews, 29, 
73-93. 
CHARLESWORTH, J. C., CURRAN, J. E., JOHNSON, M. P., GORING, H. H., DYER, T. 
D., DIEGO, V. P., KENT, J. W., JR., MAHANEY, M. C., ALMASY, L., MACCLUER, 
J. W., MOSES, E. K. & BLANGERO, J. 2010. Transcriptomic epidemiology of 
smoking: the effect of smoking on gene expression in lymphocytes. BMC Med 
Genomics, 3, 29. 
CHAWLA, N. V., BOWYER, K. W., HALL, L. O. & KEGELMEYER, W. P. 2002. SMOTE: 
synthetic minority over-sampling technique. Journal of artificial intelligence 
research, 16, 321-357. 
CHEN, C., CHENG, L., GRENNAN, K., PIBIRI, F., ZHANG, C., BADNER, J. A., 
GERSHON, E. S. & LIU, C. 2013. Two Gene Co-expression Modules Differentiate 
Psychotics and Controls. Molecular psychiatry, 18, 1308-1314. 
CHISHOLM, D., SWEENY, K., SHEEHAN, P., RASMUSSEN, B., SMIT, F., CUIJPERS, 
P. & SAXENA, S. 2016. Scaling-up treatment of depression and anxiety: a global 
return on investment analysis. The Lancet Psychiatry, 3, 415-424. 
CHOUDARY, P. V., MOLNAR, M., EVANS, S. J., TOMITA, H., LI, J. Z., VAWTER, M. P., 
MYERS, R. M., BUNNEY, W. E., JR., AKIL, H., WATSON, S. J. & JONES, E. G. 
2005. Altered cortical glutamatergic and GABAergic signal transmission with glial 
involvement in depression. Proc Natl Acad Sci U S A, 102, 15653-8. 
CHU, T. T., LIU, Y. & KEMETHER, E. 2009. Thalamic transcriptome screening in three 
psychiatric states. Journal of Human Genetics, 54, 665-675. 
CIOBANU, L. G. & BAUNE, B. T. 2018. Chapter 11 - Gene Expression of Inflammation 
Markers in Depression. In: BAUNE, B. T. (ed.) Inflammation and Immunity in 
Depression. Academic Press. 
CIOBANU, L. G., FERRARI, A. J., ERSKINE, H. E., SANTOMAURO, D. F., CHARLSON, 
F. J., LEUNG, J., AMARE, A. T., OLAGUNJU, A. T., WHITEFORD, H. A. & 
BAUNE, B. T. 2018a. The prevalence and burden of mental and substance use 
disorders in Australia: Findings from the Global Burden of Disease Study 2015. 
Australian & New Zealand Journal of Psychiatry, 52, 483-490. 
CIOBANU, L. G., SACHDEV, P. S., TROLLOR, J. N., REPPERMUND, S., 
THALAMUTHU, A., MATHER, K. A., COHEN-WOODS, S. & BAUNE, B. T. 2016. 
Differential gene expression in brain and peripheral tissues in depression across 
the life span: A review of replicated findings. Neuroscience & Biobehavioral 
Reviews, 71, 281-293. 
CIOBANU, L. G., SACHDEV, P. S., TROLLOR, J. N., REPPERMUND, S., 
THALAMUTHU, A., MATHER, K. A., COHEN-WOODS, S., STACEY, D., TOBEN, 
C., SCHUBERT, K. O. & BAUNE, B. T. 2018b. Co-expression network analysis of 
peripheral blood transcriptome identifies dysregulated protein processing in 
endoplasmic reticulum and immune response in recurrent MDD in older adults. 
Journal of Psychiatric Research. 
CIPRIANI, A., FURUKAWA, T. A., SALANTI, G., CHAIMANI, A., ATKINSON, L. Z., 
OGAWA, Y., LEUCHT, S., RUHE, H. G., TURNER, E. H., HIGGINS, J. P. T., 
EGGER, M., TAKESHIMA, N., HAYASAKA, Y., IMAI, H., SHINOHARA, K., 
TAJIKA, A., IOANNIDIS, J. P. A. & GEDDES, J. R. 2018. Comparative efficacy 
and acceptability of 21 antidepressant drugs for the acute treatment of adults with 
Transcriptome signature of depression 
179 
 
major depressive disorder: a systematic review and network meta-analysis. 
Lancet, 391, 1357-1366. 
CIUCULETE, D. M., BOSTROM, A. E., VOISIN, S., PHILIPPS, H., TITOVA, O. E., 
BANDSTEIN, M., NIKONTOVIC, L., WILLIAMS, M. J., MWINYI, J. & SCHIOTH, 
H. B. 2017. A methylome-wide mQTL analysis reveals associations of methylation 
sites with GAD1 and HDAC3 SNPs and a general psychiatric risk score. Transl 
Psychiatry, 7, e1002. 
CLAPP, M., AURORA, N., HERRERA, L., BHATIA, M., WILEN, E. & WAKEFIELD, S. 
2017. Gut microbiota’s effect on mental health: The gut-brain axis. Clinics and 
Practice, 7, 987. 
CONN, D., NGUN, T., LI, G. & RAMIREZ, C. 2015. Fuzzy Forests: Extending Random 
Forests for Correlated, High-Dimensional Data. UCLA: Biostatistics. 
CONN, D., NGUN, T., LI, G. & RAMIREZ, C. M. 2016. Fuzzy forests: a new WGCNA 
based random forest algorithm for correlated, high-dimensional data. Journal of 
Statistical Software. 
CONVERGE 2015. Sparse whole-genome sequencing identifies two loci for major 
depressive disorder. Nature, 523, 588-591. 
COURTET, P. & OLIE, E. 2012. Circadian dimension and severity of depression. Eur 
Neuropsychopharmacol, 22 Suppl 3, S476-81. 
CRAMER, A. O. J., VAN BORKULO, C. D., GILTAY, E. J., VAN DER MAAS, H. L. J., 
KENDLER, K. S., SCHEFFER, M. & BORSBOOM, D. 2016. Major Depression as 
a Complex Dynamic System. PLoS ONE, 11, e0167490. 
CUMMINGS, J. L., MEGA, M., GRAY, K., ROSENBERG-THOMPSON, S., CARUSI, D. 
A. & GORNBEIN, J. 1994a. The Neuropsychiatric Inventory. Comprehensive 
assessment of psychopathology in dementia, 44, 2308-2308. 
CUMMINGS, J. L., MEGA, M., GRAY, K., ROSENBERG-THOMPSON, S., CARUSI, D. 
A. & GORNBEIN, J. 1994b. The Neuropsychiatric Inventory: comprehensive 
assessment of psychopathology in dementia. Neurology, 44, 2308-14. 
DARBY, M. M., YOLKEN, R. H. & SABUNCIYAN, S. 2016. Consistently altered 
expression of gene sets in postmortem brains of individuals with major psychiatric 
disorders. Translational Psychiatry, 6, e890. 
DARREL A. REGIER, WILLIAM E. NARROW, DIANA E. CLARKE, HELENA C. 
KRAEMER, S. JANET KURAMOTO, EMILY A. KUHL & DAVID J. KUPFER 2013. 
DSM-5 Field Trials in the United States and Canada, Part II: Test-Retest Reliability 
of Selected Categorical Diagnoses. American Journal of Psychiatry, 170, 59-70. 
DE BERARDIS, D., MARINI, S., FORNARO, M., SRINIVASAN, V., IASEVOLI, F., 
TOMASETTI, C., VALCHERA, A., PERNA, G., QUERA-SALVA, M. A., 
MARTINOTTI, G. & DI GIANNANTONIO, M. 2013. The melatonergic system in 
mood and anxiety disorders and the role of agomelatine: implications for clinical 
practice. Int J Mol Sci, 14, 12458-83. 
DE JONG, S., NEWHOUSE, S. J., PATEL, H., LEE, S., DEMPSTER, D., CURTIS, C., 
PAYA-CANO, J., MURPHY, D., WILSON, C. E., HORDER, J., MENDEZ, M. A., 
ASHERSON, P., RIVERA, M., COSTELLO, H., MALTEZOS, S., WHITWELL, S., 
PITTS, M., TYE, C., ASHWOOD, K. L., BOLTON, P., CURRAN, S., MCGUFFIN, 
P., DOBSON, R. & BREEN, G. 2016. Immune signatures and disorder-specific 
patterns in a cross-disorder gene expression analysis. The British Journal of 
Psychiatry, 209, 202-208. 
DÍAZ-URIARTE, R. & ALVAREZ DE ANDRÉS, S. 2006. Gene selection and classification 
of microarray data using random forest. BMC Bioinformatics, 7, 3-3. 
DIMOPOULOS, N., PIPERI, C., SALONICIOTI, A., MITSONIS, C., LIAPPAS, I., LEA, R. 
W. & KALOFOUTIS, A. 2006. Elevation of plasma concentration of adhesion 
Transcriptome signature of depression 
180 
 
molecules in late-life depression. International Journal of Geriatric Psychiatry, 21, 
965-971. 
DORIS, A., EBMEIER, K. & SHAJAHAN, P. 1999. Depressive illness. The Lancet, 354, 
1369-1375. 
DOTSON, V. M., DAVATZIKOS, C., KRAUT, M. A. & RESNICK, S. M. 2009. Depressive 
symptoms and brain volumes in older adults: a longitudinal magnetic resonance 
imaging study. Journal of Psychiatry & Neuroscience : JPN, 34, 367-375. 
DRAGO, A., DE RONCHI, D. & SERRETTI, A. 2007. Incomplete Coverage of Candidate 
Genes: A Poorly Considered Bias. Current Genomics, 8, 476-483. 
DUMAN, R. S., MALBERG, J. & THOME, J. 1999. Neural plasticity to stress and 
antidepressant treatment. Biol Psychiatry, 46, 1181-91. 
DURIC, V., BANASR, M., STOCKMEIER, C. A., SIMEN, A. A., NEWTON, S. S., 
OVERHOLSER, J. C., JURJUS, G. J., DIETER, L. & DUMAN, R. S. 2013. Altered 
expression of synapse and glutamate related genes in post-mortem hippocampus 
of depressed subjects. Int J Neuropsychopharmacol, 16, 69-82. 
ERIKSSON, P. S., PERFILIEVA, E., BJORK-ERIKSSON, T., ALBORN, A. M., 
NORDBORG, C., PETERSON, D. A. & GAGE, F. H. 1998. Neurogenesis in the 
adult human hippocampus. Nat Med, 4, 1313-7. 
EVANS, D. M., VISSCHER, P. M. & WRAY, N. R. 2009. Harnessing the information 
contained within genome-wide association studies to improve individual prediction 
of complex disease risk. Human Molecular Genetics, 18, 3525-3531. 
EVANS, S. J., CHOUDARY, P. V., NEAL, C. R., LI, J. Z., VAWTER, M. P., TOMITA, H., 
LOPEZ, J. F., THOMPSON, R. C., MENG, F., STEAD, J. D., WALSH, D. M., 
MYERS, R. M., BUNNEY, W. E., WATSON, S. J., JONES, E. G. & AKIL, H. 2004. 
Dysregulation of the fibroblast growth factor system in major depression. 
Proceedings of the National Academy of Sciences of the United States of America, 
101, 15506-15511. 
EYRE, H. A., AIR, T., PRADHAN, A., JOHNSTON, J., LAVRETSKY, H., STUART, M. J. 
& BAUNE, B. T. 2016. A meta-analysis of chemokines in major depression. 
Progress in neuro-psychopharmacology & biological psychiatry, 68, 1-8. 
FENG, Y., KAPORNAI, K., KISS, E., TAMÁS, Z., MAYER, L., BAJI, I., DARÓCZI, G., 
BENÁK, I., KOTHENCNÉ, V. O., DOMBOVÁRI, E., KACZVINSZK, E., BESNYŐ, 
M., GÁDOROS, J., SZÉKELY, J., KOVACS, M., VETRÓ, Á., KENNEDY, J. L. & 
BARR, C. L. 2010. Association of the GABRD Gene and Childhood-Onset Mood 
Disorders. Genes, brain, and behavior, 9, 668-672. 
FERRARI, A. J., CHARLSON, F. J., NORMAN, R. E., PATTEN, S. B., FREEDMAN, G., 
MURRAY, C. J. L., VOS, T. & WHITEFORD, H. A. 2013. Burden of Depressive 
Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of 
Disease Study 2010. PLOS Medicine, 10, e1001547. 
FIANNACA, A., LA ROSA, M., LA PAGLIA, L., RIZZO, R. & URSO, A. 2015. Analysis of 
miRNA expression profiles in breast cancer using biclustering. BMC 
Bioinformatics, 16, S7-S7. 
FISKE, A., WETHERELL, J. L. & GATZ, M. 2009. Depression in Older Adults. Annual 
Review of Clinical Psychology, 5, 363-389. 
FLINT, J. & KENDLER, KENNETH S. 2014. The Genetics of Major Depression. Neuron, 
81, 1214. 
FOLEY, D. L., MORLEY, K. I., MADDEN, P. A. F., HEATH, A. C., WHITFIELD, J. B. & 
MARTIN, N. G. 2010. Major depression and the metabolic syndrome. Twin 
research and human genetics : the official journal of the International Society for 
Twin Studies, 13, 347-358. 
Transcriptome signature of depression 
181 
 
FOLSTEIN, M. F., FOLSTEIN, S. E. & MCHUGH, P. R. 1975. "Mini-mental state". A 
practical method for grading the cognitive state of patients for the clinician. J 
Psychiatr Res, 12, 189-98. 
FREDRICKSON, B. L., GREWEN, K. M., COFFEY, K. A., ALGOE, S. B., FIRESTINE, A. 
M., AREVALO, J. M., MA, J. & COLE, S. W. 2013. A functional genomic 
perspective on human well-being. Proc Natl Acad Sci U S A, 110, 13684-9. 
FREIS, E. D. 1954. Mental Depression in Hypertensive Patients Treated for Long Periods 
with Large Doses of Reserpine. New England Journal of Medicine, 251, 1006-
1008. 
FRIES, G. R., QUEVEDO, J., ZENI, C. P., KAZIMI, I. F., ZUNTA-SOARES, G., SPIKER, 
D. E., BOWDEN, C. L., WALSS-BASS, C. & SOARES, J. C. 2017. Integrated 
transcriptome and methylome analysis in youth at high risk for bipolar disorder: a 
preliminary analysis. Translational Psychiatry, 7, e1059. 
GAITERI, C., DING, Y., FRENCH, B., TSENG, G. C. & SIBILLE, E. 2014. Beyond 
modules and hubs: the potential of gene coexpression networks for investigating 
molecular mechanisms of complex brain disorders. Genes Brain Behav, 13, 13-
24. 
GAITERI, C., GUILLOUX, J.-P., LEWIS, D. A. & SIBILLE, E. 2010a. Altered Gene 
Synchrony Suggests a Combined Hormone-Mediated Dysregulated State in Major 
Depression. PLoS ONE, 5, e9970. 
GAITERI, C., GUILLOUX, J. P., LEWIS, D. A. & SIBILLE, E. 2010b. Altered gene 
synchrony suggests a combined hormone-mediated dysregulated state in major 
depression. PLoS ONE, 5. 
GANDAL, M. J., HANEY, J., PARIKSHAK, N., LEPPA, V., HORVATH, S. & 
GESCHWIND, D. H. 2016. Shared molecular neuropathology across major 
psychiatric disorders parallels polygenic overlap. bioRxiv. 
GARBETT, K. A., VERECZKEI, A., KALMAN, S., BROWN, J. A., TAYLOR, W. D., 
FALUDI, G., KORADE, Z., SHELTON, R. C. & MIRNICS, K. 2015a. Coordinated 
messenger RNA/microRNA changes in fibroblasts of patients with major 
depression. Biol Psychiatry, 77, 256-65. 
GARBETT, K. A., VERECZKEI, A., KÁLMÁN, S., BROWN, J. A., TAYLOR, W. D., 
FALUDI, G., KORADE, Z., SHELTON, R. C. & MIRNICS, K. 2015b. Coordinated 
messenger RNA/microRNA changes in fibroblasts of patients with major 
depression. Biological Psychiatry, 77, 256-265. 
GBD 2017. Global, regional, and national disability-adjusted life-years (DALYs) for 333 
diseases and injuries and healthy life expectancy (HALE) for 195 countries and 
territories, 1990-2016: a systematic analysis for the Global Burden of Disease 
Study 2016. Lancet, 390, 1260-1344. 
GHAHRAMANI, Z. 2004. Unsupervised Learning. In: BOUSQUET, O., VON LUXBURG, 
U. & RÄTSCH, G. (eds.) Advanced Lectures on Machine Learning: ML Summer 
Schools 2003, Canberra, Australia, February 2 - 14, 2003, Tübingen, Germany, 
August 4 - 16, 2003, Revised Lectures. Berlin, Heidelberg: Springer Berlin 
Heidelberg. 
GIBNEY, E. R. & NOLAN, C. M. 2010. Epigenetics and gene expression. Heredity, 105, 
4-13. 
GONG, Q. & HE, Y. 2015. Depression, Neuroimaging and Connectomics: A Selective 
Overview. Biological Psychiatry, 77, 223-235. 
GORENSHTEYN, D., ZASLAVSKY, E., FRIBOURG, M., PARK, CHRISTOPHER Y., 
WONG, AARON K., TADYCH, A., HARTMANN, BORIS M., ALBRECHT, 
RANDY A., GARCÍA-SASTRE, A., KLEINSTEIN, STEVEN H., TROYANSKAYA, 
OLGA G. & SEALFON, STUART C. 2015. Interactive Big Data Resource to 
Elucidate Human Immune Pathways and Diseases. Immunity, 43, 605-614. 
Transcriptome signature of depression 
182 
 
GREENBERG, P. E., FOURNIER, A.-A., SISITSKY, T., PIKE, C. T. & KESSLER, R. C. 
2015. The Economic Burden of Adults With Major Depressive Disorder in the 
United States (2005 and 2010). J Clin Psychiatry  
GRIEVE, S. M., KORGAONKAR, M. S., KOSLOW, S. H., GORDON, E. & WILLIAMS, L. 
M. 2013. Widespread reductions in gray matter volume in depression. 
NeuroImage: Clinical, 3, 332-339. 
GUILLOUX, J.-P., BASSI, S., DING, Y., WALSH, C., TURECKI, G., TSENG, G., 
CYRANOWSKI, J. M. & SIBILLE, E. 2014. Testing the Predictive Value of 
Peripheral Gene Expression for Nonremission Following Citalopram Treatment for 
Major Depression. Neuropsychopharmacology, 40, 701. 
GUPTA, R., DEWAN, I., BHARTI, R. & BHATTACHARYA, A. 2012. Differential 
Expression Analysis for RNA-Seq Data. ISRN Bioinformatics, 2012, 8. 
HAAPAKOSKI, R., EBMEIER, K. P., ALENIUS, H. & KIVIMÄKI, M. 2016. Innate and 
adaptive immunity in the development of depression: An update on current 
knowledge and technological advances. Progress in Neuro-Psychopharmacology 
and Biological Psychiatry, 66, 63-72. 
HALARIS, A. 2017. Inflammation-Associated Co-morbidity Between Depression and 
Cardiovascular Disease. Curr Top Behav Neurosci, 31, 45-70. 
HARDEVELD, F., SPIJKER, J., VREEBURG, S. A., GRAAF, R. D., HENDRIKS, S. M., 
LICHT, C. M., NOLEN, W. A., PENNINX, B. W. & BEEKMAN, A. T. 2014. 
Increased cortisol awakening response was associated with time to recurrence of 
major depressive disorder. Psychoneuroendocrinology, 50, 62-71. 
HARRISON, R. N. S., MURRAY, R. M., LEE, S. H., PAYA CANO, J., DEMPSTER, D., 
CURTIS, C. J., DIMA, D., GAUGHRAN, F., BREEN, G. & DE JONG, S. 2016. 
Gene-expression analysis of clozapine treatment in whole blood of patients with 
psychosis. Psychiatric Genetics, 26, 211-217. 
HASLER, G. 2010. PATHOPHYSIOLOGY OF DEPRESSION: DO WE HAVE ANY 
SOLID EVIDENCE. World Psychiatry, 9, 155-161. 
HASTIE, T., TIBSHIRANI, R. & FRIEDMAN, J. 2009. The Elements of Statistical 
Learning: Data Mining, Inference, and Prediction, Springer. 
HAY, S. I., ABAJOBIR, A. A., ABATE, K. H., ABBAFATI, C., ABBAS, K. M., ABD-ALLAH, 
F., ABDULKADER, R. S., ABDULLE, A. M., ABEBO, T. A., ABERA, S. F., 
ABOYANS, V., ABU-RADDAD, L. J., ACKERMAN, I. N., ADEDEJI, I. A., 
ADETOKUNBOH, O., AFSHIN, A., AGGARWAL, R., AGRAWAL, S., AGRAWAL, 
A., AHMED, M. B., AICHOUR, M. T. E., AICHOUR, A. N., AICHOUR, I., AIYAR, 
S., AKINYEMIJU, T. F., AKSEER, N., AL LAMI, F. H., ALAHDAB, F., AL-ALY, Z., 
ALAM, K., ALAM, N., ALAM, T., ALASFOOR, D., ALENE, K. A., ALI, R., 
ALIZADEH-NAVAEI, R., ALKAABI, J. M., ALKERWI, A. A., ALLA, F., ALLEBECK, 
P., ALLEN, C., AL-MASKARI, F., ALMAZROA, M. A., AL-RADDADI, R., 
ALSHARIF, U., ALSOWAIDI, S., ALTHOUSE, B. M., ALTIRKAWI, K. A., ALVIS-
GUZMAN, N., AMARE, A. T., AMINI, E., AMMAR, W., AMOAKO, Y. A., ANSHA, 
M. G., ANTONIO, C. A. T., ANWARI, P., ÄRNLÖV, J., ARORA, M., ARTAMAN, 
A., ARYAL, K. K., ASGEDOM, S. W., ATEY, T. M., ATNAFU, N. T., AVILA-
BURGOS, L., AVOKPAHO, E. F. G. A., AWASTHI, A., AWASTHI, S., 
AZARPAZHOOH, M. R., AZZOPARDI, P., BABALOLA, T. K., BACHA, U., 
BADAWI, A., BALAKRISHNAN, K., BANNICK, M. S., BARAC, A., BARKER-
COLLO, S. L., BÄRNIGHAUSEN, T., BARQUERA, S., BARRERO, L. H., BASU, 
S., BATTISTA, R., BATTLE, K. E., BAUNE, B. T., BAZARGAN-HEJAZI, S., 
BEARDSLEY, J., BEDI, N., BÉJOT, Y., BEKELE, B. B., BELL, M. L., BENNETT, 
D. A., BENNETT, J. R., BENSENOR, I. M., BENSON, J., BERHANE, A., BERHE, 
D. F., BERNABÉ, E., BETSU, B. D., BEURAN, M., BEYENE, A. S., BHANSALI, 
A., et al. 2017. Global, regional, and national disability-adjusted life-years (DALYs) 
Transcriptome signature of depression 
183 
 
for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries 
and territories, 1990–2016: a systematic analysis for the Global Burden of Disease 
Study 2016. The Lancet, 390, 1260-1344. 
HEK, K., DEMIRKAN, A., LAHTI, J., TERRACCIANO, A., TEUMER, A., CORNELIS, M. 
C., AMIN, N., BAKSHIS, E., BAUMERT, J., DING, J., LIU, Y., MARCIANTE, K., 
MEIRELLES, O., NALLS, M. A., SUN, Y. V., VOGELZANGS, N., YU, L., 
BANDINELLI, S., BENJAMIN, E. J., BENNETT, D. A., BOOMSMA, D., CANNAS, 
A., COKER, L. H., DE GEUS, E., DE JAGER, P. L., DIEZ-ROUX, A. V., PURCELL, 
S., HU, F. B., RIMMA, E. B., HUNTER, D. J., JENSEN, M. K., CURHAN, G., RICE, 
K., PENMAN, A. D., ROTTER, J. I., SOTOODEHNIA, N., EMENY, R., ERIKSSON, 
J. G., EVANS, D. A., FERRUCCI, L., FORNAGE, M., GUDNASON, V., HOFMAN, 
A., ILLIG, T., KARDIA, S., KELLY-HAYES, M., KOENEN, K., KRAFT, P., 
KUNINGAS, M., MASSARO, J. M., MELZER, D., MULAS, A., MULDER, C. L., 
MURRAY, A., OOSTRA, B. A., PALOTIE, A., PENNINX, B., PETERSMANN, A., 
PILLING, L. C., PSATY, B., RAWAL, R., REIMAN, E. M., SCHULZ, A., SHULMAN, 
J. M., SINGLETON, A. B., SMITH, A. V., SUTIN, A. R., UITTERLINDEN, A. G., 
VOLZKE, H., WIDEN, E., YAFFE, K., ZONDERMAN, A. B., CUCCA, F., HARRIS, 
T., LADWIG, K. H., LLEWELLYN, D. J., RAIKKONEN, K., TANAKA, T., VAN 
DUIJN, C. M., GRABE, H. J., LAUNER, L. J., LUNETTA, K. L., MOSLEY, T. H., 
JR., NEWMAN, A. B., TIEMEIER, H. & MURABITO, J. 2013. A genome-wide 
association study of depressive symptoms. Biol Psychiatry, 73, 667-78. 
HIRUNSATIT, R., GEORGE, E. D., LIPSKA, B. K., ELWAFI, H. M., SANDER, L., 
YRIGOLLEN, C. M., GELERNTER, J., GRIGORENKO, E. L., LAPPALAINEN, J., 
MANE, S., NAIRN, A. C., KLEINMAN, J. E. & SIMEN, A. A. 2009. Twenty-one-
base-pair insertion polymorphism creates an enhancer element and potentiates 
SLC6A1 GABA transporter promoter activity. Pharmacogenet Genomics, 19, 53-
65. 
HSIAO, T.-H., CHIU, Y.-C., HSU, P.-Y., LU, T.-P., LAI, L.-C., TSAI, M.-H., HUANG, T. H. 
M., CHUANG, E. Y. & CHEN, Y. 2016. Differential network analysis reveals the 
genome-wide landscape of estrogen receptor modulation in hormonal cancers. 
Scientific Reports, 6, 23035. 
HSU, C.-L., JUAN, H.-F. & HUANG, H.-C. 2015. Functional Analysis and Characterization 
of Differential Coexpression Networks. Scientific Reports, 5, 13295. 
HYDE, C. L., NAGLE, M. W., TIAN, C., CHEN, X., PACIGA, S. A. & WENDLAND, J. R. 
2016. Identification of 15 genetic loci associated with risk of major depression in 
individuals of European descent. 48, 1031-6. 
INIESTA, R., STAHL, D. & MCGUFFIN, P. 2016. Machine learning, statistical learning 
and the future of biological research in psychiatry. Psychological Medicine, 46, 
2455-2465. 
IWAMOTO, K., KAKIUCHI, C., BUNDO, M., IKEDA, K. & KATO, T. 2004. Molecular 
characterization of bipolar disorder by comparing gene expression profiles of 
postmortem brains of major mental disorders. Mol Psychiatry, 9, 406-16. 
JAKOBSDOTTIR, J., GORIN, M. B., CONLEY, Y. P., FERRELL, R. E. & WEEKS, D. E. 
2009. Interpretation of Genetic Association Studies: Markers with Replicated 
Highly Significant Odds Ratios May Be Poor Classifiers. PLOS Genetics, 5, 
e1000337. 
JANSEN, R., BATISTA, S., BROOKS, A. I., TISCHFIELD, J. A., WILLEMSEN, G., VAN 
GROOTHEEST, G., HOTTENGA, J.-J., MILANESCHI, Y., MBAREK, H., MADAR, 
V., PEYROT, W., VINK, J. M., VERWEIJ, C. L., DE GEUS, E. J., SMIT, J. H., 
WRIGHT, F. A., SULLIVAN, P. F., BOOMSMA, D. I. & PENNINX, B. W. 2014. Sex 
differences in the human peripheral blood transcriptome. BMC Genomics, 15, 33. 
Transcriptome signature of depression 
184 
 
JANSEN, R., PENNINX, B. W., MADAR, V. & XIA, K. 2016. Gene expression in major 
depressive disorder. 21, 339-47. 
JIANG, M., QIN, P. & YANG, X. 2014. Comorbidity between depression and asthma via 
immune-inflammatory pathways: A meta-analysis. Journal of Affective Disorders, 
166, 22-29. 
KALMAN, S., GARBETT, K. A., JANKA, Z. & MIRNICS, K. 2016. Human dermal 
fibroblasts in psychiatry research. Neuroscience, 320, 105-121. 
KANG, H. J., ADAMS, D. H., SIMEN, A., SIMEN, B. B., RAJKOWSKA, G., 
STOCKMEIER, C. A., OVERHOLSER, J. C., MELTZER, H. Y., JURJUS, G. J., 
KONICK, L. C., NEWTON, S. S. & DUMAN, R. S. 2007. Gene expression profiling 
in postmortem prefrontal cortex of major depressive disorder. J Neurosci, 27, 
13329-40. 
KAWABATA, H. 2018. Transferrin and transferrin receptors update. Free Radical Biology 
and Medicine. 
KHUMALO, H., GOMO, Z. A. R., MOYO, V. M., GORDEUK, V. R., SAUNGWEME, T., 
ROUAULT, T. A. & GANGAIDZO, I. T. 1998. Serum transferrin receptors are 
decreased in the presence of iron overload. Clinical Chemistry, 44, 40-44. 
KIM, S., HWANG, Y., WEBSTER, M. J. & LEE, D. 2016. Differential activation of 
immune/inflammatory response-related co-expression modules in the 
hippocampus across the major psychiatric disorders. Molecular Psychiatry, 21, 
376-385. 
KIRSCH, I. 2014. Antidepressants and the Placebo Effect. Z Psychol, 222, 128-134. 
KLEMPAN, T. A., SEQUEIRA, A., CANETTI, L., LALOVIC, A., ERNST, C., FFRENCH-
MULLEN, J. & TURECKI, G. 2009. Altered expression of genes involved in ATP 
biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of 
suicides with and without major depression. Mol Psychiatry, 14, 175-89. 
KOHEN, R., DOBRA, A., TRACY, J. H. & HAUGEN, E. 2014a. Transcriptome profiling of 
human hippocampus dentate gyrus granule cells in mental illness. Transl 
Psychiatry, 4, e366. 
KOHEN, R., DOBRA, A., TRACY, J. H. & HAUGEN, E. 2014b. Transcriptome profiling of 
human hippocampus dentate gyrus granule cells in mental illness. Translational 
Psychiatry, 4. 
KOHLER-FORSBERG, O., BUTTENSCHON, H. N., TANSEY, K. E., MAIER, W., 
HAUSER, J., DERNOVSEK, M. Z., HENIGSBERG, N., SOUERY, D., FARMER, 
A., RIETSCHEL, M., MCGUFFIN, P., AITCHISON, K. J., UHER, R. & MORS, O. 
2017. Association between C-reactive protein (CRP) with depression symptom 
severity and specific depressive symptoms in major depression. Brain Behav 
Immun, 62, 344-350. 
KÖHLER, O., BENROS, M. E., NORDENTOFT, M. & ET AL. 2014. Effect of anti-
inflammatory treatment on depression, depressive symptoms, and adverse 
effects: A systematic review and meta-analysis of randomized clinical trials. JAMA 
Psychiatry, 71, 1381-1391. 
KÖHLER, O., KROGH, J., MORS, O. & BENROS, M. E. 2016. Inflammation in 
Depression and the Potential for Anti-Inflammatory Treatment. Current 
Neuropharmacology, 14, 732-742. 
KROENKE K & R., S. 2002. The PHQ-9: A New Depression Diagnostic and Severity 
Measure. Psychiatr Ann. 
KROENKE, K., SPITZER, R. L. & WILLIAMS, J. B. 2001. The PHQ-9: validity of a brief 
depression severity measure. J Gen Intern Med, 16, 606-13. 
KUBOTA, T., MIYAKE, K. & HIRASAWA, T. 2012. Epigenetic understanding of gene-
environment interactions in psychiatric disorders: a new concept of clinical 
genetics. Clinical Epigenetics, 4, 1. 
Transcriptome signature of depression 
185 
 
LAI, C. K. Y. 2014. The merits and problems of Neuropsychiatric Inventory as an 
assessment tool in people with dementia and other neurological disorders. Clinical 
Interventions in Aging, 9, 1051-1061. 
LANDIS, J. R. & KOCH, G. G. 1977. The measurement of observer agreement for 
categorical data. Biometrics, 33, 159-174. 
LANGFELDER, P. & HORVATH, S. 2008. WGCNA: an R package for weighted 
correlation network analysis. BMC Bioinformatics, 9, 559. 
LANGFELDER, P. & HORVATH, S. 2012. Fast R Functions for Robust Correlations and 
Hierarchical Clustering. Journal of statistical software, 46, i11. 
LAREAU, C. A., WHITE, B. C., OBERG, A. L. & MCKINNEY, B. A. 2015. Differential co-
expression network centrality and machine learning feature selection for identifying 
susceptibility hubs in networks with scale-free structure. BioData Mining, 8, 5. 
LAU, C., NYGÅRD, S., FURE, H., OLSTAD, O. K., HOLDEN, M., LAPPEGÅRD, K. T., 
BREKKE, O.-L., ESPEVIK, T., HOVIG, E. & MOLLNES, T. E. 2015. CD14 and 
Complement Crosstalk and Largely Mediate the Transcriptional Response to 
Escherichia coli in Human Whole Blood as Revealed by DNA Microarray. PLOS 
ONE, 10, e0117261. 
LEDAY, G. G. R., VERTES, P. E., RICHARDSON, S., GREENE, J. R., REGAN, T., 
KHAN, S., HENDERSON, R., FREEMAN, T. C., PARIANTE, C. M., HARRISON, 
N. A., PERRY, V. H., DREVETS, W. C., WITTENBERG, G. M. & BULLMORE, E. 
T. 2018. Replicable and Coupled Changes in Innate and Adaptive Immune Gene 
Expression in Two Case-Control Studies of Blood Microarrays in Major Depressive 
Disorder. Biol Psychiatry, 83, 70-80. 
LEE, S. H., RIPKE, S., NEALE, B. M. & FARAONE, S. V. 2013. Genetic relationship 
between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet, 
45, 984-994. 
LEEK, J. T., JOHNSON, W. E., PARKER, H. S., JAFFE, A. E. & STOREY, J. D. 2012. 
The sva package for removing batch effects and other unwanted variation in high-
throughput experiments. Bioinformatics, 28, 882-3. 
LEONTJEVAS, R., VAN HOOREN, S. & MULDERS, A. 2009. The Montgomery-Asberg 
Depression Rating Scale and the Cornell Scale for Depression in Dementia: a 
validation study with patients exhibiting early-onset dementia. Am J Geriatr 
Psychiatry, 17, 56-64. 
LESPÉRANCE, F., FRASURE-SMITH, N., THÉROUX, P. & IRWIN, M. 2004. The 
Association Between Major Depression and Levels of Soluble Intercellular 
Adhesion Molecule 1, Interleukin-6, and C-Reactive Protein in Patients With 
Recent Acute Coronary Syndromes. American Journal of Psychiatry, 161, 271-
277. 
LEVINSON, D. F., MOSTAFAVI, S., MILANESCHI, Y., RIVERA, M., RIPKE, S., WRAY, 
N. R. & SULLIVAN, P. F. 2014. Genetic studies of major depressive disorder: Why 
are there no GWAS findings, and what can we do about it? Biological psychiatry, 
76, 510-512. 
LI, J. Z., BUNNEY, B. G., MENG, F., HAGENAUER, M. H., WALSH, D. M., VAWTER, M. 
P., EVANS, S. J., CHOUDARY, P. V., CARTAGENA, P., BARCHAS, J. D., 
SCHATZBERG, A. F., JONES, E. G., MYERS, R. M., WATSON, S. J., AKIL, H. & 
BUNNEY, W. E. 2013. Circadian patterns of gene expression in the human brain 
and disruption in major depressive disorder. Proceedings of the National Academy 
of Sciences, 110, 9950-9955. 
LI, M., KOUZMINA, E., MCCUSKER, M., RODIN, D., BOUTROS, P. C., PAIGE, C. J. & 
RODIN, G. 2017. Cytokines and depression in cancer patients and caregivers. 
Neuropsychiatric Disease and Treatment, 13, 2903-2911. 
Transcriptome signature of depression 
186 
 
LIEW, C. C., MA, J., TANG, H. C., ZHENG, R. & DEMPSEY, A. A. 2006. The peripheral 
blood transcriptome dynamically reflects system wide biology: a potential 
diagnostic tool. J Lab Clin Med, 147, 126-32. 
LIGUORI, I., RUSSO, G., CURCIO, F., BULLI, G., ARAN, L., DELLA-MORTE, D., 
GARGIULO, G., TESTA, G., CACCIATORE, F., BONADUCE, D. & ABETE, P. 
2018. Oxidative stress, aging, and diseases. Clinical interventions in aging, 13, 
757-772. 
LIN, E. & TSAI, S. J. 2016. Genome-wide microarray analysis of gene expression profiling 
in major depression and antidepressant therapy. Prog Neuropsychopharmacol 
Biol Psychiatry, 64, 334-40. 
LIN, S. M., DU, P., HUBER, W. & KIBBE, W. A. 2008. Model-based variance-stabilizing 
transformation for Illumina microarray data. Nucleic Acids Research, 36, e11. 
LIU, H. H., HU, Y., ZHENG, M., SUHOSKI, M. M., ENGLEMAN, E. G., DILL, D. L., 
HUDNALL, M., WANG, J., SPOLSKI, R., LEONARD, W. J. & PELTZ, G. 2012. 
Cd14 SNPs regulate the innate immune response. Mol Immunol, 51, 112-27. 
LIU, W., GE, T., LENG, Y., PAN, Z., FAN, J., YANG, W. & CUI, R. 2017. The Role of 
Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex. Neural 
Plasticity, 2017, 6871089. 
LIU, Z., LI, X., SUN, N., XU, Y., MENG, Y., YANG, C., WANG, Y. & ZHANG, K. 2014. 
Microarray profiling and co-expression network analysis of circulating lncRNAs 
and mRNAs associated with major depressive disorder. PLoS One, 9, e93388. 
LOFTIS, J. M., HUCKANS, M. & MORASCO, B. J. 2010. Neuroimmune mechanisms of 
cytokine-induced depression: Current theories and novel treatment strategies. 
Neurobiology of disease, 37, 519-533. 
LOPRESTI, A. L., MAKER, G. L., HOOD, S. D. & DRUMMOND, P. D. 2014. A review of 
peripheral biomarkers in major depression: the potential of inflammatory and 
oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry, 48, 
102-11. 
LORENZETTI, V., ALLEN, N. B., FORNITO, A. & YUCEL, M. 2009. Structural brain 
abnormalities in major depressive disorder: a selective review of recent MRI 
studies. J Affect Disord, 117, 1-17. 
LOTAN, A., FENCKOVA, M., BRALTEN, J., ALTTOA, A., DIXSON, L., WILLIAMS, R. W. 
& VAN DER VOET, M. 2014. Neuroinformatic analyses of common and distinct 
genetic components associated with major neuropsychiatric disorders. Frontiers in 
Neuroscience, 8, 331. 
LU, J. T., MUCHIR, A., NAGY, P. L. & WORMAN, H. J. 2011. LMNA cardiomyopathy: cell 
biology and genetics meet clinical medicine. Disease Models & Mechanisms, 4, 
562-568. 
LU, N. Z. & CIDLOWSKI, J. A. 2005. Translational regulatory mechanisms generate N-
terminal glucocorticoid receptor isoforms with unique transcriptional target genes. 
Mol Cell, 18, 331-42. 
LUSCHER, B. & FUCHS, T. 2015. GABAergic control of depression-related brain states. 
Advances in pharmacology (San Diego, Calif.), 73, 97-144. 
MACHADO-VIEIRA, R., SALVADORE, G., LUCKENBAUGH, D. A., MANJI, H. K. & 
ZARATE, C. A., JR. 2008. Rapid onset of antidepressant action: a new paradigm 
in the research and treatment of major depressive disorder. J Clin Psychiatry, 69, 
946-58. 
MAES, M. 1999. Major depression and activation of the inflammatory response system. 
Adv Exp Med Biol, 461, 25-46. 
MALKI, K., PAIN, O., TOSTO, M. G., DU RIETZ, E., CARBONI, L. & SCHALKWYK, L. C. 
2015. Identification of genes and gene pathways associated with major depressive 
Transcriptome signature of depression 
187 
 
disorder by integrative brain analysis of rat and human prefrontal cortex 
transcriptomes. Transl Psychiatry, 5, e519. 
MALKI, K., TOSTO, M. G., JUMABHOY, I. & LOURDUSAMY, A. 2013. Integrative mouse 
and human mRNA studies using WGCNA nominates novel candidate genes 
involved in the pathogenesis of major depressive disorder. Pharmacogenomics, 
14, 1979-1990. 
MARIC, N. P. & ADZIC, M. 2013. Pharmacological modulation of HPA axis in depression 
- new avenues for potential therapeutic benefits. Psychiatr Danub, 25, 299-305. 
MARONDE, E., SAADE, A., ACKERMANN, K., GOUBRAN-BOTROS, H., PAGAN, C., 
BUX, R., BOURGERON, T., DEHGHANI, F. & STEHLE, J. H. 2011. Dynamics in 
enzymatic protein complexes offer a novel principle for the regulation of melatonin 
synthesis in the human pineal gland. J Pineal Res, 51, 145-55. 
MATHEW, S. J., KEEGAN, K. & SMITH, L. 2005. Glutamate modulators as novel 
interventions for mood disorders. Rev Bras Psiquiatr, 27, 243-8. 
MCAFOOSE, J. & BAUNE, B. T. 2009. Evidence for a cytokine model of cognitive 
function. Neurosci Biobehav Rev, 33, 355-66. 
MCCLUNG, C. A. 2007. Circadian Genes, Rhythms and the Biology of Mood Disorders. 
Pharmacology & therapeutics, 114, 222-232. 
MEHTA, D., MENKE, A. & BINDER, E. B. 2010. Gene Expression Studies in Major 
Depression. Current Psychiatry Reports, 12, 135-144. 
MENKE, A., ARLOTH, J., PUTZ, B., WEBER, P., KLENGEL, T., MEHTA, D., GONIK, M., 
REX-HAFFNER, M., RUBEL, J., UHR, M., LUCAE, S., DEUSSING, J. M., 
MULLER-MYHSOK, B., HOLSBOER, F. & BINDER, E. B. 2012. Dexamethasone 
stimulated gene expression in peripheral blood is a sensitive marker for 
glucocorticoid receptor resistance in depressed patients. 
Neuropsychopharmacology, 37, 1455-64. 
METCALF, T. U., CUBAS, R. A., GHNEIM, K., CARTWRIGHT, M. J., GREVENYNGHE, 
J. V., RICHNER, J. M., OLAGNIER, D. P., WILKINSON, P. A., CAMERON, M. J., 
PARK, B. S., HISCOTT, J. B., DIAMOND, M. S., WERTHEIMER, A. M., 
NIKOLICH-ZUGICH, J. & HADDAD, E. K. 2015. Global analyses revealed age-
related alterations in innate immune responses after stimulation of pathogen 
recognition receptors. Aging Cell, 14, 421-32. 
MILLS, N. T., SCOTT, J. G., WRAY, N. R., COHEN-WOODS, S. & BAUNE, B. T. 2013. 
Research review: the role of cytokines in depression in adolescents: a systematic 
review. J Child Psychol Psychiatry, 54, 816-35. 
MISTRY, M., GILLIS, J. & PAVLIDIS, P. 2013. Meta-analysis of gene coexpression 
networks in the post-mortem prefrontal cortex of patients with schizophrenia and 
unaffected controls. BMC Neuroscience, 14, 105-105. 
MOSTAFAVI, S., BATTLE, A., ZHU, X., POTASH, J. B., WEISSMAN, M. M., SHI, J., 
BECKMAN, K., HAUDENSCHILD, C., MCCORMICK, C., MEI, R., GAMEROFF, 
M. J., GINDES, H., ADAMS, P., GOES, F. S., MONDIMORE, F. M., MACKINNON, 
D. F., NOTES, L., SCHWEIZER, B., FURMAN, D., MONTGOMERY, S. B., 
URBAN, A. E., KOLLER, D. & LEVINSON, D. F. 2014. Type I interferon signaling 
genes in recurrent major depression: increased expression detected by whole-
blood RNA sequencing. Mol Psychiatry, 19, 1267-74. 
NICODEMUS, K. K. & MALLEY, J. D. 2009. Predictor correlation impacts machine 
learning algorithms: implications for genomic studies. Bioinformatics, 25, 1884-90. 
OKBAY, A., BASELMANS, B. M. L., DE NEVE, J.-E., TURLEY, P., NIVARD, M. G., 
FONTANA, M. A., MEDDENS, S. F. W., LINNÉR, R. K., RIETVELD, C. A., 
DERRINGER, J., GRATTEN, J., LEE, J. J., LIU, J. Z., DE VLAMING, R., 
AHLUWALIA, T. S., BUCHWALD, J., CAVADINO, A., FRAZIER-WOOD, A. C., 
FURLOTTE, N. A., GARFIELD, V., GEISEL, M. H., GONZALEZ, J. R., HAITJEMA, 
Transcriptome signature of depression 
188 
 
S., KARLSSON, R., VAN DER LAAN, S. W., LADWIG, K.-H., LAHTI, J., VAN DER 
LEE, S. J., LIND, P. A., LIU, T., MATTESON, L., MIHAILOV, E., MILLER, M. B., 
MINICA, C. C., NOLTE, I. M., MOOK-KANAMORI, D., VAN DER MOST, P. J., 
OLDMEADOW, C., QIAN, Y., RAITAKARI, O., RAWAL, R., REALO, A., RUEEDI, 
R., SCHMIDT, B., SMITH, A. V., STERGIAKOULI, E., TANAKA, T., TAYLOR, K., 
THORLEIFSSON, G., WEDENOJA, J., WELLMANN, J., WESTRA, H.-J., 
WILLEMS, S. M., ZHAO, W., LIFELINES COHORT, S., AMIN, N., BAKSHI, A., 
BERGMANN, S., BJORNSDOTTIR, G., BOYLE, P. A., CHERNEY, S., COX, S. 
R., DAVIES, G., DAVIS, O. S. P., DING, J., DIREK, N., EIBICH, P., EMENY, R. 
T., FATEMIFAR, G., FAUL, J. D., FERRUCCI, L., FORSTNER, A. J., GIEGER, C., 
GUPTA, R., HARRIS, T. B., HARRIS, J. M., HOLLIDAY, E. G., HOTTENGA, J.-J., 
DE JAGER, P. L., KAAKINEN, M. A., KAJANTIE, E., KARHUNEN, V., KOLCIC, I., 
KUMARI, M., LAUNER, L. J., FRANKE, L., LI-GAO, R., LIEWALD, D. C., KOINI, 
M., LOUKOLA, A., MARQUES-VIDAL, P., MONTGOMERY, G. W., MOSING, M. 
A., PATERNOSTER, L., PATTIE, A., PETROVIC, K. E., PULKKI-RÅBACK, L., 
QUAYE, L., RÄIKKÖNEN, K., RUDAN, I., et al. 2016. Genetic variants associated 
with subjective well-being, depressive symptoms, and neuroticism identified 
through genome-wide analyses. Nature Genetics, 48, 624. 
OKSER, S., PAHIKKALA, T., AIROLA, A., SALAKOSKI, T., RIPATTI, S. & AITTOKALLIO, 
T. 2014. Regularized Machine Learning in the Genetic Prediction of Complex 
Traits. PLOS Genetics, 10, e1004754. 
PANDEY, G. N., RIZAVI, H. S., REN, X., FAREED, J., HOPPENSTEADT, D. A., 
ROBERTS, R. C., CONLEY, R. R. & DWIVEDI, Y. 2012. Proinflammatory 
cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res, 46, 
57-63. 
PAPAKOSTAS, G. I. A. F., MAURIZIO 2010. Pharmacotherapy for Depression and 
Treatment-Resistant Depression. 
PARIANTE, C. M. & LIGHTMAN, S. L. 2008. The HPA axis in major depression: classical 
theories and new developments. Trends in Neurosciences, 31, 464-468. 
PARIKSHAK, NEELROOP N., LUO, R., ZHANG, A., WON, H., LOWE, JENNIFER K., 
CHANDRAN, V., HORVATH, S. & GESCHWIND, DANIEL H. 2013. Integrative 
Functional Genomic Analyses Implicate Specific Molecular Pathways and Circuits 
in Autism. Cell, 155, 1008-1021. 
PEARSON-FUHRHOP, K. M., DUNN, E. C., MORTERO, S., DEVAN, W. J., FALCONE, 
G. J., LEE, P., HOLMES, A. J., HOLLINSHEAD, M. O., ROFFMAN, J. L., 
SMOLLER, J. W., ROSAND, J. & CRAMER, S. C. 2014. Dopamine Genetic Risk 
Score Predicts Depressive Symptoms in Healthy Adults and Adults with 
Depression. PLoS ONE, 9, e93772. 
PONTES, B., GIRÁLDEZ, R. & AGUILAR-RUIZ, J. S. 2015. Biclustering on expression 
data: A review. Journal of Biomedical Informatics, 57, 163-180. 
PORTO, G. & DE SOUSA, M. 2007. Iron overload and immunity. World journal of 
gastroenterology, 13, 4707-4715. 
POWER, R. A., TANSEY, K. E., BUTTENSCHØN, H. N., COHEN-WOODS, S., BIGDELI, 
T., HALL, L. S., KUTALIK, Z., LEE, S. H., RIPKE, S., STEINBERG, S., TEUMER, 
A., VIKTORIN, A., WRAY, N. R., AROLT, V., BAUNE, B. T., BOOMSMA, D. I., 
BØRGLUM, A. D., BYRNE, E. M., CASTELAO, E., CRADDOCK, N., CRAIG, I. W., 
DANNLOWSKI, U., DEARY, I. J., DEGENHARDT, F., FORSTNER, A. J., 
GORDON, S. D., GRABE, H. J., GROVE, J., HAMILTON, S. P., HAYWARD, C., 
HEATH, A. C., HOCKING, L. J., HOMUTH, G., HOTTENGA, J. J., KLOIBER, S., 
KROGH, J., LANDÉN, M., LANG, M., LEVINSON, D. F., LICHTENSTEIN, P., 
LUCAE, S., MACINTYRE, D. J., MADDEN, P., MAGNUSSON, P. K. E., MARTIN, 
N. G., MCINTOSH, A. M., MIDDELDORP, C. M., MILANESCHI, Y., 
Transcriptome signature of depression 
189 
 
MONTGOMERY, G. W., MORS, O., MÜLLER-MYHSOK, B., NYHOLT, D. R., 
OSKARSSON, H., OWEN, M. J., PADMANABHAN, S., PENNINX, B. W. J. H., 
PERGADIA, M. L., PORTEOUS, D. J., POTASH, J. B., PREISIG, M., RIVERA, M., 
SHI, J., SHYN, S. I., SIGURDSSON, E., SMIT, J. H., SMITH, B. H., 
STEFANSSON, H., STEFANSSON, K., STROHMAIER, J., SULLIVAN, P. F., 
THOMSON, P., THORGEIRSSON, T. E., VAN DER AUWERA, S., WEISSMAN, 
M. M., BREEN, G. & LEWIS, C. M. 2017. Genome-wide Association for Major 
Depression Through Age at Onset Stratification: Major Depressive Disorder 
Working Group of the Psychiatric Genomics Consortium. Biological Psychiatry, 81, 
325-335. 
RIPKE, S., WRAY, N. R., LEWIS, C. M., HAMILTON, S. P., WEISSMAN, M. M., BREEN, 
G., BYRNE, E. M., BLACKWOOD, D. H., BOOMSMA, D. I., CICHON, S., HEATH, 
A. C., HOLSBOER, F., LUCAE, S., MADDEN, P. A., MARTIN, N. G., MCGUFFIN, 
P., MUGLIA, P., NOETHEN, M. M., PENNINX, B. P., PERGADIA, M. L., POTASH, 
J. B., RIETSCHEL, M., LIN, D., MULLER-MYHSOK, B., SHI, J., STEINBERG, S., 
GRABE, H. J., LICHTENSTEIN, P., MAGNUSSON, P., PERLIS, R. H., PREISIG, 
M., SMOLLER, J. W., STEFANSSON, K., UHER, R., KUTALIK, Z., TANSEY, K. 
E., TEUMER, A., VIKTORIN, A., BARNES, M. R., BETTECKEN, T., BINDER, E. 
B., BREUER, R., CASTRO, V. M., CHURCHILL, S. E., CORYELL, W. H., 
CRADDOCK, N., CRAIG, I. W., CZAMARA, D., DE GEUS, E. J., DEGENHARDT, 
F., FARMER, A. E., FAVA, M., FRANK, J., GAINER, V. S., GALLAGHER, P. J., 
GORDON, S. D., GORYACHEV, S., GROSS, M., GUIPPONI, M., HENDERS, A. 
K., HERMS, S., HICKIE, I. B., HOEFELS, S., HOOGENDIJK, W., HOTTENGA, J. 
J., IOSIFESCU, D. V., ISING, M., JONES, I., JONES, L., JUNG-YING, T., 
KNOWLES, J. A., KOHANE, I. S., KOHLI, M. A., KORSZUN, A., LANDEN, M., 
LAWSON, W. B., LEWIS, G., MACINTYRE, D., MAIER, W., MATTHEISEN, M., 
MCGRATH, P. J., MCINTOSH, A., MCLEAN, A., MIDDELDORP, C. M., 
MIDDLETON, L., MONTGOMERY, G. M., MURPHY, S. N., NAUCK, M., NOLEN, 
W. A., NYHOLT, D. R., O'DONOVAN, M., OSKARSSON, H., PEDERSEN, N., 
SCHEFTNER, W. A., SCHULZ, A., SCHULZE, T. G., SHYN, S. I., SIGURDSSON, 
E., SLAGER, S. L., SMIT, J. H., et al. 2013. A mega-analysis of genome-wide 
association studies for major depressive disorder. Mol Psychiatry, 18, 497-511. 
RITCHIE, M. D., HOLZINGER, E. R., LI, R., PENDERGRASS, S. A. & KIM, D. 2015. 
Methods of integrating data to uncover genotype–phenotype interactions. Nature 
Reviews Genetics, 16, 85. 
RIVERA, M. & MCGUFFIN, P. 2015. The successful search for genetic loci associated 
with depression. Genome Medicine, 7, 92. 
ROSENBLAT, J. D., CHA, D. S., MANSUR, R. B. & MCINTYRE, R. S. 2014. Inflamed 
moods: a review of the interactions between inflammation and mood disorders. 
Prog Neuropsychopharmacol Biol Psychiatry, 53, 23-34. 
ROSTOKER, G., GRIUNCELLI, M., LORIDON, C., MAGNA, T., MACHADO, G., DRAHI, 
G., DAHAN, H., JANKLEWICZ, P. & COHEN, Y. 2015. Reassessment of Iron 
Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study. PLOS ONE, 
10, e0132006. 
ROYCHOWDHURY, S. & CHINNAIYAN, A. M. 2016. Translating cancer genomes and 
transcriptomes for precision oncology. CA Cancer J Clin, 66, 75-88. 
SACHDEV, P. S., BRODATY, H., REPPERMUND, S., KOCHAN, N. A., TROLLOR, J. N., 
DRAPER, B., SLAVIN, M. J., CRAWFORD, J., KANG, K., BROE, G. A., MATHER, 
K. A. & LUX, O. 2010. The Sydney Memory and Ageing Study (MAS): methodology 
and baseline medical and neuropsychiatric characteristics of an elderly 
epidemiological non-demented cohort of Australians aged 70-90 years. Int 
Psychogeriatr, 22, 1248-64. 
Transcriptome signature of depression 
190 
 
SACHDEV, P. S., LAMMEL, A., TROLLOR, J. N., LEE, T., WRIGHT, M. J., AMES, D., 
WEN, W., MARTIN, N. G., BRODATY, H. & SCHOFIELD, P. R. 2012. A 
Comprehensive Neuropsychiatric Study of Elderly Twins: The Older Australian 
Twins Study. Twin Research and Human Genetics, 12, 573-582. 
SAHAY, B., PATSEY, R. L., EGGERS, C. H., SALAZAR, J. C., RADOLF, J. D. & 
SELLATI, T. J. 2009. CD14 Signaling Restrains Chronic Inflammation through 
Induction of p38-MAPK/SOCS-Dependent Tolerance. PLOS Pathogens, 5, 
e1000687. 
SANACORA, G., TRECCANI, G. & POPOLI, M. 2012. Towards a glutamate hypothesis 
of depression: An emerging frontier of neuropsychopharmacology for mood 
disorders. Neuropharmacology, 62, 63-77. 
SANDERS, A. R., DRIGALENKO, E. I., DUAN, J., MOY, W., FREDA, J., GÖRING, H. H. 
H. & GEJMAN, P. V. 2017. Transcriptome sequencing study implicates immune-
related genes differentially expressed in schizophrenia: new data and a meta-
analysis. Translational Psychiatry, 7, e1093. 
SAVITZ, J., FRANK, M. B., VICTOR, T., BEBAK, M., MARINO, J. H., BELLGOWAN, P. 
S., MCKINNEY, B. A., BODURKA, J., KENT TEAGUE, T. & DREVETS, W. C. 
2013. Inflammation and neurological disease-related genes are differentially 
expressed in depressed patients with mood disorders and correlate with 
morphometric and functional imaging abnormalities. Brain Behav Immun, 31, 161-
71. 
SCHACHTER, J., MARTEL, J., LIN, C. S., CHANG, C. J., WU, T. R., LU, C. C., KO, Y. 
F., LAI, H. C., OJCIUS, D. M. & YOUNG, J. D. 2018. Effects of obesity on 
depression: A role for inflammation and the gut microbiota. Brain Behav Immun, 
69, 1-8. 
SCHATZBERG, A. F., KELLER, J., TENNAKOON, L., LEMBKE, A., WILLIAMS, G., 
KRAEMER, F. B., SARGINSON, J. E., LAZZERONI, L. C. & MURPHY, G. M. 
2014. HPA axis genetic variation, cortisol and psychosis in major depression. Mol 
Psychiatry, 19, 220-227. 
SCHILDKRAUD, J. J. 1965. THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE 
DISORDERS: A REVIEW OF SUPPORTING EVIDENCE. American Journal of 
Psychiatry, 122, 509-522. 
SCHOEPP, D. D. 2001. Unveiling the functions of presynaptic metabotropic glutamate 
receptors in the central nervous system. J Pharmacol Exp Ther, 299, 12-20. 
SEGMAN, R. H., GOLTSER-DUBNER, T., WEINER, I., CANETTI, L., GALILI-
WEISSTUB, E., MILWIDSKY, A., PABLOV, V., FRIEDMAN, N. & HOCHNER-
CELNIKIER, D. 2010. Blood mononuclear cell gene expression signature of 
postpartum depression. Mol Psychiatry, 15, 93-100, 2. 
SEIFUDDIN, F., PIROOZNIA, M., JUDY, J. T., GOES, F. S., POTASH, J. B. & ZANDI, P. 
P. 2013. Systematic review of genome-wide gene expression studies of bipolar 
disorder. BMC Psychiatry, 13, 213-213. 
SEQUEIRA, A., GWADRY, F. G., FFRENCH-MULLEN, J. M., CANETTI, L., GINGRAS, 
Y., CASERO, R. A., JR., ROULEAU, G., BENKELFAT, C. & TURECKI, G. 2006. 
Implication of SSAT by gene expression and genetic variation in suicide and major 
depression. Arch Gen Psychiatry, 63, 35-48. 
SEQUEIRA, A., KLEMPAN, T., CANETTI, L., FFRENCH-MULLEN, J., BENKELFAT, C., 
ROULEAU, G. A. & TURECKI, G. 2007. Patterns of gene expression in the limbic 
system of suicides with and without major depression. Mol Psychiatry, 12, 640-55. 
SEQUEIRA, A., MAMDANI, F., ERNST, C., VAWTER, M. P., BUNNEY, W. E., LEBEL, 
V., REHAL, S., KLEMPAN, T., GRATTON, A., BENKELFAT, C., ROULEAU, G. A., 
MECHAWAR, N. & TURECKI, G. 2009. Global brain gene expression analysis 
Transcriptome signature of depression 
191 
 
links glutamatergic and GABAergic alterations to suicide and major depression. 
PLoS One, 4, e6585. 
SERAFINI, G. 2012. Neuroplasticity and major depression, the role of modern 
antidepressant drugs. World Journal of Psychiatry, 2, 49-57. 
SHEEHAN, D. V., LECRUBIER, Y., SHEEHAN, K. H., AMORIM, P., JANAVS, J., 
WEILLER, E., HERGUETA, T., BAKER, R. & DUNBAR, G. C. 1998. The Mini-
International Neuropsychiatric Interview (M.I.N.I): The development and validation 
of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The 
Journal of Clinical Psychiatry, 59, 22-33. 
SHELTON, R. C., CLAIBORNE, J., SIDORYK-WEGRZYNOWICZ, M., REDDY, R., 
ASCHNER, M., LEWIS, D. A. & MIRNICS, K. 2011. Altered expression of genes 
involved in inflammation and apoptosis in frontal cortex in major depression. 
Molecular Psychiatry, 16, 751-762. 
SIBILLE, E., ARANGO, V., GALFALVY, H. C., PAVLIDIS, P., ERRAJI-BENCHEKROUN, 
L., ELLIS, S. P. & JOHN MANN, J. 2004. Gene expression profiling of depression 
and suicide in human prefrontal cortex. Neuropsychopharmacology, 29, 351-61. 
SIBILLE, E. & FRENCH, B. 2013. Biological substrates underpinning diagnosis of major 
depression. International Journal of Neuropsychopharmacology, 16, 1893-1909. 
SIBILLE, E., WANG, Y., JOEYEN-WALDORF, J., GAITERI, C., SURGET, A., OH, S., 
BELZUNG, C., TSENG, G. C. & LEWIS, D. A. 2009. A molecular signature of 
depression in the amygdala. Am J Psychiatry, 166, 1011-24. 
SINGHAL, G. & BAUNE, B. T. 2018. Chapter 8 - Do Chemokines Have a Role in the 
Pathophysiology of Depression? In: BAUNE, B. T. (ed.) Inflammation and 
Immunity in Depression. Academic Press. 
SLATTERY, D. A., HUDSON, A. L. & NUTT, D. J. 2004. Invited review: the evolution of 
antidepressant mechanisms. Fundamental & Clinical Pharmacology, 18, 1-21. 
SMITH, K. M., RENSHAW, P. F. & BILELLO, J. 2013. The diagnosis of depression: 
current and emerging methods. Comprehensive psychiatry, 54, 1-6. 
SPIJKER, S., VAN ZANTEN, J. S., DE JONG, S., PENNINX, B. W., VAN DYCK, R., 
ZITMAN, F. G., SMIT, J. H., YLSTRA, B., SMIT, A. B. & HOOGENDIJK, W. J. 
2010. Stimulated gene expression profiles as a blood marker of major depressive 
disorder. Biol Psychiatry, 68, 179-86. 
STEPTOE, A., KUNZ-EBRECHT, S. R. & OWEN, N. 2003. Lack of association between 
depressive symptoms and markers of immune and vascular inflammation in 
middle-aged men and women. Psychol Med, 33, 667-74. 
SULLIVAN, P. F., NEALE, M. C. & KENDLER, K. S. 2000. Genetic epidemiology of major 
depression: review and meta-analysis. Am J Psychiatry, 157, 1552-62. 
SZEBENI, A., SZEBENI, K., DIPERI, T., CHANDLEY, M. J., CRAWFORD, J. D., 
STOCKMEIER, C. A. & ORDWAY, G. A. 2014. Shortened telomere length in white 
matter oligodendrocytes in major depression: Potential role of oxidative stress. 
International Journal of Neuropsychopharmacology, 17, 1579-1589. 
TAN, A. C. & GILBERT, D. 2003. Ensemble machine learning on gene expression data 
for cancer classification. Appl Bioinformatics. 
TAYLOR, D., SPARSHATT, A., VARMA, S. & OLOFINJANA, O. 2014. Antidepressant 
efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 
: British Medical Journal, 348. 
TOCHIGI, M., IWAMOTO, K., BUNDO, M., SASAKI, T., KATO, N. & KATO, T. 2008. 
Gene expression profiling of major depression and suicide in the prefrontal cortex 
of postmortem brains. Neurosci Res, 60, 184-91. 
TONELLI, L. H., STILLER, J., RUJESCU, D., GIEGLING, I., SCHNEIDER, B., MAURER, 
K., SCHNABEL, A., MÖLLER, H. J., CHEN, H. H. & POSTOLACHE, T. T. 2008. 
Transcriptome signature of depression 
192 
 
Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta 
Psychiatrica Scandinavica, 117, 198-206. 
TRULLAS, R. & SKOLNICK, P. 1990. Functional antagonists at the NMDA receptor 
complex exhibit antidepressant actions. Eur J Pharmacol, 185, 1-10. 
UHER, R., PAYNE, J. L., PAVLOVA, B. & PERLIS, R. H. 2014. Major depressive disorder 
in DSM-5: implications for clinical practice and research of changes from DSM-IV. 
Depress Anxiety, 31, 459-71. 
VAN DEN AKKER, E. B., PASSTOORS, W. M., JANSEN, R., VAN ZWET, E. W., 
GOEMAN, J. J., HULSMAN, M., EMILSSON, V., PEROLA, M., WILLEMSEN, G., 
PENNINX, B. W., HEIJMANS, B. T., MAIER, A. B., BOOMSMA, D. I., KOK, J. N., 
SLAGBOOM, P. E., REINDERS, M. J. & BEEKMAN, M. 2014. Meta-analysis on 
blood transcriptomic studies identifies consistently coexpressed protein-protein 
interaction modules as robust markers of human aging. Aging Cell, 13, 216-25. 
VOINEAGU, I., WANG, X., JOHNSTON, P., LOWE, J. K., TIAN, Y., HORVATH, S., MILL, 
J., CANTOR, R., BLENCOWE, B. J. & GESCHWIND, D. H. 2011. Transcriptomic 
Analysis of Autistic Brain Reveals Convergent Molecular Pathology. Nature, 474, 
380-384. 
VREEBURG, S. A., HOOGENDIJK, W. J., VAN PELT, J., DERIJK, R. H., VERHAGEN, 
J. C., VAN DYCK, R., SMIT, J. H., ZITMAN, F. G. & PENNINX, B. W. 2009. Major 
depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from 
a large cohort study. Arch Gen Psychiatry, 66, 617-26. 
WALKER, E. M., JR. & WALKER, S. M. 2000. Effects of iron overload on the immune 
system. Ann Clin Lab Sci, 30, 354-65. 
WANDERS, R. J. & WATERHAM, H. R. 2006. Biochemistry of mammalian peroxisomes 
revisited. Annu Rev Biochem, 75, 295-332. 
WANG, J., HODES, G. E., ZHANG, H., ZHANG, S., ZHAO, W., GOLDEN, S. A., BI, W., 
MENARD, C., KANA, V., LEBOEUF, M., XIE, M., BREGMAN, D., PFAU, M. L., 
FLANIGAN, M. E., ESTEBAN-FERNÁNDEZ, A., YEMUL, S., SHARMA, A., HO, 
L., DIXON, R., MERAD, M., HAN, M.-H., RUSSO, S. J. & PASINETTI, G. M. 2018. 
Epigenetic modulation of inflammation and synaptic plasticity promotes resilience 
against stress in mice. Nature Communications, 9, 477. 
WANG, L., LOCKSTONE, H. E., GUEST, P. C., LEVIN, Y., PALOTAS, A., PIETSCH, S., 
SCHWARZ, E., RAHMOUNE, H., HARRIS, L. W., MA, D. & BAHN, S. 2010. 
Expression profiling of fibroblasts identifies cell cycle abnormalities in 
schizophrenia. J Proteome Res, 9, 521-7. 
WANG, T., JI, Y. L., YANG, Y. Y., XIONG, X. Y., WANG, I. M., SANDFORD, A. J., LIANG, 
Z. A. & HE, J. Q. 2015. Transcriptomic profiling of peripheral blood CD4(+) T-cells 
in asthmatics with and without depression. Gene, 565, 282-7. 
WEBER, D. & O’BRIEN, K. 2017. Cancer and Cancer-Related Fatigue and the 
Interrelationships With Depression, Stress, and Inflammation. Journal of Evidence-
based Complementary & Alternative Medicine, 22, 502-512. 
WEI, Z., WANG, W., BRADFIELD, J., LI, J., CARDINALE, C., FRACKELTON, E., KIM, 
C., MENTCH, F., VAN STEEN, K., VISSCHER, PETER M., BALDASSANO, 
ROBERT N. & HAKONARSON, H. 2013. Large Sample Size, Wide Variant 
Spectrum, and Advanced Machine-Learning Technique Boost Risk Prediction for 
Inflammatory Bowel Disease. The American Journal of Human Genetics, 92, 1008-
1012. 
WEINBERG, E. 1996. Iron withholding: a defense against viral infections. Biometals, 9, 
393-399. 
WEISKOPF, D., WEINBERGER, B. & GRUBECK-LOEBENSTEIN, B. 2009. The aging of 
the immune system. Transpl Int, 22, 1041-50. 
Transcriptome signature of depression 
193 
 
WHITEFORD, H. A., DEGENHARDT, L., REHM, J., BAXTER, A. J., FERRARI, A. J., 
ERSKINE, H. E., CHARLSON, F. J., NORMAN, R. E., FLAXMAN, A. D., JOHNS, 
N., BURSTEIN, R., MURRAY, C. J. & VOS, T. 2013. Global burden of disease 
attributable to mental and substance use disorders: findings from the Global 
Burden of Disease Study 2010. Lancet, 382, 1575-86. 
WHITEFORD, H. A., FERRARI, A. J., DEGENHARDT, L., FEIGIN, V. & VOS, T. 2015. 
The Global Burden of Mental, Neurological and Substance Use Disorders: An 
Analysis from the Global Burden of Disease Study 2010. PLoS ONE, 10, 
e0116820. 
WISE, T., CLEARE, A. J., HERANE, A., YOUNG, A. H. & ARNONE, D. 2014. Diagnostic 
and therapeutic utility of neuroimaging in depression: an overview. 
Neuropsychiatric Disease and Treatment, 10, 1509-1522. 
WIUM-ANDERSEN, M., ØRSTED, D., NIELSEN, S. & NORDESTGAARD, B. 2013. 
Elevated c-reactive protein levels, psychological distress, and depression in 
73 131 individuals. JAMA Psychiatry, 70, 176-184. 
WRAY, N. R., RIPKE, S., MATTHEISEN, M., TRZASKOWSKI, M., BYRNE, E. M., 
ABDELLAOUI, A., ADAMS, M. J., AGERBO, E., AIR, T. M., ANDLAUER, T. M. F., 
BACANU, S. A., BAEKVAD-HANSEN, M., BEEKMAN, A. F. T., BIGDELI, T. B., 
BINDER, E. B., BLACKWOOD, D. R. H., BRYOIS, J., BUTTENSCHON, H. N., 
BYBJERG-GRAUHOLM, J., CAI, N., CASTELAO, E., CHRISTENSEN, J. H., 
CLARKE, T. K., COLEMAN, J. I. R., COLODRO-CONDE, L., COUVY-
DUCHESNE, B., CRADDOCK, N., CRAWFORD, G. E., CROWLEY, C. A., 
DASHTI, H. S., DAVIES, G., DEARY, I. J., DEGENHARDT, F., DERKS, E. M., 
DIREK, N., DOLAN, C. V., DUNN, E. C., ELEY, T. C., ERIKSSON, N., ESCOTT-
PRICE, V., KIADEH, F. H. F., FINUCANE, H. K., FORSTNER, A. J., FRANK, J., 
GASPAR, H. A., GILL, M., GIUSTI-RODRIGUEZ, P., GOES, F. S., GORDON, S. 
D., GROVE, J., HALL, L. S., HANNON, E., HANSEN, C. S., HANSEN, T. F., 
HERMS, S., HICKIE, I. B., HOFFMANN, P., HOMUTH, G., HORN, C., 
HOTTENGA, J. J., HOUGAARD, D. M., HU, M., HYDE, C. L., ISING, M., JANSEN, 
R., JIN, F., JORGENSON, E., KNOWLES, J. A., KOHANE, I. S., KRAFT, J., 
KRETZSCHMAR, W. W., KROGH, J., KUTALIK, Z., LANE, J. M., LI, Y., LI, Y., 
LIND, P. A., LIU, X., LU, L., MACINTYRE, D. J., MACKINNON, D. F., MAIER, R. 
M., MAIER, W., MARCHINI, J., MBAREK, H., MCGRATH, P., MCGUFFIN, P., 
MEDLAND, S. E., MEHTA, D., MIDDELDORP, C. M., MIHAILOV, E., 
MILANESCHI, Y., MILANI, L., MILL, J., MONDIMORE, F. M., MONTGOMERY, G. 
W., MOSTAFAVI, S., MULLINS, N., NAUCK, M., NG, B., et al. 2018. Genome-
wide association analyses identify 44 risk variants and refine the genetic 
architecture of major depression. 50, 668-681. 
WRIGHT, F. A. & SULLIVAN, P. F. 2014. Heritability and genomics of gene expression 
in peripheral blood. 46, 430-7. 
XIE, Y., WANG, X. & STORY, M. 2009. Statistical methods of background correction for 
Illumina BeadArray data. Bioinformatics, 25, 751-7. 
XU, F., YANG, J., CHEN, J., WU, Q., GONG, W., ZHANG, J., SHAO, W., MU, J., YANG, 
D., YANG, Y., LI, Z. & XIE, P. 2015. Differential co-expression and regulation 
analyses reveal different mechanisms underlying major depressive disorder and 
subsyndromal symptomatic depression. BMC Bioinformatics, 16, 112. 
YANG, Y., HAN, L., YUAN, Y., LI, J., HEI, N. & LIANG, H. 2014. Gene co-expression 
network analysis reveals common system-level properties of prognostic genes 
across cancer types. Nature communications, 5, 3231-3231. 
YESAVAGE, J. A., BRINK, T. L., ROSE, T. L., LUM, O., HUANG, V., ADEY, M. & 
LEIRER, V. O. 1982a. Development and validation of a geriatric depression 
screening scale: A preliminary report. Journal of Psychiatric Research, 17, 37-49. 
Transcriptome signature of depression 
194 
 
YESAVAGE, J. A., BRINK, T. L., ROSE, T. L., LUM, O., HUANG, V., ADEY, M. & 
LEIRER, V. O. 1982b. Development and validation of a geriatric depression 
screening scale: a preliminary report. J Psychiatr Res, 17, 37-49. 
YI, Z., LI, Z., YU, S., YUAN, C., HONG, W., WANG, Z., CUI, J., SHI, T. & FANG, Y. 2012. 
Blood-based gene expression profiles models for classification of subsyndromal 
symptomatic depression and major depressive disorder. PLoS One, 7, e31283. 
ZANONI, I. & GRANUCCI, F. 2013. Role of CD14 in host protection against infections 
and in metabolism regulation. Frontiers in cellular and infection microbiology, 3, 
32-32. 
ZHANG, B. & HORVATH, S. 2005. A general framework for weighted gene co-expression 
network analysis. Stat Appl Genet Mol Biol, 4, Article17. 
ZHANG, M., ZHANG, L., ZOU, J., YAO, C., XIAO, H., LIU, Q., WANG, J., WANG, D., 
WANG, C. & GUO, Z. 2009. Evaluating reproducibility of differential expression 
discoveries in microarray studies by considering correlated molecular changes. 
Bioinformatics, 25, 1662-1668. 
ZHENG, C.-H., YUAN, L., SHA, W. & SUN, Z.-L. 2014. Gene differential coexpression 




Transcriptome signature of depression 
195 
 
List of Figures 
Figure 1.1. Proportions of DALYs explained by mental and substance use disorders 
globally in 2010 .................................................................................................................... 9 
Figure 1.2. Proportions of DALYs for mental and substance use disorders in Australia in 
2015 .................................................................................................................................. 10 
Figure 2.1. Selection process flowchart  ............................................................................ 27 
Figure 2.2. Workflow chart  ............................................................................................... 28 
Figure 2.3. Replicated differentially expressed genes identified in periphery cells in 
depression  ........................................................................................................................ 36 
Figure 2.4. The 25 replicated differentially expressed genes identified genes identified in 
the brain are involved in depression and cardiovascular diseases  .................................... 41 
Figure 2.5. The 6 replicated differentially expressed genes identified genes identified in the 
periphery are involved in depression and cardiovascular diseases  ................................... 42 
Figure 2.6. Peroxisome and the role of PXMP2 in lipid and reactive oxygen species (ROS) 
metabolism  ....................................................................................................................... 50 
Figure 3.1. Heatmap plot of correlations between the module eigengenes depression 
subtypes ............................................................................................................................ 67 
Figure 3.2. Scatterplots depicting correlations between Module Membership (MM) and 
Gene Significance (GS) ..................................................................................................... 68 
Figure 4.1. Balancing training dataset using SMOTE ........................................................ 89 
Figure 4.2. Module membership distribution plot visualizing the relative importance of the 
modules for recurrent MDD ................................................................................................ 90 
Figure 4.3. The TFRC immune-related functional relationships  ........................................ 93 
Figure 5.1.  Differentially expressed genes in recurrent MDD  ......................................... 115 
Figure 5.2.  Interaction network for CD14 ........................................................................ 119 
Figure 5.3. A candidate pathway network ....................................................................... 123 
Figure 6.1. Summary of the findings on investigation of transcriptome signature of 
depression  ...................................................................................................................... 126 
Transcriptome signature of depression 
196 
 
List of Tables 
Table 2.1. The 57 replicated differentially genes expressed mapped to the 6 cortical areas 
in depression  .................................................................................................................... 30 
Table 3.1. Summary of MDD patient subgroups  ............................................................... 65 
Table 3.2. Pathway enrichment analysis on the modules associated with recurrent MDD in 
older adults  ....................................................................................................................... 70 
Table 3.3. Signaling Pathway Impact Analysis (SPIA) on the modules associated with 
recurrent MDD in older adults  ........................................................................................... 71 
       Table 5.1. Studies on the dysregulation of immune genes and oxidative stress factors in 
brain tissues in depression  .............................................................................................. 101 
       Table 5.2. Studies on the dysregulation of immune genes in peripheral tissues  ............. 108 
       Table 5.3. Thirteen KEGG pathways associated with recurrent MDD .............................. 112 
       Table 5.4. The top 6 differentially expressed genes in recurrent MDD  ............................ 116 
        
 
 
